var title_f19_40_20096="TT fungal overgrowth";
var content_f19_40_20096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fungal overgrowth of tympanostomy tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 381px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF9AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fPTryafn1xTcdulKOR6UFDs9MHigHr/Sgcke3vR396BhkY4xS56YFIPqf8aXjt/+ugAB49s5zmlycfrTeO31/wD10v16etAB9D1oPp0o6EZzjpx3pQOh64oGGfSgcHv6UgHGO3T3xRz7UgE655P59aXPNGOTwR35oGc/QUxB9RkfrRnr3oABxnpTWZVHJ5oAfnAw3NA/n0q3Y6Xf3uGt7dlj/wCesnyqPxNa1t4ct0I+3Xbyt/cgXA/M0m0tzSNKctkc40qjOW+gqza2V7eHFpZXE3bKocfnXY2dtZWgH2WxhVs/ekG9v1rR+03D5BlYD0HA/Sp50brCvqzlYfCGsygGVLe2T/ptKM/kKuxeCwAPtWsRDPaKIt/hXRR89R3zyanVf7p+lHOylQijn08IaSuPNvb6T2CqtTL4W0MdUvm7cyAVtqmCPpTggP8A+rpS52P2UV0MYeGdCGAbW7JP/Tf/AOtUbeGdDPSC9X3E2f6VvmPpwM0wx8cDv1p8zD2cexzsnhTR2J2SagnYcqary+D7Q/6nVJk7jzIen5GuoMfGcd6Qx45xRzsTpx7HGTeEbwH/AEe+s5vQElCfzqhc+H9YtuXsmkXruiIf+Vd88eB0z+FR7CpyhKnpkHBp85m6Meh5jKWibbNG8bjsy4IoDKT8pBB6+temys8qhJ1jmX+7KobFZV1oWlXQybR7Zz0aBjj8jT5kZui+hxFJ1Ud/bpmuguvCdwpJ0+7iuR1EcnyOfwPBrCure4sZAl7bywN/tLjP0p+hm01uMzye1GcdjSKcgcjnuKD0x2oJDOAO/wBKM+nb0HSgjPpzzk0HPY9KADuO3fNIc0pH4e1NHftQAueM9qM+/Hr60Y5/Dr60enpmgQZP40hOB1pMcD1oOTkdqAD88dKCexoPVhzn2pD7f/roACe/bP1o7H06Uhx/jijn2PegA7dcUhweu2lOB/PpRxk5Az70CH9j+lO+tJ2wR+NKvbH/ANagoXHOOuOtAOQOeCaB6n9O9KPU59iKBhxx2xS4/wD1UY7E5I9qMc8daAAdu1AHp370o68Ug6dOf6UgD6AfjRjn39DQOxHNKBz7YoATGFGOtGOTwSAad7g/0pGZUUbjQAAHI/yKZuAOBkseABya2dG8OX+qxrcEfZLH/nvKMAj/AGR3rprLTbLSx/oMe+UDm4l5b8B0FKUlHc3p0JT12Ry9l4eu7hA92RZwnn5uXb6LW5ZafY2WDBb+ZJ182bk/gOgrRKNIWZyWPvThATz39Kyc2zup0IQIHZpTmQljn8BSqhzjtU/k8dD+VPMXbH5VJrYhSPp7ZqxHH04qRY8cjGeuamRSCcj/AOtTCxGsZAAI4qRcjtzmpihOMjn1pAnPTg80ybDo2OMYqXjGRkDv/hTUjP1P86lKHJwOKdyGhmzkgdaVh6gjPtTsY6+lOxwevTHFBDRFs56EHFNKAYqbHU9M96RhkZ7e9MgrNH83fio2TgYHTvVplOPXApoTkUCKjRev15FNaLg8fpVzZ7Eil8vj6UCM5osZ46UHc0RikCzQn+CUbl/WrrJ1GA3NRmPnGPwxRclnNah4Z0+6LPaM1jP2Xloz/UVzGqaTqGlHN3DmI9Jo/mQ/jXpDRYPqKYA8asowVbqjDKn6irUn1M5U09jy1WUg7SPWlxzgV2eqeGrO9JksSLK6POw/6pz6D+7/ACrkb+0udOuDDfwtE/UHHDe4PQ1S12MJRcdyHtnr/Wg+nQUA5HH557UHpjnjjj+dBInf1oPv+lLnOe+O1B4JH4UAN5x60Edh39aU+nrwDSHpmgAOdx6Z7DNN4IHX/CnHOANv5UhHJPJGaAEOcc8c+lGBnnt2pexHTjPtSHke9AhOw4zQW28YoI6n+tLx3H60DH4596UZPoc0nPH9KcOScHkUDFB54JwPbigcj1x680Zz179qX2z+tAB9fSlGcnnnPag8AUYH4dc+lIYDGM+g7mgjHy9uuaXpkcbc0vQ+vpQAnsSOeuaOT7EfrSkccke9aXhzQb7xHdNFZAR28fM1xJwkY+vr7UDSb0RQtIJ727S1sIHuLlzhUQZr0HQvB1rpJWfWNl7qA5EAOYoj7n+I10Gk6dY6HafZdIQ7mGJbpx+8l/8AiR7VYWPB4/8A11EqnSJ106KjrLcp3QknO6Q5wMBV4A9gKoywZPqR+VbflDnOMj07VXlhyenQVkdSZkCPnIA+lOCcc8Ve8kZJI578U3yuxHf60F3KpjOOe5pBFzV8Q/lTTHhulMLkSQgDOM8Y96kEeOvUDpUkafXNTbOD2NMVyqFzx3pVQE8jjtUrpyM9PpSrGc8jP9KAEVSB71Iq54xnNLs4AwffPanIOv580EMTyxwfw5puz5c1Pjjj0pSMZwfzpkMqspHpmmY+bpVhwBkfnUbLzzTJZFt/HjikI55NTbeg701gcDFIRFjPGB9PSnAZxgCggk9T0796cBnnHPWmSxgUHHHtTSnA/nVjbyeTntRtGcgdaQiq0fB4NQvF1AFaBTqO/t3pjIOenB5oEZUkXQdqgnjjntzb3kIntjz5bfw+6nqDWs0XHoRmqzxHHTr600xbnB634Zls0a60xmubNeWUj95F9R3HuK59WDjjrXquHjcPGzKw6EVha54dh1MtPp4W3vzy0XSOX6eje3StFK+5hOn1RxPbHQ0fyFEgeKV4Z0aOWM4ZGGCD6UdhzTMhOg5x6kUc596Ufhg0nBI7+tACDtikPT0HtS9efSjHJ9aAGt0yPzpTyeo60v1I/KmkZ49uKAAep79qaQeMbT9acerZ/KkbBOefyoESds08dQAelN9cnpSjpnseo9aCh3+TSj26joMUnOfelHOPekAYwcZ596X9eaMHj1FKBxjtQMBwT1Hag8Zzx/nrQSNvP410XgrwtJ4kuXnumaDR7cjzZscuf7i+5/SgqKcnZEfhDwvP4jmaeVzbaTC3724I5b/ZX1P8q9RiigtbOOx06H7PZRn5Yx1Y/wB5j3NWG8sRRW1rCLeygG2GFeij19yfWhUAU9fxrCU76LY7qdJQXmRInp24qQJgZ9/zqcKB3zS7evHFTc0ICmARzUMic896uFc5/OmsnXtQGxQaPjnk03y85ParxTnpSbMj1qh3KJXnn0pRF7Z+lW2i5OMnHX3oRcZ/OmFyIRYxkHOaUxEdB14+tWQBx6U8DnoOnegVykY+OBwKVY8k8Vd2AjkDil24IpjuUmTj6etNZcdOnarTKc4qPGT8w46cUCIh0xxigjr9MDNSY54PI4pMZ7nHSglkLDnFMKjJODxVjHTPXGDTAvK9c9KCSJlOCRTGUdqs44B/KmsOcDp0HFAEG3HX8qXbjJqXbxjnFG3nAHApkMjxz6etKBgjpkCn49+M80dO2OfpQSNC5X26daTbjnHNShfofwp2OemQeaQFVo++Dg1C8Q7/AMqu7eRnpjNRsuR3z2yKAM6WP25qpLF78n0rWkj4I71Wli5HHHemIwda0mDWowJWWG/QYiuOm70V/wDHtXn91bz2N21textFPGcFT39/cV6nLHnrms/V9Mg1q0EFywjuYxi3uPT/AGW/2f5Val0ZlOF9UecDsaQ9M579BUlzbzWV3LbXcbRzxnBBpnQ8cgVTMBD1Gf07UnbHrS4GRjjOOlIMCgBD1HXPrRgnGfWjqOn4Udc8c9PagQg680jZJ6Z/GnHr1pp+uKAuSjIOfc04DI+vbvTe47YHX0pwzjg8ikUOHX37UvtzSe3QCnY4H9O9Aw+ueO1LjAxzmk+p/SrOmafdavqdvpunIXuJjgeijux9h1oDc0fCHh2fxRqpgVjDYQjfdXB6Ivp9T2r2FVgitobPT4vIsLcbYYv/AGY+pNQ6dYWui6XFpOmYMER3TS955O7H29KtKODn/wDVXPOfNotj0KVLkWu41U+XNPVe4Pan7cfhTtuT+GKzubDAOR6djQB064PWpMcdzj9KMDn0HWmIixx70Bfzp5GMDpSgHr3xzVCI9vA46DNNIwe9Shcc4/Wjbxz9frVAQsP0poXnjr1qYr14zzSYI96YCKmfz/WnbPUcUqtjAB4q1GpbtxmgCBVwAT9KcE4zyexzV0RjBP4CmmPtTApNGDz74qCSLAPrWi0OeQcioCmAfXrQBQKdQTikKkE84x3q0U4OfSmMDz6igTKxX24ppXnPGPWrJX19KaVxz+lBBBtyB9elBT2qcKAOh9aRlOD9aAIAucce9IVqYjBx/OkYdeOlBLISvrnijHtxj1qTAxxnpgZoxwM54FMhjQD607Gc4pcYPrTgMdewzSAZj14FRsmPT8PSp8f/AFqRlz257UAVHXgjpUMi5ycCrjjk8nJqFl5z3NMRnTR5zzyRVKaM/ieK2WTLYqrNF+HNNCOc1zS11u2ERwt/EMQSn+Mf3G/oa89ZXjkeKZWSVGKspGCDXqk8fHoc9a57xZpX9oWzahbL/psA/fKP+WqD+L6jvVp9DKpHqjjCD68/oaO/oKRWDDORnrQeP8aZgHOAKD975s49qU85wM89j0pPpgjrxQA3qD6UuCxJzj1oGT3688Uc+uPxoAkPoegp39Tz700YOeOf1pw6e9IocvoODSqOvGOaPUDA+tO6YPQCgYyR/LXP8XYV7F4I8PHwzoXnXCn+2dQQNJnrBEei+xPU1y/wk8Npq2qza3qMW/S9NIKqRxNN/Cvv6mvTrkvPM885Jkckk+9Y1p2XKjrw1O/vsqIm0AdcCpgOoP60m0Dt0FSAdcVz3O2wo/Wn9BjPPekxj8+/pS/xHOPzpki9zikx0xx+NKBnj39aB745pgNwf/rUAYPTH0p+M+lKBx7mqRIwDoc+2BSbeBx3496lxz+pNCrz/WqQhgXOeuaQx9CBmrKAcYz6Dmn7RzkcZpgUFQ7sVqWsQ2c9++elQquDyO+Pwq/GRsIJGP50DuMK9hnkdKjMfOD+JFWGwOSCM+/NIFOCB6dqoRUYY5PTvio2GTz696vMmQcCoJEwCRzQBRkjIYH168VCy9TzV115wBkjpUMi9efxoApkY6AetIen+FSMpz/nimkdeOlBI0d6GGelKBjjqe9Pxycc8UhFZhxnqMUbMZ9hUrAfTt1puO3bpTJI2GO9IeSeevFSMM9Ppmm46Z/SmQxp6n+VLj8u3egdOevtS9s/qKQhOMjt1prY6808/mOTmggbeKYXImHr3NMKZx054qxs9e9P8vK8YpgUzH65PuagmQ4/zxWiY8Y9P51C8ZxznigdjDuIT17n3rMk3QzCSPhl5/8ArV0cyZznGayLuHkiqRNjz3xVpa2Vwl5ari0uDyv/ADzfuv8AUVjDk+4/WvSLi3iuIJbS5H7mfg/7DdmH0NedXdtLZXktpcLiSJsEj+f0qkc9SPKyP+WaTgnntxindST70g7egoMxPwx+NISFJB3fhS/TGaaRn/EGgCYYyMfjT145BPNNGefT1zT1A4/rQUOUc4x781LZ2lzqeoWunWMZe6upBFGg9ScVEMKCTjg9a9a+A2g+TBf+LbuPlM2lgD3kI+Zx9BSvbVlxjzOx3NvpVvoWk2WhWOGhsl/eOP8AlrMfvt+fApHi4HHHvV5IxjJySec02WPA6Z5/OuGcm3dnqwSSsjIdNp6Hihep5qzMuCaixgj068ntUlMQDgnp+NGMenT1pwXp1pwXPPY84p3JG45xxxxzRj05+tSqv5GmspwcY47VSERD73WpEGccH1zTQnccjvUqjirRDALx0pFHt+OaeO2RUipwKoQij5sc809V57c0qpnucYqUJgcj/wCvTAj2DjP86kj4HQEfWnEAA+g9KTH3jkk0DJkAOfXHFTeXxxz6VXRiMe3NWYpM8MfxpiYzZnj37VBInGR+VaCqCPUVG8fy/wA8mmFzMZMnoKhkjxnBGDV+SMc5BOD61G8ec4weKBmZInX3quyZHTNaTxE89PaoGiw3XPcUyWilg5/DqaeFJxwMYqz5ZyOPwpwjJIxknoKQWKrJnOOtNEXUjpjtVvZjoT7e9IUyM4PagTRSKHHI7VHtxx361dkTk+me9RPHxjHOcjvTM2imRx39aBjpxnr71ZaPr70zyz+HtTsQyLqffFSKufenLHjaKmVD+FA0RbSOn509FG4Adj0qZY+npTlTABPbOc0FWIjH8o9emKgkj4wB+FXwpwBz0qF07f1pDsZM0fPTms65i/IdK3JEAA/P1qhPHn647U0xWOauYcZwOD0Fc34x083WnrqEQP2i1wkvqydm/DpXb3UII6dfyFZxVYpSZVDQsCkin+JSMEVaJlHmVjygHcMjP1oHQEn1q5renNpGrXFm/wAyqcxt/eQ8qfyqnzyc80zj20E6Y/rRnHGM0dhjjFJ9DQInx8vHFPUH+tMAwPf/ADzUijoPWkUh9taT6jfWun2aFrm6lWJFHck4FfVjabBoun6doNlt+zabCIiR/HIeXb868i/Z20VbvxTqHiK4QNbaNCWjyODM+Qv5cmvYlUuWaQks5JZvU1nWeiR1YeP2iuI9uD1+tRSx56Y46c1eK8Zxio5E3DHrxXIztizFmQ88dagKAHjPpWnNH1PX6Gqrx/n2qbllYL9R39akC47ZFP29wO/FLgcD0oQhoAGOcgc0xuhzU2MDtUT9PrVohkR4Jz0709DxgEnHamd+lPB9Oa0RI49TjnPFPQ8AVECPapl5z2GeKoRKh559OBT1OSPbj60gHGe+eBnvUqIMUxDkww56mnGP160q8HOKl2ZB4NIZXCkHuKkTjoOc+tS+Wd3TNOVcE+lMLixsfUk4p+ARjGcD86VF759+tWEjA68HPXNMTKTR/Xp1qEpg9PpWoy/Lj/IqtIg6DrTAoMgPWoGj544/Wrzx4H070wpjH9aBmeY+KcI+PX3NXDHjt+FLsycD6Y9KAKXl/wA6QxD3/Or4j59ehoMY9R9KQGa0Oc4HbtUZh5wOtahjHHSojGCR34z1p3FYzmj7/hUZhA/AZrRaLjkH1zmm+UcZx+tNMhxKPl9CPr+NSCPpxgZx1q0IuMVIsRHOMdqYrFRYhnnPpjNO8rjntVxY8E8cDjmn+T3/AAFA7FFk5z+tV5RgEc1pypjPas25BGM9aQyhIM81XkTjPpVtl4OcVE+CT3pgZNyhxyO/Ssy4i6jB9ya6OVAVyOD3rMuYhziqRJw3jvTzdaLBqCAmezbyZT6xn7p/A8fjXCgg8+vXvXs0cEU7TWlzxb3SGF/QbhwfwODXjt1bS2V7cWlwCssDtGy+4OKpbHLWjZ3I+47HBoBI42k0eh7ClUAD7xoMSXrx69SKdK2yJ27kcGgd/Wrui6bLrev6XpMIy93cJFgehIB/rQtSj6O+GWjjw/8ACzSYGXZdaqzX8/HO3ogP4CugUdP6Ve1cRLqDW9sNtvZqltGB0CoMVAqZByCR3Fc03eTZ3wXKkiIqcexpjrz06irYjzjv61G8ffnANYs1izOlQc9apypt9u/0rXkjJHPaqUqYrNmqZQKZYfXn2pMcfT1qcr09aTbz36YoQMgIwPf+VVZHOTirkwIRunI/OsuWT5yD2PFaRIkyZcYB5+lSIMnPQdfpVUSbRzkj1p4mBBBrVGZYYqpBpysTgDP1quJAzkDPHHtVuIZ9fTmgCxCvHU5FWY4xn2HFRIvsf51OnIP0oAkC57VYQbRjoKiH4n3q3GqsvHU80CuRYHoefakAz2HNTsAD06UwEcDuaYCBTzxUyDsTnkfjSKRnnnjp70/A/DtTAB3Jx15xUbAE9PqKmIHfOBTcBc9h0pgV2iOeMdahKdM1cYccdAfWo8cmgZW2D/JoCY7ds1YCnbx9KNn1x0oGQBemMcc0behAqxsJ/wA9aXb3xzQIqGPB/XFMMR4zyOgq6V6H3ppTC8DPvQBQaPIz26UgjzgdMdKvFOpppj5piKgQ9cY+vSnBOOcYq0sfGelATn365oEVwvTGOTSheMnjB5zUpXAppODntTAqzLnIGPTH+NZ1ynXuK1JeDn25qhccjPoaaAzXXqAOR09qhkTvVxh1HWoJBk80wKbe/NU7kZHJ49u9X3BHTPFVpVz3OaBGLcpgcZyeRXCfFCzEetW+oIPkv4Q7Ef8APRflb+h/GvRLlOT6H3rmvG9p9s8HTMB+8sJ1mX/cb5T+uKpGVVXieZDv647UhJX1/ChTkc454pQM84z+FM4yyvJ549K9M/Zw00X3xKOoSrmHSLSW6PoGxtX9WrzQdO3Ne/8A7NOm+R4E8UauykPd3MVmjf7Kjc386L2uzWCvJI79CWJduXY5JPvVpAOhPGcVGqYA/SplUgfXmuSR2jwox9aa8fHSpUzj3FOK9hWTLRQePGfTOap3CHOR19u1asie/I61SmTPrj0qGaJmS64Jz04NNxyevWrcseDUDjGPakMrTrlDnnHasa5iwxOenat8jn+dZ9+mxcgDNaQepMkZWQuPUDvT0UNwTx2xVCWUhzn7v61YhlHfGBWxkaUSJjIAP41etiM8j9Kz4JB3yMVbjxwyk0gNcIGU7fXnmkKEdR9aitZSAA3I9eKvMNwPXr0oArjGff8AlViKTaDzimMg5Hr7U1gRmmBPI+WJ6EmmbsH5/XmqwlIbB69DT1YsfahDL67SM9D3pzDBGaijX5ee5596kxgZzjvVCB/lBOfrQpJ5Jz3pjZHrjrzToyG+v8qYxWyeopCucY+lPK/40BeuQetADcc8jmnbR1o6dc0uOeh54oAbtxjHc4xQFz/KpVGBn8KFHUEGgRDtwCfem7ealkHduuO1NC9BigLiKuR0Hvmk257flUmBjPt2pnRhTFcaRz0GKYw9B+NSMRj8KQr+YGaEBWdTn+lRMcD0qywHOOBUUiDJ496pCKkrZJ9MVSlBbsfpWhcIMGqTrnpk5NCC5SkXGffnFQuOM+nerbpn+lRmPHOPypjKbKMgVXnXGfr3q9JGVbPbriqsvXp0oAy7peDjr6iqS2ovBd2B6Xlu8X/AiMr+oq/cr1wcc4qpE3k3lvMMjY6knHvTRLXQ8LQFcqR8wOCDThkDv+Va3jKyGn+L9XtVGFW4YqPYnI/Q1k8H1/OqZ570LEmFiY89K+tfg3pn2D4IeH1K4a9nmu29xuIH6AV8kXJAgbHsK+5vC1gbH4deDrI8GPTI2I92AJ/nUz+Bm9L40UZICCfToKb5XXj/AOvWzJByeOneqxh2sPb171zXudhSCfln86Xy8DjP+NXGix04AOeaaU7DsM1mxoz5Vx1+pqpIDjIGa0Z1zxxzVGVc9azZaKUg45qvInFW3B9Oe9RYz9OmPekVcpOvI9OlUr9MwkgVqSIe/U1RvFIiJ7VaEzjrvKynHfimxTBWx0xUl4SJDkc5qoo5PP6VuYm1CxIDAir8LHAzzWDbyFCMZ4rTtrhWABOD70gNm2Y1oLJ8vXtj2rEjlHHP61djm4HOcjrQBpDLc+vFR3DhQd3YVGsyquM4H8qpXcxfIXoeaY0ODl5MelW4VI/oazrZ8OM9c/lW1bEbR0/KgplmFhsPbIpxbn6j9Kbt9PTNMZdpPrVEjsg4pUAB56YqFclsdOe9WYvc80ASYyAT9OO9Kcg/l09KcvX3xxSHjt7UAM9h6/nTgvI6EUnQAe/elTqOO/GRmgBwU4GPwxQAM85/GpCnQ4OKNvpnnmlcRCwGeO1R5wTjp0qSTvjHpULHBwc+3FUA/wBe4o25PQcVGGz9KfnPbk0CDbTCOoxipcjP68Uxu+OfencCNhzz6VC/I59fyqc8dR0PaopFJzxTuBUlGR2z0qu6Hb04q8Y+fambM9MZp3AoNGepX2qJk/AjtWkUBByPwFVZo8tx09TVbgVCoIIrOuYcEkdDWoVYAkH2NVZ+SScYPGKRRhzISPmzVC7T5Djjj1rXuFyT3xxVCZQQQf0HamSzzP4sxFfFqTgf8fNpFJn1O3af5VxwJ7A4/Gu++LceY/D1xjlreSIn/df/AOvXA8k8HA+lWcNRWkye6BaNFzyWxiv0JltxBZ6TABgQ2UUf5KBX59Ebri1XOcyqP1r9FtVi/fwYA4iUfpWdVe5fzNaPxXMRo+uRmoJIuBnpWi0eB9DioJE68DNcp1ma6gdvxNQuoxxn6VclTk4+lVXGRxxmpZSKUydQOnUGqEqEnHOK1JFyp4qnInWs2UjPZc59DUBXkkirrpyeKiZOfQ0kwKzpnsDVG5jyhGcmtUpwAQKqXK/KfWqQjhdVi8t2+tZJYhmro/ECbTnPBHrXO/KWJroWqMnoya2Y7uePSrg3Llh9RWfHkP15PFWS5454PFMC/HJjrjNXI5mGcc1mwuGIHUVq2wTAJ9aCkSKWb1+lOKkD9ePSrC7ccY9qjkIIIA5pDICCrZHIx6Vo2l0QgHJH86zSGVxkYBpwcx7SuPpTsM6KC6D43YxjH1qdyHwB1xisG3mBOCMVoxTADr9KEJothQD04A596k3YyPbNVPPOOT9KXzgx9PpTAuIwHsB3qbdwPX0qqgDDI9KkGQMe3pQIk7A45Bx7UsY5HHf0pinGMmnKQWHvz+NIC3HygHb2ppGKZG+PXp6USH06YpCI34PXnFQumf51NnPOBjrQM7ufp0qhFbHelBPbORT5cc46ZpigknA796skD3B6dOKXaT7jpUix5/pU0cW7Hr04pIZXCZzkewpskePp3q75X6/pUcsfGR06/SgLmeVzx/CR+VJs/CrGz8OacI+AD68VQXKax5GTRJCAoIH4mrixnG3bzintCNgPNUK5iSQgy45ArMvI9jHnOK35Y9jEjA+tY1+TuY0izIuF69M1l3HBJI/CtS6xg/zrMuMA4PTFAmcP8VE3eGdEl7pcTx/ntNeb8mvT/icP+KK088cag4H0KV5hnHQcexq+hxVfjZcHy3dqfSZf5iv0e1Jd0sJ65iUivzduXCrEwz8rg+1fpAJBPZadOvIltkYH6gH+tTU+Aqk/eKbx8Zx9KrSxd60mQZPQcnpUDoCO3vXIzsTMaeI/Nxmqbp2wa2po+uR7fSqMsXOcHrUNlozHXk471Wmj64rQkj9KqyLweOSM81DKM6SPt0zzzULJ3xgfTvV6QcH2qu+M5xx/SkgK23nke9VbgfLzkA1oMB78VUnX5eKtEnE+KTt/AetcrCNwNdN4nfLsCeB71zURwvHbpW8NjKT1HAkYyMkVIs4KgDgnjNRFsZP5VDKAxBQ81QI2INgGQeatecV6Vk28vQHGcVbRwR156c0ijVgvOME8sKkErF8jODWLA2ZcE/StZMsvToKBmlGglXDY+tQXEewHH+fempKyL39PoKjnmLnAOSaYyeB8n39qv2pDtg/jWbBE64bGOM9Kv27gc4osUXHjxUbIc579OfSnebyc5696kP3SwoEOhkcAe5qwkmDVYDJ9weRipwMEA4FAmTA4AIHHpUg5x2yMVHGAAAB0pQcDHYjHSkIfu5zzjFAbJOe/FR5J59OKVO4/pSESAn249BT/AMD9KhB2nLDjNTKOh/pQIQr2pVUZPbvUigj6+1LGOOT1qriBU68cYqdVIPAz7UIM+5+mKnSME5poCNu+Rz3xULkYxz71PcAjIP8A+uqbE5we5yapCAKOMYPfpSqozkc/QUcr1GB70u7bj9c00IHUbQOtQvJhQCcYolkz0/Oq7kncadxpFW9mHzEfn6Vz19JySc+9aeovgkY/WsC7fczZ6UkapFOeb1rOuJcKcYq5dKQue3pWZMMjJ+lANHNfEyTPgzTxxk37ngeiV5mGC8Hn8K9D+JhK+G9GQ9XuJn/RRXnZ685B+taLY4K+k2WbwZtz14NfoZ4MuhqHw/8AC14v/LTT4cn/AIAv+FfnrMubdgeu3Nfc/wAAr4al8EfDUmctbo1u3f7rsv8ALFTP4WKDtJHcMOenGelRuuR05qYjr34zTXH1rkZ2IozJnNU5Vz1FaMq/gCKqSLyc496zZojOljA9MiqUqjn8q05Bnr0qlOvykY5NQyzLmByPXoarsuT9T+lXJhkHHOaruM5z06U0hMgP/wCuq8qYU/1q23AqpcnbHyT0+lUSeeeLciRyD065NcvE2eO+a6zxjgAtnqOea4qGQAEEjj8q6I/CZPctscc5/WmLgngc1A7EnGePzqSLcFAH60xosZUAkdc+lPWZiMjp64qoGJ5yMdKcrN93GBSuUXoHO8Nn2ratpCwGKwYGwCuOM/jV23mMY4PSi4zXklyuB160+1jDS8jrz0zWXbyyPMGZCF6nNdBaBcKeAetNaDRqRW42D5fqKcbQBC3r14qWNgiYOOmaeZcArjgimmTcoGInpzU0eYxhhwTkHFKxCYweSaY8m5doxnpihlXLMYzkj61Z2jaPz6VnwybWwcYNaSfMdo7jipExgHPrR1656dqWYbWZR0FRA8jA4FADlPJz0qQcc9e9QE5FSI30z0pASFeM+lPiYqeRQDxzjjjmlAB69aQicANx0/xqUL+VNiAwR3NWlAKnPP4U7iEgTcw4P5VcaPy05zgjFU1YK4+vpV5gxi3E8AZqkSyjORj8MVTfAIHHFTzEkt6Z61Bznjv0qxCt0AbPI6VE5wo7/T0p7tnHGBVeVumP1pjI3eq80uB7Usjd/Xviqk7EjJ/wpMpIz9Rm5JzyKwppOfxq/fyHeQT7e1Y8jnkZwfWn0NbCzODHwc54rPmGVyB17VPI3sPXFVpH+Rh0OKQmcT8VXC23h+DuIpJSPq2P6VwWOexHuK7T4tSg+J7W2ByLWziQj0JBY/zrjAM9q1Wx51V3my6BuDL6+hr6z/Y61I3vw21fTGPz2V6WUZ/hdQR+oavk1T7nnjng17t+xvrH2Lx7rWjSMQl/aeai+rxtn+TNRumib2PqkjIB68VGRyO+KtSR7SwA6GoGU5IriZ2p3K0i/jxVSYe3er8nIPH0qnOOT/Os2aIouOSTyKp3HftWi6YJyOOoqpcKOtSy0ZM64I4GKquMe561eugQfU1TYc8cU0Jld6pXh+U884q8/YnPSs+8yYyPyqiTzzxlP1Hcf7QriUb5Tkdec11fjFHLPgn17VyqriPpjjNbpWiZ31COXJw3X0qZWxj+lUwCH6HOf0qxAc+nXtSKLSKSRkYB9auRweuAR1qTT7SW4JESMx9ga6nTvDTNta4OD/dAp8vcVzl0t5XbEMTNjqQOK6HR/D8jjzLlME8FcdK66w0mOFcRxLye4rTS3UKMD9O9D8g5jCj0qJYgrRDb9OaqSaUU3eU23noa6ryeelQvAOvGRS1QcxyDPNbyBJc/XtirK3IKkHHpXRS26FGDAEdORmuU1W1e0lD/AC+WT24qlqVc0YXRkHf60kiqACCPpWRbl2bhiPwq8VZT8x9M0xkhYEdfmqzBdbAATnHcVnsRjPbvQrHINJoo2DOHzkn60pOc+mM1SiORnpjvU6vgc/596kViYnpnqaAwBwPSo93XHt+PvQpyRxnOaQi0rZXntT0PJHeq59QOatWieY4JGee1IRfhjLZwDz3q0YmC49e1S28YUDgevQ1Ps44pk3MyX5MA569aVblljVOi0XmN4x2BNVGfGAPTNWgFkfPT1OaarMiE49uagL5IHekLApkHnsKsQM564qGR8jjJB9KbJJjOMioDJyOmOtFxpDpGyRjp7VRuZMCppHPas65f5Tj+dSaIzL1tzGsyUdf61enOTVCTIB9Kq5ZXfoeuKrxxmW7hiUE73AqWZsZ2+npTLGVYJp7uT7lpBJOc+oXihEs8o8dXgvvGWrTqdyCYxrx2X5f6ViEgdh+dG9pHeRyS7sWJ9c0jDnj09cVseW3d3LyH8xXU/CnXR4Y+KPhvVWYrCtysU3+4/wAjfo2fwrlFJ6dM0XSlrfcOGU5BFJaDP0zuEy2RyDVORMZx6YrA+EniIeLPhpoOrFw072yxzY/56p8rfqM/jXSyr19656sbM2py6FKQd/bmqcq5Pr1GavSd/fmq0i85/GuZnSmU2T5uPwqvMgx9farrDj3Ax6VBKP3frx6VLLRhXann2rPYdMdula90nXuMdBWXMp4A/wAmmBUft3A4+tUZxxjuKvScnjjI/Kqsy5GQKYjgPF0I+Yn156VySRZRsfpXY+LASSOefoaxbHTJbgjaPxHpW8fhMnuZEVi0hCouW+ma6LQ/DBkYNccD0ANdFpekxwKpZMv+NdFawAEAcg9sU0+wFbTNJit1CogAA+tayWmMHGfoOtWbcAIBsHPpVqNOBxxk1RNytFARnHf1qdoMc4wR6elSKvcY9fb61KMYPQ0AUjDyM89earyJjHGDz2q+5AyPyFZt9K6giPA9e9ZykUiNhzznA9az9ds47u1Ko2McgVR1J5LdRMZDnPOTVUa1E8Dhm2kjgGiLb1RVjNQmP5c+xzSS3JVge/f2qqtxuY7frmmsrs2QMY59q2tcakaIbdHkNzUaOc/N0/nTFUiP6UDrx+FS0UmaFvJj05GanZuMgnOO1Ubb2PQelW1XHBPAxipsMerZyOfSp1OR/WquMOQOeKnh5BBGOMVLAsHIB+ufYVs6VHnBIGCc9Kx4fvKp7nrjtW9aAIqYHApEyOgt7QtHkYxiokjLswH3h2pttqAVAh78VYssMxAOOvFCZBy96WSaRTx9apO3cGtfW4SkmT2P5isF2xnnIH61oNCM4OcdemKjeQ4IPemMdvH6VG59OKdxjySTz9KhlcLgYNLnA4PvUU3PPegEI7fKSOuOKzbt8K3rVtm4IzjHTNZ11JxycUItFCY8n1/OqcgJJPPrVhzk4qCViTj060xlaYYU8c1g+MLr7B4H1BwQJL2VbVD6qPmb9BW+6MV4GSa4z4zS/ZrnR9FTO62t/PmB675OcH6AD86uETGtO0WecoPlFKf880Z44pCSMYPGK0OAtjgnrn3qVQCp/u1CO+evWpUOB7Uiz6V/Yy8UbDrfhK5kGVP261BPXosgH/jp/OvpqUYz7V+d/gLxLL4M8d6P4gh3GO3mAnUH70Z4cf8AfJNfodFPDeWkF1bOslvOgdHB4ZWGQfyqKqvG44uzKso5Pt0qrIOuR3/Sr8y8fSqrrzn09a42dUWVCuevTNRSjK/SrTA559aikXgnFZs1TMe5TKn371mzw+nrW3OnUdvaqrx7shuhPNUhnOyxFWPHFVnXgAd+K27mDn6+grOkjwT/AEp2JOQ1ixSWTL8mktYFjG1VAArT1WL58+2apQ4yRkj296dwLkCjjAHar8J+vXAqlCQT6/TvVqI8cc81aZDRqW5ON3ccVajYFRnnHH4VnW78Mc//AK6mWZ5MgYA6ZFHOTYvM4AwcY9qgld8dMDmnWsyROD8gYH7xJGT7VLqdxDcSboi5boflAGfwqXO47GZJK4J5Hp+FROd45PJqxsUtxx9TVS5kA6Y6/wCTWdykZPie0M2lTbSRIoJB9fzrz6I7ogedw6g16NfXBeBkLA7gQfpXFDS2eWeKMMWzuG3pit6L0sKRDpR+clwcVrm4j8gKVA/2qzbWMQJ87AN3DUycle4Y9sVuRcvLcIyFFwD7URjewB5qtYAjJYflVxFKsSOoOM1LNEywq7ePbNXIznjvxVJDvI/Wp1bGCDj1qGUSyfeGO3FWbWMvuI655qpGNzjHTrWjEgCgHrjP41DGPtkY3HzAEDv6VsZAUEYFZSfLyPTn2qbzmxgHoKRLLhlwfXIqxDqGxMMxyOnvWSZAQctnAz9KrmTex2mqFY1tRv1uYnBJJ7VhTgoRu6E1M+BnJxxjiqszfOQcHjFUhiFvXjJxTd3XPemMeDgceuaYzYA5/wDrCgCUkg+1N+9k+tMMgPsf5U5W3DAPai4ynOpVjzWdc8g469q1Lg8nHQ8VRZQQATxTKuZMgwTxx+VRBGc7VPXrV6dASOOO3NT6NbfaLkADjPPWtIxuTKVjY8KaHHPepNdkJZ26tc3DkHCxoMn+VfM/jHW38SeLNU1d/lF1OzIp/hToo/BQBX0r8bNYXwh8JWs4WC6l4hbyFAPK264Ln8eB+NfKKjAxxmtVscNWXM7Dgee/I7UbvXB+tA5PHJpQAe5FBmTjORn06+tSKcYJI61EvTvx7VIh+6R+nekUSSp5kTKep6fWvsD9k7xqPEPgWTw9fS51HRjsUN1aA/dP/ATlfyr5AQ/NyK6X4Z+L5/APjzTtdiLNa7vKu41/jhbhh9e49xQtdBs/QWQev0NVpB/hU8Fzb31nb3tnKstrcRrJHIp4ZSMg/lTHHtXHONnY3g9Csw/OoHXrVphjI96ryjAGetZG6ZSlXLDPSqzAA4q5MOvv0qqzA896CitKgIwcZrIu1Cn9K2Jhn0rIvuBx0HtVCZgX6bgCegNZbRkH3rTuTj34qix6ccVDGh0ZIwDzUySZGQcdue9VicAY65+tCnPHU5pcwrGlakSLjJ9qtQO3T5eeM1m2jfeHOfrVmKXoG60XFYu7sknHfp6VJH8x5PrVeNuQc8YqRDy/+NAh7ISSv4VSkhA+9yRx+FXUbcWAYZ44qG5QkHuTxTURXOb1gmJd0ePTFcrJcyQys5LIWPY12WtQ7rdyFyw6e9cPczJNMI3XBU89q2pqwN3Q2QFwCQMk5znmpcEdfWlKIEDqRn0J/lRuLZyK6LmZbtMbCCferyAHpnJ5+lZVq+GznGP5VdWRgODUMpC58tyOnvmrCEldw6/0qqzFvQE1PbYPHbHrUstMvwDDDGcA461oRNxtA/Os+M/KMnqO1TpJgjJIHvUDZcAOfmHJ/nUVyCFByM9wKGmyOT97ioi3TPX1oSC5EScMOQe/NLCzeZhjkY9acy8Ej8cU0fK+c/rVBcldjj8M4qtJ8xzkD3qycsDyPwqJlIJz16UxXKvQ7c/hSGPOdp5Jwak2cj17e1KAR8o6+lJsZXdCDx1zxzTUJBHQYq267sdKjZNin+lK4ytcAkZHX3qkVLHFaXl7sep9+1a2maKZ2UkYB6AGtIRvuKUrGFZ6VJduOOO59K7bwj4YEl3FHt+XOZGyflXvXQ6XpEdtDl0HP1rl/j14xTwF8Op4bR/L1zWw1vbgH5o48fO/tgHA92HpXRF9Ec05nzZ+0D4zXxl8RLt7N92lacPsVmAeCqHlh/vNk/TFecj0x7mmKO/apAMDrgU2c4dh60hzngA0tOXgYwfyqRkg4+uKkHKjPfqaj446+1OXtz+NAyYHHI605lEkbI/Ixj6VGvUduKkUnnvmgZ9Rfsk/EL7bp0vgjWJf9KtFMlgzH78XVox/u9R7H2r6GkXBKnqK/ODTtRvdE1ey1jSZjDf2ciyxOp7j+nbHpX318N/GVl8QPBtnrenlVnK+XcwA8wygfMp/mPUEVnVjzK6Ki7M3pP1qs3A4xnNWZev61AcbelcbOqJTuPTrWe5wSPzrRmGfz6elUGXJI6/40kaIjlI2H3rEv+hPUVrTsAGHXtWJqUmEb/OKEDMO4O58dapyKSAe/vVhmG8nPfOaZJgjk8d6GIqM5BweuKfE3y5zTJASxx69cVLEucc8e9ZMotWmA5yOCO9PY/Pxxj1psK4GMnp0pWGCSKZJZRyzc9BxViM5DqeCRwM1RQn1/XpU8chRskZB6g1cSWWgxUnpyP1pXcnJOD7UOMBCQqiQZG1s4+tRseOcVqkQyvegNGQwBPcV554osjZ3f2mHIjfrgdDXos3K4OTnmsTVrVLuCSGTlGHcdDVrRgcLBcBlAyAfapi7y8DHrVR9OuIrp4egU8EmrkFjIuMSjkc1d7CsTL0Xnp6HpU6uV5zwOfpUX2WVRnIbjsaTaynDqVGMYobuCLquGGOhxxk9Ks2/UEdB+lZ6OD+I/KrcL9u/aoZZpRtwB04x9Kk7j6evSq0LBsDPJ45qwGHXnpipGO3fIemMU9Tg96jzxwcdsUoPHPQ9ulMCwF3DIP1/+tTXXaf5io0c88j2p8pJwBzVIRIrDCjPbtUbfePA4HNQ7jk9cYxTmc885z6UCHKAR/SkK9SO1PU5zySevWrENuZvlAHvUqLbC9irHEzk8E596sDTpmH3cnHFdLpOj+YygAn15roE0ZQBg5HtWqikTznDaXo0kk671z7etd5p1lFZxKzfM3FX7OwWHooz2qx9n81lQDL9AAelbJJmcpXKgmjCzXd9KsGn2iGeeRjgKoBJz+VfC3xh8cz/ABA8cXmrNuWyT9xZxH/lnCp4/E9T9a9s/as+IsdpbjwJoUwycSapLGfoVi/kT+A9a+X0HPTp1q3orGDd2OAxjHTsadjnvRjk+tHp781IhOvvShsD1/Gk60qjIzjP4UAS8k46HtTgc88UzODzTl6Y/P1pFEgOM4P4U8H/ABqMH2705TnHfmgZKpwOfTnFd18FviHcfDXxalw5eTQr0iO9gHOB2cD+8v6jIrglOBk5z609lEiFWAwf1o2Gfo+k9vfWcF/YTJPZ3CCSORDlWBGQR7VE/GRXyp+zZ8Wv+EYvE8J+J5/+JJcvi0nc5Fs5P3Sf7hP5Gvq27i8llIOY25Vgeo9K5a1Pl95bG1KfRlOc/KTxzWZOxXPTNaEx4rOuBwTya5zpRQkbrz/9asPVJMkgDrWxcg89+1Yd+pyfTHSgGYzMd3pTlOeD1Hao5OvofyqWP5uenpg0gGFRnjr0p8QHGM/Sn9TgfhT0TB9QeRSYXJEBI+UkcYpH56cEcVKkZIzn/wCtTjGAMnpQkSQphfXI689KmTDEg8n29ahPyt2xTlPpTEyVAckY6fpTt3XP0qNJDu+X+LjrUkiMjANg/Q1rFksZIevFU51yD+lWmZeAT659qinAB4IPGc1VxI5+9s1Z9+ME9xUUdvgHgcVrTR5JPc1EIwPQf1p3GZ5j557VDPAHQD16HvmtN48/UioXU8jGfpQBilSpw3X0qSM4PJH4elWLmEg7vaqyNx1oGXUc4OPboashuOfyqhGwwcHp05qwj5B70hk5Yg5Bxn3qUvlevPtVeIbmOKtKnAz0poLiqOARzjpzSyOcc/8A6zSDC56etNZtzYH1qiRQegyDn3pcds/So1JLHB7Z9s1fsrYysAB+tUlcTdiW0h3sBiuo0nT1AU8YHPWmaXYKo3Pjjsa37ZApwMDmqSsZt3LtnCsagKMCtGFBtHTGPXpVWFlGSew/KlmvAinnoeRmqiSy7kAcnt0zXA/G74kW/wANvCrPA0b+IL5SllAednrIw/ur+p49a1vGPjLTfA/hmbX9ek+QfLaWwPz3EmOAB/XsOa+EvHPivVPG/iW61rWpd88xwqA/LEg6Io7Af/XrVLqzKT6Ixbq4nvrya6u5XmuJnMksjnLMxOST+NNA7c9OTTlGOlAHJ/pSZImDxwKCP5UvYYFJ3xigYnTGcYpRuxwpNJzzngelIB9KQEoxz6d6cD0pvpnFOGcc420DHjp15zTu5z2pnU9MEe9KD1Pp29KBjx3PH+FPB7Zz71Hnpz79O1OzyMj/ABoGOljE0ZDZJ9cdK+jv2dfjKFW38HeNbjKHEdhfSHp6RuT+h/CvnFT+I75NJKizIOcMOQR2/Gl6gfotfW7W7kNyDyrdjWZKuTntXhHwG+OCxxQeFfHs5MfEdpqMh+72Cuf5N+dfQ95aeVtYEPCwyrryCPXNcdWlyarY6qdS+j3MKeHcuRgt0NYGoxYHqQeK694+OcYxzWPqVsDnjrWKNmcRcqVY46Zohb0q9f25Bbsf51nqSpwewzzQItKSuD1xzUqyZIC1V34XI5xyKSO4CE45I5pMRoI27j8uelPb58/z7iqS3SySEcKMdKfNKu7AoQmOLL0OcntTevPf61GHBJJ5p2ST6881QiROT2z71OoJ92zVcEBuefX2qwrgY96pEjGhY9GHsRQts7cgjH1qwzhgNqgY6YpwmHzblz0xiqQik1oxIBYYzVdrZgcA5NaDHvyMGm45HAJ6CqQFL7MccnH09KjkiUZ2itBx7DHaqsuR0oBGNqJVIj6msPdgnJroryBZgdw61iXdq0PIOQaEUNhfOfbqKnDDn6d6o7yD06U6JiW7k0DNW0JOGB+laUbAo2eeOlUbKJioJ4FXYeAcdu1UiSK5+VwW5B6c9ahdjuJORmpJCN5DfwjimOQWIzg0XAsWaBiCfp1rpdJgSNd7YNcxbz+WQWIHcVsWuphBhj075p3JaudH9owODgfWp0vdnBbHtmucfUkAJX9azp9XYnjpn1qucnlO4bU0VRh/1qrrXiLTPDegza94kn8nTov9XGD89w3ZUHeuD1rxVp3hvTpNT16UhE/1NqD887dlA9Pevm34geNtX8eayL3VZCltH8tvaofkhT0A9fU1pBGc3bQl+J/j7VPiJ4kk1HUmMdqmUtbVT8kCdgPc9zXKKNuOOacoAXjj6UN93GffFaXMrCEc9KaenPIznrTj+OKTOB056igBp7exo/i9RS9Bx+OTTT34H0oAKAAetIe9L8w6foKAJMnB9fanDnt9aYDkE49jTxnHTH1pDF9yM+1OHbPpzmmgYJ55oPA6cZ/OgY4HGO2Kf/Fnj6GmdSOvTnilHPQ84zQA8H9PWnA54pgyT15PPTpQD93PFIY6VFmXDD3yK9o+Cnxwu/CRi0Hxc0l9oDYSKc5aS2H9V9uorxfPOMf4UrBXG1wDmgD9DIZLTUNPi1LRrqO8sJl3JLG24YrJvHDKR1zXxx8NviRr/wAOr4tpsxudMZszWUpyh9SPQ+9fUPhTx54f8f2Hn6LOttqQH72ylOGB9q5KlG2sdjpp1b6MdqGMjNYU3ByPrWrqBkWYpKhUj1rKlyDx2rA2IhIe/PvVGZisvJwD2q2c5OMGo5Y9y9ASOlAMWB8Hg9O/tWhBiVwNoIz61mRblXBPA71YSYoQEbaegINFiWXZYjGcsBtx1oRsgZ/EVV82SQFSS2eetOWZVByNxrRK5BaEgPB4pyuScZzz6VSEm4g9cn86lRugz14qkhF1Xz75qVTk4OOe1U0b0OB/WrUJz9adhE4Q4Hv/ACpShxnjrUqqRyTwe1Nfv6ds0xFdzzyPY5qpMw6McVYlyePXiuW13UpbWYRxgE0m+xSNefYCDurM1Fd8DADJ6Vgy6ldSMD5xHsK2bG486IFuW7ip1W5RnW9nPLIFVCB6scVqW+nRwkeZIGPoKs+aAOuPQVA0x3ZB/GquI0UZIyc4wBVC6eTzD5ecH0NM84MByT3qPz+g70INh6EqGLE7sdT3phkx/wDrqCS4Zsg9B6VDv568Z6+lUFy35h4we2aBMykYbnr1qgZcHOTUttFJclmBCRKMvIxwqj1zRcCx9oeRlVdzMTwF6ms/xT4q0zwTaibUtt1qrrmCxQ5I/wBpz2Fcj4x+J1po4ksPCmy5vz8j37DKJ/uep9+leOXMs95dSXN9M81zI255JG3EmtI076yMp1baRLniDWr/AMSatLqGqyl5XOQgOFQeijsKoj0/AUdMnPf86O/qO9bnOJ1HPPGPxpM/QnrS56frSH15xQAh4PPIzSE8kE9+9B/kMcUZ468dqAEPHr1oAJOM9KCMcc8UnfHQUAJnoc/pScN3xjjrSg4GRQRz1FAiTPJ4569acPTpimnr0H50o4P9fWkUOH4Yx3704d+TyOabjjHJNL1x9OlAxRyQelKM/T/Ck7A9KM9OowaAHDOB1+p6U4HnI/L1pgxn3PSlz6kUAOXGMcY9jSjoCcjnmmZzyeBSjGe/vQMfuz0/M0trLPZXcd1p08ltcodwkRsEUznIP8qCSBzQB7Z4I+NiTJHp3jaEEj5Vvox0/wB4f1r1FUgv7RbvSbqO8tXGQ0bAnFfILgMNpGeK0vD3iDV/DNz5+iXskQ6tETlG+orCdGMtVozWFZx0Z9PNkMQeCD0NKOR2HPWuA8NfGPS9S2W/im0Nnc9DcR8qfc+leg2yQX8K3GlXcN5CeRsYE4rmlTlHc6FOMtirPIY35Hy9aj89RgkdfepLzegIdCv+8Kz2fPYYzkcUJXBmisnGQec5pQ3B7c1RikGOp5qyrjrmrRDLat19fSpUzn2zxVNG4P0qUOACPatEiC8P72aswTBMHrj+VZokG3nFI10FzgEk+lJsdjoI7jAyRyBnNNnvgYhGEA9CD0rmpdRn2naP/rVQ1F7twM3TRg8/J/jUjsjY1bWYrGEksC5HAHNcLeXUt7OZpQfpVpdOV5t087SH1PenvaxoSM5FC0GQQRnrjk9K0rZWQbs4zUEO0MoC8dKsmQcHP5UmwRKZGB6npnj0pN+Bz1quZM8jrjrTGk4znn1oSHcs+YR+PFMMnBOefzqo8gXjNMQyTNtiQt/IVaJuTuwweR6cUi75X2xKXc9AKxtZ13R9CUnVb5DKOlvD8zn8ulef+IfiVqV+j22iQjTbUjBccysPdu34Vag2Zuokej+INf0fwzGW1a4E12OUs4Tlj/veleT+LvHWr+Js2+77Dpg+7bQnAI/2j3rlypaQyTO0kjHJZjkk+uadxg8ZP+ea1jBRMpTchioF4H504fw46YoIwcc/Q9/ejjI6/jVkADzj9fWjuOOfWk44yMAcUg44GfoaAA5456elJ1wCPfigdulJxg44xQAdsjuaRuvr7Gl/iyMn8aT25oAOBjB/wpOMnoD/AEpQccjPHHFJ07igBPfikJOeMke1KfalAB6n9aAHY4OOhNOHQdce9P8AKHydfmpyxDBOelIZH1GDnkU4HgcjA61KIBt+8aXygW6ngUDIentS9jjOamEIOBk80v2cYbk8GgCEHrz7Y9aP4SDz3IqYQjGMnil8gYPJxigCEex49R2o6kg1P5AL7QSOmTQYBgENyTjkdKQyDPyg9e3NLwCBnOKmNuu7bk9M5pWgGOWJB9qBFfvz9PQUZ/MHGAKnaADB3E54pPJGBycHtTAhZQ2QwBHerWlalqOjXHnaRfT2sgIPyPx+I6UzyB6nilFsM43HpnpSA9I0T4y6hCiweIrCO9iHHmxja/5dDXY6b4w8K63j7LqAtJm/5ZT/AC/zrwc24GQWJApr2MbcnP4VDpxfQtVJI+lEtpHCtC8cyHvGwOaMyxlg6sD/ALQr52sbrUNLbdp2pXVvjsrnH5V0um/FjxBp0vk3nkX8YI/1q7T+Ypey7Mr2q6ntkbls+9KWzwWwTXD6X8X7GVB9t8KrKT1MV+Y//ZDWqPifoJ5HhK6XPpq//wBppOnJB7SJ0nIbAGT0p0i7QQeW7Y7VzP8Aws3QwMDwregf9hf/AO000/EzQwT/AMUref8Ag3/+01PJIftInRliG9iKqyOQCF6HrXPv8SdDPH/CL3mDz/yFh/8AGaik+I2iH/mWLz/wbf8A2ml7ORSnE2gfm6dDTJGwQBwOtYB+IOiE/wDItXnPP/IVH/xmkHxA0TIz4avPT/kK/wD2ml7OXYfPHudCrcc49RQ8o3deBziuYn+I+koP3fhmb/gWpZ/9piue1X4sTqSmn6Na2/ozyGQj9BQqcmJ1Io9IWOeXmONyPWor2W002Pfqd/a2i4zh3GT+FeI6l488Q6llZdRlijI+5BiMfpWBJKJX3z+ZLIerPJk1oqPch1ux6/q/xH0OyLJptvNqMo6Mw2JXD634517V1ZBOtlbkf6u3G3P1PWuZE0agkREf8C/+tSmdAciNv++v/rVqopbGTm3uAjyzO5Lt1JY5J/Gnc4x2/rTDMmCPLP8A31/9ajzlJ/1Z9Pvf/WpkjsgjPagnHJ4pomXH3D0/vf8A1qQTLx8hz/vf/WoGPBwe3T8qTP4npmm+auc7D/31/wDWpPNUj7p/76/+tTEP69Mn0pPQZ496b5q/3DjP96gyrgfIeB/eoAUdR6/ypM9844polXA+U/nR5i4J2n86AHN3NIeP5Z9aQyL/AHT09aTzFA4U/nQA7uOPrSdFzTfMGD8p9uaN45yCfxoAXAzk8/SgAnkE/hTdy4yV6+9G4Hqv60Af/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prolonged use of any topical antimicrobial agent may result in fungal overgrowth. Children present with thick fungal debris, as depicted above, and clogged, itchy, or painful ears.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C. Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20096=[""].join("\n");
var outline_f19_40_20096=null;
var title_f19_40_20097="Tracheomalacia bronchoscopy";
var content_f19_40_20097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Tracheomalacia by bronchoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Branchoscopic view of tracheomalacia. A) The normal status during inhalation; B) near total collapse during quiet exhalation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. P Boiselle.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20097=[""].join("\n");
var outline_f19_40_20097=null;
var title_f19_40_20098="Robotic surg robot arms";
var content_f19_40_20098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Robot-assisted laparoscopy surgical device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    da Vinci&reg; S Surgical System patient side cart",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Intuitive Surgical, Inc, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20098=[""].join("\n");
var outline_f19_40_20098=null;
var title_f19_40_20099="Acne";
var content_f19_40_20099=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acne (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/40/20099/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20099/contributors\" id=\"au8136\">",
"       Emmy Graber, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/40/20099/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20099/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20099/contributors\" id=\"se3543\">",
"       Mark V Dahl, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/40/20099/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20099/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?19/40/20099?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ACNE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Acne is a skin condition in which the pores become blocked, causing pimples to develop. Acne is the most common skin disorder in North America, affecting an estimated 85 percent of adolescents.",
"    </p>",
"    <p>",
"     Effective acne treatments are available to treat existing pimples and prevent new ones from developing. In addition, cosmetic treatments can help to reduce scarring and changes in skin color caused by acne.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW DOES ACNE DEVELOP?",
"     </span>",
"    </p>",
"    <p>",
"     There are four basic steps involved in the development of an acne lesion.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hair follicles become blocked with an overabundance of normal skin cells (",
"       <a class=\"graphic graphic_figure graphicRef73364 \" href=\"UTD.htm?27/18/27942\">",
"        figure 1",
"       </a>",
"       ). These cells combine with sebum (an oily substance that lubricates the hair and skin), creating a plug in the follicle.",
"      </li>",
"      <li>",
"       The glands that produce sebum, known as sebaceous glands, enlarge during adolescence and sebum production increases (",
"       <a class=\"graphic graphic_figure graphicRef73146 \" href=\"UTD.htm?30/10/30884\">",
"        figure 2",
"       </a>",
"       ). Numerous sebaceous glands are found on the face, neck, chest, upper back, and upper arms.",
"      </li>",
"      <li>",
"       The increase in sebum production allows for the overgrowth of bacteria that normally lives on the skin.",
"      </li>",
"      <li>",
"       Bacterial overgrowth causes local inflammation, which causes rupture of the follicle (",
"       <a class=\"graphic graphic_figure graphicRef56190 \" href=\"UTD.htm?5/12/5318\">",
"        figure 3",
"       </a>",
"       ). This can lead to the formation of a red or tender pimple.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ACNE CAUSES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Hormonal changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hormonal changes during adolescence cause the sebaceous glands to become enlarged and sebum production increases. In most people with acne, hormone levels are normal, but the sebaceous glands are highly sensitive to the hormones.",
"    </p>",
"    <p>",
"     Less often, women's hormone levels are affected by an underlying medical problem known as polycystic ovary syndrome (PCOS). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Acne tends to resolve between ages 30 to 40, although it can persist into or develop for the first time during adulthood. Post-adolescent acne predominantly affects women, in contrast to adolescent acne, which predominantly affects men. Acne can flare before a woman's menstrual period, especially in women older than 30 years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      External factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oil-based cosmetics may contribute to the development of acne. Oils and greases in hair products can also worsen skin lesions. Water-based or \"non-comedogenic\" products are less likely to worsen acne.",
"    </p>",
"    <p>",
"     People with acne often use soaps and astringents. While these treatments remove sebum from the skin surface, they do not decrease sebum production; frequent or aggressive scrubbing with these agents can actually worsen acne.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;The role of diet in acne is controversial. Some studies have found weak associations between cow's milk and an increased risk of acne, perhaps because of hormones that occur naturally in milk. However, there is no strong evidence that milk, high-fat foods or chocolate increase the risk of acne.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Stress",
"     </span>",
"     &nbsp;&mdash;&nbsp;Psychological stress can probably worsen acne. In several studies of students, acne severity appeared to worsen during times of increased stress [",
"     <a class=\"abstract\" href=\"UTD.htm?19/40/20099/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ACNE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no single best treatment for acne, and combinations of treatments are sometimes recommended. Since acne lesions take at least eight weeks to mature, you should use a treatment for a minimum of two to three months before deciding if the treatment is effective. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link\">",
"      \"Treatment of acne vulgaris\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Acne skin care",
"     </span>",
"     &nbsp;&mdash;&nbsp;Skin care is an important aspect of acne treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Skin hygiene",
"     </span>",
"     &nbsp;&mdash;&nbsp;Wash your face no more than twice daily using a gentle non-soap facial skin cleanser (eg, Cetaphil&reg;, Oil of Olay&reg; bar or foaming face wash, or Dove&reg; bar) and warm (not hot) water. Some providers recommend avoiding use of a washcloth or loofah, and instead using the hands to wash the face. Vigorous washing or scrubbing can worsen acne and damage the skin's surface.",
"    </p>",
"    <p>",
"     Do not pick or squeeze pimples because this may worsen acne and cause skin swelling and scarring. It can also cause lesions to become infected.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Moisturizers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Use of a moisturizer minimizes dryness and skin peeling, which are common side effects of some acne treatments. Moisturizers that are labeled as \"non-comedogenic\" are less likely to block skin pores.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Sun protection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some acne treatments increase the skin's sensitivity to sunlight (eg, retinoids, doxycycline). To minimize skin damage from the sun, avoid excessive sun exposure and use a sunscreen with SPF 15 or higher before sun exposure. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Can I treat my own acne?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have mild acne, you can try to treat yourself with non-prescription products initially. Non-prescription acne treatments may include salicylic acid, benzoyl peroxide, sulfur, alpha hydroxy acids, or tea tree oil, all of which are available in non- prescription strengths. A combination of these treatments may be more effective than using one single product alone. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/54/33639?source=see_link\">",
"      \"Light-based, adjunctive, and other therapies for acne vulgaris\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you do not improve after three months of using non-prescription products or you have moderate or severe acne, consult a healthcare provider for advice on the most effective treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1405677\">",
"     <span class=\"h2\">",
"      Noninflammatory acne",
"     </span>",
"     &nbsp;&mdash;&nbsp;Noninflammatory acne causes whiteheads or blackheads without redness or skin swelling (",
"     <a class=\"graphic graphic_picture graphicRef80316 \" href=\"UTD.htm?20/58/21413\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Retinoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Topical retinoid medications are often recommended for noninflammatory acne. Examples of these medications include tretinoin (Retin-A&reg;, Avita&reg;, Atralin&reg;), adapalene (Differin&reg;) and tazarotene (Tazorac&reg;).",
"    </p>",
"    <p>",
"     Retinoids are usually applied once per day, although people who develop skin irritation can reduce this to every other day or less, then increase as tolerated over time. Most people become more tolerant of retinoids over time.",
"    </p>",
"    <p>",
"     Most retinoids are available in a gel or cream. People with oily skin may prefer gels because they have a drying effect, while people with dry skin may prefer a cream.",
"    </p>",
"    <p>",
"     Retinoids can cause skin irritation. While using topical retinoids, you should apply a sunscreen with SPF 15 or greater before sun exposure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Other acne products",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who cannot tolerate retinoids may try other topical medications, such as salicylic acid, glycolic acid, or azelaic acid (Azelex&reg;, Finacea&reg;). All of these treatments can be helpful in reducing noninflammatory acne, and azelaic acid may reduce acne-related darkening of skin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Mild to moderate inflammatory acne",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mild to moderate acne with some inflammation (",
"     <a class=\"graphic graphic_picture graphicRef70916 \" href=\"UTD.htm?1/0/1027\">",
"      picture 2",
"     </a>",
"     ) is usually treated with topical retinoids (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Retinoids'",
"     </a>",
"     above), topical antibiotics, or benzoyl peroxide.",
"    </p>",
"    <p>",
"     A combination of two medications, usually benzoyl peroxide with a topical antibiotic or retinoid (eg, tretinoin), is more effective than treatment with one agent alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Benzoyl peroxide",
"     </span>",
"     &nbsp;&mdash;&nbsp;Benzoyl peroxide is usually applied twice per day. It may be combined with a topical retinoid, in which case the benzoyl peroxide is applied in the morning and the retinoid is applied at night. Benzoyl peroxide can irritate the skin, sometimes causing redness and skin flaking, and it can bleach clothing, towels, bedding, and hair.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Topical antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Topical antibiotics (creams or liquids) control the growth of acne bacteria and reduce inflammation. Topical antibiotics include erythromycin, clindamycin, sulfacetamide, and dapsone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Moderate to severe inflammatory acne",
"     </span>",
"     &nbsp;&mdash;&nbsp;For people with moderate to severe inflammatory acne (",
"     <a class=\"graphic graphic_picture graphicRef54107 \" href=\"UTD.htm?18/42/19108\">",
"      picture 3",
"     </a>",
"     ), oral antibiotics or an oral retinoid known as isotretinoin (Amnesteem&reg;, Clavaris&reg;, Sotret&reg;) may be recommended. Topical medication may be used in combination with oral treatments.",
"    </p>",
"    <p>",
"     Women often benefit from hormonal treatment with a birth control pill (see",
"     <a class=\"local\" href=\"#H23\">",
"      'Hormone therapy'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Oral antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral antibiotics work to slow the growth of acne-producing bacteria. However, oral antibiotics can have bothersome side effects, including vaginal yeast infections in women and stomach upset.",
"    </p>",
"    <p>",
"     Doxycycline and minocycline are the most commonly prescribed oral antibiotics for acne. They cannot be used during pregnancy or in children less than 9 years of age.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Oral isotretinoin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral isotretinoin (Amnesteem&trade;, Claravis&trade;, Sotret&reg;) is a potent retinoid medication that is extremely effective in the treatment of severe acne. It cures or significantly improves acne in the majority of patients. Oral isotretinoin is effective in treating the most disfiguring types of acne. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link\">",
"      \"Oral isotretinoin therapy for acne vulgaris\"",
"     </a>",
"     .) Isotretinoin used to be sold as Accutane&reg;, but that brand name is no longer available",
"    </p>",
"    <p>",
"     Oral isotretinoin is usually taken in pill form once or twice daily with food for 20 weeks, then stopped. In some cases, acne can initially worsen before it improves. To reduce the risk for this initial flare of acne, isotretinoin is sometimes given at a lower dose for the first month of treatment. After treatment is stopped, improvement can continue for up to five months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9164143\">",
"     <span class=\"h4\">",
"      Side effects and risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;Despite its positive effects, oral isotretinoin can have serious side effects and should be used with caution. Taking isotretinoin during pregnancy can cause miscarriage and life-threatening malformations in the baby. For these reasons, there are strict rules in the United States for healthcare providers, pharmacists, and patients regarding the use and prescription of oral isotretinoin. Prescriptions of isotretinoin are regulated by the iPLEDGE program (",
"     <a class=\"external\" href=\"file://www.ipledgeprogram.com/\">",
"      www.ipledgeprogram.com",
"     </a>",
"     ), which requires the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       All women must have two negative pregnancy tests before receiving a prescription, and then they must have monthly pregnancy tests throughout the course of treatment.",
"      </li>",
"      <li>",
"       Women who could become pregnant must fill their prescription within seven days of receiving it; after this time, a new prescription must be written.",
"      </li>",
"      <li>",
"       Any woman who is or might become sexually active with a male partner must use two forms of birth control for at least one month before starting therapy and continue until one month after stopping isotretinoin.",
"      </li>",
"      <li>",
"       Women who cannot become pregnant and men must also participate in iPLEDGE, but do not require pregnancy testing or use of birth control.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Information about oral isotretinoin can be found at the United States Food and Drug Administration web site, (",
"     <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085227.htm\">",
"      www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085227.htm",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     A variety of non-pregnancy related side effects may occur during isotretinoin therapy:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Dryness or peeling of skin, soreness and cracking of the lips, itching, muscle pain, nosebleeds, difficulty wearing contact lenses, and sensitivity to the sun may occur during treatment.",
"      </li>",
"      <li>",
"       There is concern about the relationship between isotretinoin and depression and suicidal behavior. While there is not enough evidence to conclude that it causes depression or suicidal behavior, patients taking isotretinoin should report any sadness, depression, or anxiety to their healthcare provider.",
"      </li>",
"      <li>",
"       Isotretinoin can cause increases in blood levels of triglycerides (fatty substances related to cholesterol), liver damage, pancreatitis, and changes in the blood counts. It is unclear whether isotretinoin treatment increases the risk for inflammatory bowel diseases such as ulcerative colitis and Crohn&rsquo;s disease.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     While many of these side effects can be managed without stopping the drug, others can be dangerous and require that you immediately stop taking it. Stay in touch with your doctor, and follow instructions for getting regular blood tests to monitor cholesterol, triglycerides, liver function, and blood counts.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Hormone therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The hormone estrogen can help to offset the effect of androgens (hormones responsible for acne development). Estrogen treatment in the form of a birth control pill is sometimes recommended for women with moderate or severe acne. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Not all oral contraceptives should be used for the treatment of acne; some can actually worsen acne. Certain types of intrauterine devices (IUDs) and some injectable forms of birth control also may worsen acne. Discuss the best options with your healthcare provider. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link\">",
"      \"Hormonal therapy for women with acne vulgaris\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other medications are available to reduce the effects of androgens in women, including spironolactone. Rarely, spironolactone can cause high blood levels of potassium. In addition, spironolactone can cause birth defects.",
"    </p>",
"    <p>",
"     The benefits of birth control pills and other hormonal medications may not be noticeable until three to six months after treatment is started.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Acne and pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many acne treatments are not safe for use during pregnancy. Women who are pregnant or intending to become pregnant should consider stopping all acne treatments before becoming pregnant. If acne therapy becomes necessary, discuss the options with your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H251\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17219199\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/14/40161?source=see_link\">",
"      Patient information: Rosacea (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/39/9842?source=see_link\">",
"      Patient information: Keloids (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/61/28626?source=see_link\">",
"      Patient information: Sertoli-Leydig cell tumor (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17219207\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/54/33639?source=see_link\">",
"      Light-based, adjunctive, and other therapies for acne vulgaris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link\">",
"      Hormonal therapy for women with acne vulgaris",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aad.org/public/publications/pamphlets/common_acne.html\">",
"        www.aad.org/public/publications/pamphlets/common_acne.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/acne.html\">",
"        www.nlm.nih.gov/medlineplus/acne.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Acne\">",
"        www.niams.nih.gov/Health_Info/Acne",
"       </a>",
"       , available in Spanish and Chinese)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?19/40/20099/abstract/2-5\">",
"      2-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 14, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?19/40/20099?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20099/abstract/1\">",
"      Chiu A, Chon SY, Kimball AB. The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. Arch Dermatol 2003; 139:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20099/abstract/2\">",
"      Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20099/abstract/3\">",
"      Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999; 63:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20099/abstract/4\">",
"      Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004; 364:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20099/abstract/5\">",
"      Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54:644.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f19_40_20099=[""].join("\n");
var outline_f19_40_20099=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ACNE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW DOES ACNE DEVELOP?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ACNE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ACNE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/18/27942\" title=\"figure 1\">",
"           Shedding epithelial cell PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/10/30884\" title=\"figure 2\">",
"           Excessive sebum PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/12/5318\" title=\"figure 3\">",
"           Inflamm follicle PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/58/21413\" title=\"picture 1\">",
"           Noninflammatory lesions PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/0/1027\" title=\"picture 2\">",
"           Inflammatory acne PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/42/19108\" title=\"picture 3\">",
"           Severe cystic acne PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20100="Recombinant human factor IX: Patient drug information";
var content_f19_40_20100=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Recombinant human factor IX: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/20/34118?source=see_link\">",
"     see \"Recombinant human factor IX: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16255881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BeneFix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16255882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BeneFix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F16328943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16328945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16328944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to Factor IX, mice, hamsters, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16328949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16328950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever and chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16328951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16328947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16328948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16328952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16328953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88614 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20100=[""].join("\n");
var outline_f19_40_20100=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328943\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328945\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328944\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328949\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328950\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328951\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328947\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328948\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328952\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328953\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/20/34118?source=related_link\">",
"      Recombinant human factor IX: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20101="Albumin: Pediatric drug information";
var content_f19_40_20101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Albumin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/59/27574?source=see_link\">",
"    see \"Albumin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/2/30755?source=see_link\">",
"    see \"Albumin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Albuked&trade; 25;",
"     </li>",
"     <li>",
"      Albuked&trade; 5;",
"     </li>",
"     <li>",
"      Albuminar&reg;-25;",
"     </li>",
"     <li>",
"      Albuminar&reg;-5;",
"     </li>",
"     <li>",
"      AlbuRx&reg; 25;",
"     </li>",
"     <li>",
"      AlbuRx&reg; 5;",
"     </li>",
"     <li>",
"      Albutein&reg;;",
"     </li>",
"     <li>",
"      Buminate;",
"     </li>",
"     <li>",
"      Flexbumin 25%;",
"     </li>",
"     <li>",
"      Human Albumin Grifols&reg; 25%;",
"     </li>",
"     <li>",
"      Kedbumin&trade;;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-25;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-5",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alburex&reg; 25;",
"     </li>",
"     <li>",
"      Alburex&reg; 5;",
"     </li>",
"     <li>",
"      Albutein 25%;",
"     </li>",
"     <li>",
"      Albutein 5%;",
"     </li>",
"     <li>",
"      Buminate-25%;",
"     </li>",
"     <li>",
"      Buminate-5%;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-25;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-5",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Plasma Volume Expander",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Albumin",
"     <b>",
"      5%",
"     </b>",
"     should be used in hypovolemic or intravascularly depleted patients; albumin",
"     <b>",
"      25%",
"     </b>",
"     should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome). Dose depends on condition of patient:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypoproteinemia: 0.5-1 g/kg/dose of 25% albumin; may repeat every 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypovolemia, hypotension: Usual dose: 0.5 g/kg/dose of 5% albumin (10 mL/kg/dose); range: 0.25-0.5 g/kg/dose of 5% albumin (5-10 mL/kg/dose)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/59/27574?source=see_link\">",
"      see \"Albumin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Albumin",
"     <b>",
"      5%",
"     </b>",
"     should be used in hypovolemic or intravascularly depleted patients; albumin",
"     <b>",
"      25%",
"     </b>",
"     should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome). Dose depends on condition of patient:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypoproteinemia: 0.5-1 g/kg/dose of 25% albumin; may repeat every 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypovolemia: 0.5-1 g/kg/dose (10-20 mL/kg/dose of 5% albumin); may repeat as needed; maximum dose: 6 g/kg/day (120 mL/kg/day of 5% albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephrotic syndrome: 0.25-1 g/kg/dose of 25% albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 25 g; no more than 250 g should be administered within 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephrotic syndrome: 12.5-50 g/day in 3-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [human, preservative free]: 5% [50 mg/mL] (250 mL, 500 mL); 20% [200 mg/mL] (50 mL, 100 mL); 25% [250 mg/mL] (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albuked&trade; 5: 5% [50 mg/mL] (250 mL) [contains sodium 145 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albuked&trade; 25: 25% [250 mg/mL] (50 mL) [contains sodium 145 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albuminar&reg;-5: 5% [50 mg/mL] (250 mL, 500 mL) [contains potassium &le;1 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albuminar&reg;-25: 25% [250 mg/mL] (50 mL, 100 mL) [contains potassium &le;1 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buminate: 5% [50 mg/mL] (250 mL, 500 mL); 25% [250 mg/mL] (20 mL) [contains natural rubber/natural latex in packaging, potassium &le;2 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flexbumin 25%: 25% [250 mg/mL] (50 mL, 100 mL) [contains potassium &le;2 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasbumin&reg;-5: 5% [50 mg/mL] (50 mL, 250 mL) [contains sodium 145 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasbumin&reg;-25: 25% [250 mg/mL] (20 mL, 50 mL, 100 mL) [contains potassium &le;2 mEq/L, sodium ~145 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [human/low aluminum formulation, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AlbuRx&reg; 5: 5% [50 mg/mL] (250 mL, 500 mL) [contains potassium &le;2 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AlbuRx&reg; 25: 25% [250 mg/mL] (50 mL, 100 mL) [contains potassium &le;2 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albutein&reg;: 5% [50 mg/mL] (250 mL, 500 mL); 25% [250 mg/mL] (50 mL, 100 mL) [contains potassium &le;2 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Human Albumin Grifols&reg; 25%: 25% [250 mg/mL] (50 mL, 100 mL) [contains potassium &le;2 mEq/L, sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kedbumin&trade;: 25% [250 mg/mL] (50 mL) [contains sodium 130-160 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasbumin&reg;-5: 5% [50 mg/mL] (50 mL, 250 mL) [contains potassium &le;2 mEq/L, sodium ~145 mEq/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasbumin&reg;-25: 25% [250 mg/mL] (20 mL, 50 mL, 100 mL) [contains potassium &le;2 mEq/L, sodium ~145 mEq/L]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes low aluminum formulation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Too rapid infusion may result in vascular overload",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Albuminar&reg;: May administer via the administration set provided (in-line 60 micron filter) or via any administration set; use of filter is optional; size of filter may vary according to institutional policy. Method of filter sterilization used by manufacturer includes 0.2 micron filter; however, aggregates may form under storage, shipping, and handling. Administration via very small filter will not damage product, but will slow flow rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Albutein&reg;: May administer via the administration set provided (in-line 50 micron filter) or via any administration set; use of filter is optional; size of filter may vary according to institutional policy. Method of production includes passage through 0.22 micron filter. May administer via filter as small as 0.22 microns.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Buminate&reg;: Administer via the administration set provided (in-line 15 micron filter) or via any filtered administration set; use &ge;5 micron filter to ensure adequate flow rate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasbumin&reg;: May administer with or without an I.V. filter; filter as small as 0.22 microns may be used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypoproteinemia: Infuse over 2-4 hours; for neonates, dose may be added to hyperalimentation fluid and infused over 24 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Hyperalimentation fluid containing &gt;25 g/L of albumin is more likely to occlude 0.22 micron in-line filters; but hyperalimentation solutions containing albumin in concentrations as low as 10.8 g/L have also occluded 0.22 micron filters; use &ge;5 micron filter to ensure adequate flow rate; addition of albumin to hyperalimentation solutions may increase potential for growth of bacteria or fungi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypovolemia: Rate of infusion depends on severity of hypovolemia and patient's symptoms; usually infuse dose over 30-60 minutes (faster infusion rates may be clinically necessary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum rates of I.V. infusion after initial volume replacement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5%: 2-4 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25%: 1 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     To prepare 5% albumin from 25%, see Precautions.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F130927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in D",
"     <sub>",
"      5",
"     </sub>",
"     W, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sterile water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diltiazem, lorazepam.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Drotrecogin alfa, fat emulsion (Intralipid&reg;), micafungin, midazolam, vancomycin, verapamil.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use within 4 hours after opening vial, do not use if turbid or contains a deposit; do not use SWI to dilute albumin",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypovolemia; plasma volume expansion and maintenance of cardiac output in the treatment of certain types of shock or impending shock; hypoproteinemia resulting in generalized edema or decreased intravascular volume (eg, hypoproteinemia associated with acute nephrotic syndrome, premature neonates)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     PALS and Neonatal Resuscitation 2000 Guidelines recommend isotonic crystalloid solutions (eg, NS or LR) as initial volume expansion; albumin is used less frequently due to limited supply, potential risk of infections, and an association with an increase in mortality (identified by meta-analyses); few studies in these analyses included children, so no firm conclusions in pediatric patients can be made",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F130929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Albutein&reg; may be confused with albuterol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Buminate&reg; may be confused with bumetanide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F130926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: CHF precipitation, edema, hypertension, hypervolemia, hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to albumin or any component; patients with severe anemia or cardiac failure",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapid infusion of albumin solutions may cause vascular overload. Do not administer albumin to burn patients for the first 24 hours after the burn (capillary exudation of albumin will occur); use with caution in patients with hepatic or renal failure (added protein load) and in patients who require sodium restriction; monitor for signs of hypervolemia",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Due to the occasional shortage of 5% human albumin, 5% solutions may at times be prepared by diluting 25% human albumin with NS or with D",
"     <sub>",
"      5",
"     </sub>",
"     W (if sodium load is a concern); however,",
"     <b>",
"      do not use sterile water",
"     </b>",
"     to dilute albumin solutions, as this may result in hypotonic-associated hemolysis which can be fatal",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use 25% concentration with extreme caution and infuse slowly in preterm neonates, due to increased risk of IVH (from rapid expansion of intravascular volume). Some products (eg, Albuminar&reg;, Buminate&reg;) contain natural rubber latex (in certain components of the product packaging) which may cause allergic reactions in susceptible individuals; avoid use in patients with allergy to latex",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13334387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Albumin is used for the treatment of ovarian hyperstimulation syndrome (ASRM, 2008). Use for other indications may be considered in pregnant women when contraindications to nonprotein colloids exist (Liumbruno, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs of hypervolemia, pulmonary edema, cardiac failure, vital signs, I &amp; O, Hgb, Hct, urine specific gravity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provides increase in intravascular oncotic pressure and causes mobilization of fluids from interstitial into intravascular space",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration of volume expansion: &sim;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life: 21 days",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In certain conditions (eg, hypoproteinemia with generalized edema, nephrotic syndrome), doses of albumin may be followed with I.V. furosemide: 0.5-1 mg/kg/dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Both albumin 5% and 25% contain 130-160 mEq/L of sodium; albumin 5% is osmotically equivalent to an equal volume of plasma; albumin 25% is osmotically equivalent to 5 times its volume of plasma.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Department Health and Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Part 10: Pediatric Advanced Life Support, The American Heart Association in Collaboration With the International Liaison Committee on Resuscitation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(8 Suppl):I306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20101/abstract-text/10966679/pubmed\" id=\"10966679\" target=\"_blank\">",
"        10966679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Part 11: Neonatal Resuscitation, The American Heart Association in Collaboration With the International Liaison Committee on Resuscitation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(8 Suppl):I352.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20101/abstract-text/10966680/pubmed\" id=\"10966680\" target=\"_blank\">",
"        10966680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Hemolysis Associated With 25% Human Albumin Diluted With Sterile Water - United States, 1994-1998,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1999, 48(8):157-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20101/abstract-text/10079061/pubmed\" id=\"10079061\" target=\"_blank\">",
"        10079061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynch SK, Mullett MD, Graeber JE, et al, \"A Comparison of Albumin-Bolus Therapy Versus Normal Saline-Bolus Therapy for Hypotension in Neonates,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2008, 28(1):29-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20101/abstract-text/17989698/pubmed\" id=\"17989698\" target=\"_blank\">",
"        17989698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13277 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20101=[""].join("\n");
var outline_f19_40_20101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130904\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050830\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431407\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050824\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130890\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130876\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050833\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130927\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050826\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050832\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130929\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130926\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050837\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050823\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050822\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298693\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130884\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130886\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334387\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050829\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050821\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050835\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050836\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050838\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13277|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/59/27574?source=related_link\">",
"      Albumin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/2/30755?source=related_link\">",
"      Albumin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20102="Antithymocyte globulin (equine, Atgam): Drug information";
var content_f19_40_20102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antithymocyte globulin (equine, Atgam): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/27/26036?source=see_link\">",
"    see \"Antithymocyte globulin (equine, Atgam): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/20/22853?source=see_link\">",
"    see \"Antithymocyte globulin (equine, Atgam): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atgam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atgam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Immune Globulin;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent;",
"     </li>",
"     <li>",
"      Polyclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     An intradermal skin test is recommended prior to administration of the initial dose of ATG; use 0.1 mL of a fresh 1:1000 dilution of ATG in normal saline; observe every 15-20 minutes for 1 hour. A positive skin reaction consists of a wheal &ge;10 mm in diameter. If a positive skin test occurs, the first infusion should be administered in a controlled environment with intensive life support immediately available. A systemic reaction precludes further administration of the drug. The absence of a reaction does",
"     <b>",
"      not",
"     </b>",
"     preclude the possibility of an immediate sensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with diphenhydramine, hydrocortisone, and acetaminophen is recommended prior to first dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aplastic anemia protocol:",
"     </b>",
"     I.V.: 10-20 mg/kg/day for 8-14 days, then give every other day for 7 more doses for a total of 21 doses in 28 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     40 mg/kg/day for 4 days (Rosenfeld, 1995).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal allograft rejection, prevention:",
"     </b>",
"     I.V.: 15 mg/kg/day for 14 days, then give every other day for 7 more doses for a total of 21 doses in 28 days; the initial dose should be administered within 24 hours before or after transplantation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal allograft rejection, treatment:",
"     </b>",
"     I.V.: 10-15 mg/kg/day for 14 days, then administer every other day for 7 more doses for a total of 21 doses in 28 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute GVHD treatment (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/kg/dose every other day for 6 doses (MacMillan, 2007)",
"     <b>",
"      or",
"     </b>",
"     15 mg/kg/dose twice daily for 10 doses (MacMillan, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myelodysplastic syndrome (unlabeled use):",
"     </b>",
"     I.V.: 40 mg/kg/dose once daily for 4 days; an intradermal test dose was administered prior to treatment (Molldrem, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/20/22853?source=see_link\">",
"      see \"Antithymocyte globulin (equine, Atgam): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     See adult dosing for notes on intradermal skin testing and premedication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aplastic anemia protocol:",
"     </b>",
"     I.V.: 10-20 mg/kg/day for 8-14 days; then administer every other day for 7 more doses; additional doses may be given every other day for 21 total doses in 28 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     Children &gt;10 kg: 40 mg/kg/day for 4 days (Rosenfeld, 1995).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal allograft:",
"     </b>",
"     I.V.: 5-25 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute GVHD treatment (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/kg/dose every other day for 6 doses (MacMillan, 2007)",
"     <b>",
"      or",
"     </b>",
"     15 mg/kg/dose twice daily for 10 doses (MacMillan, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9885370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Anaphylaxis: Stop infusion immediately; administer epinephrine. May require corticosteroids, respiration assistance, and/or other resuscitative measures. Do not resume infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemolysis (severe and unremitting): May require discontinuation of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atgam&reg;: 50 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse dose over at least 4 hours. Any severe systemic reaction to the skin test, such as generalized rash, tachycardia, dyspnea, hypotension, or anaphylaxis, should preclude further therapy. Epinephrine and resuscitative equipment should be nearby. Patient may need to be pretreated with an antipyretic, antihistamine, and/or corticosteroid. Mild itching and erythema can be treated with antihistamines. May cause vein irritation (chemical phlebitis) if administered peripherally. Infuse into a vascular shunt, arterial venous fistula, or high-flow central vein through a 0.2-1 micron in-line filter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     First dose: Premedicate with diphenhydramine orally 30 minutes prior to and hydrocortisone I.V. 15 minutes prior to infusion and acetaminophen 2 hours after start of infusion.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of acute renal allograft rejection; treatment of moderate-to-severe aplastic anemia in patients not considered suitable candidates for bone marrow transplantation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F190631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of other solid organ allograft rejection; prevention or treatment of graft-versus-host disease (GVHD) following allogeneic stem cell transplantation; treatment of myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F190640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Antithymocyte globulin equine (Atgam&reg;) may be confused with antithymocyte globulin rabbit (Thymoglobulin&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Atgam&reg; may be confused with Ativan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria, wheal/flare",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac irregularity, chest pain, edema, heart failure, hyper-/hypotension, myocarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, encephalitis, lethargy, lightheadedness, listlessness, seizure, viral encephalopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatosplenomegaly, liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (pain, redness, swelling), phlebitis, thrombophlebitis, burning soles/palms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Aches, back pain, joint stiffness, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria, renal function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, pleural effusion, respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, diaphoresis, lymphadenopathy, night sweats, serum sickness, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening: Abdominal pain, acute renal failure, anaphylactoid reaction, anemia, aplasia, apnea, confusion, cough, deep vein thrombosis, disorientation, dizziness, eosinophilia, epigastric pain, epistaxis, erythema, faintness, flank pain, GI bleeding, GI perforation, granulocytopenia, hemolysis, hemolytic anemia, herpes simplex reactivation, hiccups, hyperglycemia, iliac vein obstruction, infection, involuntary movement, kidney enlarged/ruptured, laryngospasm, malaise, neutropenia, pancytopenia, paresthesia, pulmonary edema, renal artery thrombosis, rigidity, sore mouth/throat, tachycardia, toxic epidermal necrosis, tremor, vasculitis, viral hepatitis, weakness, wound dehiscence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of severe systemic reaction to prior administration of antithymocyte globulin or other equine gamma globulins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity and anaphylactic reactions can occur; discontinue for symptoms of anaphylaxis; immediate treatment (including epinephrine 1:1000) should be available. Rash, dyspnea, hypotension, tachycardia, or anaphylaxis precludes further administration of the drug. Respiratory distress, hypotension, or pain (chest, flank, or back) may indicate an anaphylactoid/anaphylactic reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic toxicity: Discontinue if severe and unremitting leukopenia or thrombocytopenia occur in transplant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis: Clinically significant hemolysis has been reported (rarely). Severe and unremitting hemolysis may require treatment discontinuation. Chest, flank or back pain may indicate hemolysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Monitor closely for signs of infection; there may be an increased incidence of cytomegalovirus (CMV) infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Discontinue if severe and unremitting thrombocytopenia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Must be administered via central line due to chemical phlebitis. Dose must be administered over at least 4 hours; patient may need to be pretreated with an antipyretic, antihistamine, and/or corticosteroid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Disease transmission: Product of equine and human plasma; may have a risk of transmitting disease, including a theoretical risk of Creutzfeldt-Jakob disease (CJD).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should only be used by physicians experienced in immunosuppressive therapy or management of solid organ or bone marrow transplant patients. Adequate laboratory and supportive medical resources must be readily available in the facility for patient management.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potency: Product potency and activity may vary from lot to lot.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin testing: Intradermal skin testing is recommended prior to first-dose administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F190606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted; use during pregnancy is not recommended. Use in pregnant women is not recommended and should be considered only in exceptional circumstances. Women exposed to Atgam&reg; during pregnancy may be enrolled in the National Transplantation Pregnancy Registry (877-955-6877).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F190625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Atgam Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (5 mL): $884.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F190597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lymphocyte profile, CBC with differential and platelet count, vital signs during administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atgam (AU, BG, IN, MY, NZ, SG);",
"     </li>",
"     <li>",
"      Lymphoglobuline (TW);",
"     </li>",
"     <li>",
"      Thymogam (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunosuppressant involved in the elimination of antigen-reactive T lymphocytes (killer cells) in peripheral blood or alteration in the function of T-lymphocytes, which are involved in humoral immunity and partly in cell-mediated immunity; induces complete or partial hematologic response in aplastic anemia",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Poorly into lymphoid tissues; binds to circulating lymphocytes, granulocytes, platelets, bone marrow cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, plasma: 1.5-12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brunstein CG, Barker JN, Weisdorf DJ, et al, &ldquo;Umbilical Cord Blood Transplantation After Nonmyeloablative Conditioning: Impact on Transplantation Outcomes in 110 Adults With Hematologic Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(8):3064-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/17569820/pubmed\" id=\"17569820\" target=\"_blank\">",
"        17569820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hardinger KL, Rhee S, Buchanan P, et al, &ldquo;A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10 Year Results,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2008, 86(7):947-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/18852661/pubmed\" id=\"18852661\" target=\"_blank\">",
"        18852661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacMillan ML, Couriel D, Weisdorf DJ, et al, &ldquo;A Phase 2/3 Multicenter Randomized Clinical Trial of ABX-CBL versus ATG as Secondary Therapy for Steroid-Resistant Acute Graft-Versus-Host-Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(6):2657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/17110457/pubmed\" id=\"17110457\" target=\"_blank\">",
"        17110457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacMillan ML, Weisdorf DJ, Davies SM, et al, &ldquo;Early Antithymocyte Globulin Therapy Improves Survival in Patients With Steroid-Resistant Acute Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2002, 8(1):40-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molldrem JJ, Caples M, Mavroudis D, et al, &ldquo;Antithymocyte Globulin for Patients With Myelodysplastic Syndrome,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1997, 99(3):699-705.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/9401087/pubmed\" id=\"9401087\" target=\"_blank\">",
"        9401087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molldrem JJ, Leifer E, Bahceci E, et al, &ldquo;Antithymocyte Globulin for Treatment of Bone Marrow Failure Associated With Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Ann Intern Med,",
"      </i>",
"      2002, 137(3):156-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/12160363/pubmed\" id=\"12160363\" target=\"_blank\">",
"        12160363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenfeld SJ, Kimball J, Vining D, et al, &ldquo;Intensive Immunosuppression With Antithymocyte Globulin and Cyclosporine as Treatment for Severe Acquired Aplastic Anemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(11):3058-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/7756640/pubmed\" id=\"7756640\" target=\"_blank\">",
"        7756640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor DO, Edwards LB, Aurora P, et al, &ldquo;Registry of the International Society for Heart and Lung Transplantation: Twenty-Fifth Official Adult Heart Transplant Report - 2008,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2008; 27(9):943-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/18765186/pubmed\" id=\"18765186\" target=\"_blank\">",
"        18765186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whitehead B, James I, Helms P, et al, &ldquo;Intensive Care Management of Children Following Heart and Heart-Lung Transplantation,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 1990, 16(7):426-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/40/20102/abstract-text/2269710/pubmed\" id=\"2269710\" target=\"_blank\">",
"        2269710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9107 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20102=[""].join("\n");
var outline_f19_40_20102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708631\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190616\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190617\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190635\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190618\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190629\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190619\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9885370\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190599\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190586\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190601\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190600\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190631\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190640\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190633\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190604\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190590\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298763\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190595\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190606\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190625\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323348\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190597\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038667\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190589\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190603\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9107|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/27/26036?source=related_link\">",
"      Antithymocyte globulin (equine, Atgam): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/20/22853?source=related_link\">",
"      Antithymocyte globulin (equine, Atgam): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20103="Opioid withdrawal in adolescents";
var content_f19_40_20103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Opioid withdrawal in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20103/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20103/contributors\">",
"     Kevin C Osterhoudt, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20103/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20103/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/40/20103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids have analgesic and central nervous system (CNS) depressant effects and the potential to cause euphoria.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     Morphine",
"    </a>",
"    is the prototypic opioid. Heroin is a derivative of morphine and is a commonly abused opioid.",
"   </p>",
"   <p>",
"    Opioids are effective in the treatment of acute and chronic pain as analgesics and sedatives and as anesthetic agents. They have the potential to be abused for these effects and the associated feeling of euphoria. The epidemiology, pharmacology, clinical manifestations, and management of opioid withdrawal in adolescents are reviewed here. Opioid withdrawal in the neonate and acute opioid intoxication in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link\">",
"     \"Opioid intoxication in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioid abuse, intoxication, withdrawal, and treatment in adults are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS OF OPIOID WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tolerance and physical and psychologic dependence on opioids usually occur after three weeks of daily usage. Higher tolerance is created as the user decreases the interval and increases the dose to achieve euphoria. Tolerance does not develop to the following physiologic effects: miosis, constipation, or respiratory depression.",
"   </p>",
"   <p>",
"    Heroin,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/13/3289?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    have great addictive potential. Heroin provides a \"rush\" because it easily crosses the blood brain barrier and can be used by multiple routes. Hydromorphone is almost 100 times more potent than is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"     codeine",
"    </a>",
"    for analgesic effect. Methadone is long-acting. Codeine, a prescription drug that must be ingested orally, has weaker analgesic effects and a lower addictive potential.",
"   </p>",
"   <p>",
"    The discontinuation of opioids leads to a constellation of withdrawal symptoms known as the abstinence syndrome (",
"    <a class=\"graphic graphic_table graphicRef78321 \" href=\"UTD.htm?3/26/3499\">",
"     table 1",
"    </a>",
"    ). The severity of the abstinence syndrome depends upon the type and frequency of the drug used. The abstinence syndrome usually is elicited if opioid use is discontinued after several months of daily usage.",
"   </p>",
"   <p>",
"    Withdrawal symptoms occur in stages, depending upon the time of the last dose and the elimination time of the drug, the typical findings are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three to four hours after blood levels decline &ndash; Drug craving, anxiety, fear of withdrawal",
"     </li>",
"     <li>",
"      Eight to 14 hours &ndash; Anxiety, restlessness, insomnia, yawning, rhinorrhea, lacrimation, diaphoresis, stomach cramps, and mydriasis",
"     </li>",
"     <li>",
"      One to three days &ndash; Tremor, muscle spasms, vomiting, diarrhea, hypertension, tachycardia, fever, chills, and piloerection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1692947\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of opioid withdrawal in adolescents are similar to those seen in adults (",
"    <a class=\"graphic graphic_table graphicRef81045 \" href=\"UTD.htm?21/47/22267\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12678872\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In opioid-dependent individuals, opioid withdrawal may begin immediately after receiving an antagonist, or after cessation of use. Partial agonists (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/29/26071?source=see_link\">",
"     buprenorphine",
"    </a>",
"    ) and agonist-antagonists (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5382?source=see_link\">",
"     pentazocine",
"    </a>",
"    ) can also produce withdrawal, so for the purpose of this review, the term \"antagonist\" will be discussed in relation to these drugs as well.",
"   </p>",
"   <p>",
"    Signs and symptoms of withdrawal may begin 6 to 12 hours after the last dose of a short-acting opioid and 24 to 48 hours after cessation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    . Withdrawal symptoms typically peak within 24 to 48 hours of onset, but may persist for several days with short-acting agents and up to two weeks with methadone.",
"   </p>",
"   <p>",
"    Patients experiencing opioid withdrawal may complain of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysphoria and restlessness",
"     </li>",
"     <li>",
"      Rhinorrhea and lacrimation",
"     </li>",
"     <li>",
"      Myalgias and arthralgias",
"     </li>",
"     <li>",
"      Nausea, vomiting, abdominal cramping, and diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some or all of these symptoms may be present, and the severity depends on the individual's tolerance to opioids, the continued presence of opioid in the serum and end organs, and the duration of time over which the withdrawal has occurred. As an example, a person who is tolerant to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    who was administered two milligrams of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    intravenously would experience much more severe symptoms than someone taking 10 mg of methadone daily who stopped abruptly (ie, \"cold turkey\"). A thorough history should ascertain why the patient discontinued opioid use to ensure there is not another underlying medical condition that precluded them from obtaining the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12678879\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid withdrawal is characterized by mydriasis (pupillary dilation), yawning, increased bowel sounds, and piloerection (",
"    <a class=\"graphic graphic_table graphicRef81045 \" href=\"UTD.htm?21/47/22267\">",
"     table 2",
"    </a>",
"    ). If the patient is in severe distress, heart rate, blood pressure, and respiratory rate may be increased. Hypotension may be present in the setting of volume depletion from vomiting and diarrhea. Temperature is normal, and with the exception of very severe cases, mental status is preserved.",
"   </p>",
"   <p>",
"    Most patients in opioid withdrawal have good insight into their problem, and the diagnosis is usually established by history alone. When present, the findings of yawning and lacrimation are helpful because of their specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693162\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid withdrawal may appear similar to other withdrawal or intoxication syndromes. However, significant tachycardia or hypertension is rare. Many patients in opioid withdrawal have a pulse and blood pressure within normal limits. Although some in opioid withdrawal have a tachycardia that reflects their agitation, discomfort, or hypovolemia, only a small minority of patients manifest both hypertension and tachycardia. When present, these signs are almost always a result of a surge in catecholamines from iatrogenically-induced withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link&amp;anchor=H7#H7\">",
"     \"Opioid withdrawal in the emergency setting\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693195\">",
"    <span class=\"h2\">",
"     Ethanol withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethanol withdrawal may present with a broad spectrum of severity and vital sign abnormalities. It is much more likely to cause tachycardia and hypertension than opioid withdrawal. In contrast to opioid withdrawal, seizures and altered mental status may be prominent.",
"   </p>",
"   <p>",
"    A rapid overview of moderate and severe ethanol withdrawal is provided (",
"    <a class=\"graphic graphic_table graphicRef64745 \" href=\"UTD.htm?15/18/15661\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693203\">",
"    <span class=\"h2\">",
"     Sedative-hypnotic withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to ethanol withdrawal, patients with sedative-hypnotic withdrawal are more likely to have tachycardia and hypertension than patients with opioid withdrawal. Unlike typical opioid withdrawal, sedative-hypnotic withdrawal may cause seizures and hyperthermia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link&amp;anchor=H16#H16\">",
"     \"Benzodiazepine poisoning and withdrawal\", section on 'Withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693211\">",
"    <span class=\"h2\">",
"     Sympathomimetic intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine, amphetamine, or other sympathomimetic intoxication may produce mydriasis, agitation, tachycardia, and hypertension, but these findings are usually much more severe than occur in opioid withdrawal. Severe sympathomimetic intoxication is associated with seizures and hyperthermia which is not seen with typical opioid withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"     \"Methamphetamine intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H2#H2\">",
"     \"Designer drugs of abuse\", section on 'Amphetamine analogs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H20#H20\">",
"     \"Designer drugs of abuse\", section on 'Methcathinone analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693219\">",
"    <span class=\"h2\">",
"     Cholinergic poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poisoning with cholinergic agents (eg, organophosphates or carbamates) may cause diarrhea and vomiting, but can be distinguished from opioid withdrawal by the presence of altered mental status, bradycardia, and salivation. In patients with organophosphate poisoning, fasciculations, muscle weakness, and seizures may occur, which would further differentiate that clinical entity from opiate withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link&amp;anchor=H3#H3\">",
"     \"Organophosphate and carbamate poisoning\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rapid overview for the treatment of organophosphate and carbamate poisoning is provided (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"UTD.htm?18/23/18813\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF OPIOID WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview of the treatment of opioid withdrawal is provided (",
"    <a class=\"graphic graphic_table graphicRef68306 \" href=\"UTD.htm?22/15/22780\">",
"     table 5",
"    </a>",
"    ). Limited evidence exists regarding the efficacy of opioid detoxification in adolescents and pharmacologic therapies are primarily derived from experience in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/1\">",
"     1",
"    </a>",
"    ]. In the emergency setting, administration of any pure opioid agonist will be able to abort abstinence symptoms, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    may also reduce symptom severity. The long acting opioid agonist",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    is commonly used to eliminate withdrawal symptoms and to provide a means for weaning.",
"   </p>",
"   <p>",
"    Drug dependence is pharmacologic (withdrawal symptoms occur when drug use is discontinued) and psychologic (compulsive drug use despite problems related to use, inability to reduce the frequency or intensity of use, preoccupation with drug-seeking behavior) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the treatment of adolescents with opioid addiction requires medical, behavioral, and psychologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short and long-acting opioids may be used in the medical management of opioid withdrawal. Short-acting drugs (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    ) are preferred when the patient is in a monitored setting; long-acting agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    ) are more convenient to use and are preferred in medically stable patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     Methadone",
"    </a>",
"    , a long-acting opioid with a half-life of 24 to 36 hours, is the cornerstone of medical therapy for opioid addiction (",
"    <a class=\"graphic graphic_table graphicRef54978 \" href=\"UTD.htm?37/35/38460\">",
"     table 6",
"    </a>",
"    ). Its use relieves opioid craving and withdrawal symptoms and when given in sufficient doses, blocks the euphoric effects of opioids. Methadone detoxification involves the use of tapering doses of methadone to achieve a smooth transition from opioid use to a drug-free state.",
"   </p>",
"   <p>",
"    A method of treating opioid withdrawal symptoms using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    without causing over-sedation or severe patient discomfort is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other withdrawal symptoms (eg, pain, muscle spasm, diarrhea) can be treated with NSAIDs, analgesics, muscle relaxants, and antidiarrheals (",
"    <a class=\"graphic graphic_table graphicRef54978 \" href=\"UTD.htm?37/35/38460\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who need analgesia for coexisting medical problems during",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    treatment should be treated with NSAIDS if possible. Narcotics with antagonist action (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5382?source=see_link\">",
"     pentazocine",
"    </a>",
"    [Talwin],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/15/26869?source=see_link\">",
"     nalbuphine",
"    </a>",
"    [Nubain], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    [Stadol]) should be",
"    <strong>",
"     avoided",
"    </strong>",
"    because they can precipitate immediate withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/29/26071?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    , a partial opioid agonist, is effective for detoxification in adults but experience in adolescents is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     Clonidine",
"    </a>",
"    may be used as an alternative to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    treatment. It decreases withdrawal symptoms by blocking the release of norepinephrine. It can be used with methadone when methadone is tapered below 15 mg. In higher doses (greater than 1.2 mg per day), clonidine can cause dry mouth, sedation, orthostasis, and constipation. Patients taking clonidine should be monitored for hypotension. The use of clonidine to manage acute withdrawal from opioids is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rapid detoxification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrarapid Opioid Detoxification has been extensively promoted as a faster, more comfortable means of stopping use. In this practice, opioid antagonists are administered under general anesthesia or heavy sedation with the intent of producing withdrawal. These methods are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link&amp;anchor=H12#H12\">",
"     \"Opioid withdrawal in the emergency setting\", section on 'Ultrarapid opioid detoxification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1692489\">",
"    <span class=\"h1\">",
"     TREATMENT PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of relapse after detoxification for heroin use requires proper aftercare in a comprehensive, long-term program. Important factors to consider before discharge from a short-stay detoxification unit include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The extent and duration of drug abuse",
"     </li>",
"     <li>",
"      The integrity and function of the nuclear family",
"     </li>",
"     <li>",
"      The use of alcohol or drugs by family members",
"     </li>",
"     <li>",
"      The risk of suicide",
"     </li>",
"     <li>",
"      The current major life stressors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adolescents with opioid addiction should be assessed for dual diagnoses (eg, addiction and depression) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. They usually require long-term treatment that is of moderate intensity with individual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    group counseling and serial spot urine tests for drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/3\">",
"     3",
"    </a>",
"    ]. The effects of attendance at 12-step groups, such as Alcoholics Anonymous or Narcotics Anonymous, have not been evaluated in teenagers with opiate addiction. Such programs are believed by many addiction specialists to decrease the rate of relapse.",
"   </p>",
"   <p>",
"    Long-term addiction treatment options for adolescent opioid users include residence in a drug-free community, outpatient day programs, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1692511\">",
"    <span class=\"h2\">",
"     Residential programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic residential treatment programs usually focus on behavior therapy. However, certain models allow the use of pharmacologic interventions, particularly for detoxification. The structured atmosphere of these therapeutic communities usually is best for adolescents who lack family support, are involved in criminal activities or prostitution, have run away from home, or have relapsed with protocols of lesser intensity. Treatment usually is required for 12 to 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding the outcomes of adolescent graduates of drug-treatment programs for opiate abuse are lacking. However, 40 to 60 percent of adolescent marijuana, alcohol, or cocaine users who completed long-term programs remained abstinent, had jobs, and were not involved with the police or judicial system [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1692518\">",
"    <span class=\"h2\">",
"     Outpatient day programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient treatment usually focuses on individual, group, or family counseling and other services (eg, skills training and educational supports). However, some programs may offer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance or prescribed medications to ameliorate prolonged withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outpatient day programs may be successful for adolescents who have family support and can still attend school or keep a job or for those who have received treatment in a therapeutic community. However, day programs are not the best first-line aftercare program for most adolescents who require removal from their family, school, and social environments to avoid relapse. Day programs are not appropriate for adolescents who have serious medical or psychiatric disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence is very limited regarding the best approach to maintenance of abstinence in opioid addicted adolescents. Two intervention studies published during the past three decades did not evaluate",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    , the most commonly used medication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1692649\">",
"    <span class=\"h2\">",
"     Non-pharmacologic support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-pharmacologic support services are crucial to successful maintenance therapy. The immediate institution of these services leads to higher retention and more comprehensive and effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/8\">",
"     8",
"    </a>",
"    ]. These support services include treatment for comorbid psychiatric disorders, behavior therapy, ongoing substance abuse counseling, and other psychosocial therapies. Vocational rehabilitation is a useful adjunct to the treatment program because stable employment is a good predictor of clinical outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The daily oral administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    has been used in the United States and abroad to successfully treat tens of thousands of individuals who are dependent upon opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/9\">",
"     9",
"    </a>",
"    ]. Methadone maintenance programs must be licensed by the Food and Drug Administration (FDA) and are required to provide counseling and social services in addition to dispensing methadone. They are subject to state and federal laws.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance programs usually require their participants to be at least 18 years old and to be physically dependent on opiates for at least one year (continuously or intermittently over several years). Teenagers who are younger than 18 years of age may be admitted to methadone maintenance programs if they have current physical dependence and have had two previous attempts at detoxification or drug-free substance abuse treatment. Consent of a designated responsible adult, such as a parent or guardian, is required.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of opioid abuse and dependence\", section on 'Methadone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/29/26071?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    , a partial opioid agonist, effective for maintenance in adults, but studies in adolescents are limited. In one randomized trial, adolescents who received buprenorphine for withdrawal therapy had significantly higher retention in treatment than those who received",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/10\">",
"     10",
"    </a>",
"    ]. Another trial of 154 adolescents comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/5/41046?source=see_link\">",
"     buprenorphine-naloxone",
"    </a>",
"    maintenance for nine weeks versus 14 days of buprenorphine detoxification found that maintenance therapy was associated with a 63 percent lower dropout rate (95% CI: 0.25-0.54) and a 27 percent reduction in reported heroin use (95% CI: 0.57-0.95) versus detoxification. However, the frequency of positive urine drug screens at the end of one year or use of other substances of abuse did not differ between the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/29/26071?source=see_link\">",
"     buprenorphine",
"    </a>",
"    for the treatment of opioid dependence in adults is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of opioid abuse and dependence\", section on 'Buprenorphine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the prognosis for the adolescent with opioid addiction is poor. A systematic review of observational studies found that length of time in treatment was the best predictor of outcome as opposed to modality of treatment (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance, therapeutic communities, psychotherapy, short-term detoxification or long-term detoxification) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/12\">",
"     12",
"    </a>",
"    ]. Most patients relapse and require a lifetime of therapy. In one 10-year follow-up study of adolescents enrolled in a methadone maintenance program in New York City, the relapse rate was 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20103/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood for successful treatment increases with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration in the treatment program",
"     </li>",
"     <li>",
"      Skills training that is linked to treatment",
"     </li>",
"     <li>",
"      Family therapy",
"     </li>",
"     <li>",
"      Maintenance of school or other educational program",
"     </li>",
"     <li>",
"      Older age at initiation of drug use",
"     </li>",
"     <li>",
"      Avoidance of criminal activity and recreational drug use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14461782\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview for the management of opioid withdrawal (",
"    <a class=\"graphic graphic_table graphicRef68306 \" href=\"UTD.htm?22/15/22780\">",
"     table 5",
"    </a>",
"    ) and a medication table are provided (",
"    <a class=\"graphic graphic_table graphicRef54978 \" href=\"UTD.htm?37/35/38460\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The discontinuation of opioids leads to a constellation of withdrawal symptoms known as the abstinence syndrome (",
"      <a class=\"graphic graphic_table graphicRef78321 \" href=\"UTD.htm?3/26/3499\">",
"       table 1",
"      </a>",
"      ). The severity of the abstinence syndrome depends upon the type and frequency of the drug used. The withdrawal syndrome usually is elicited if opioid use is discontinued after several months of daily usage (three to four times per day). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms of opioid withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of opioid withdrawal in adolescents are similar to adults and pharmacologic management is also similar (",
"      <a class=\"graphic graphic_table graphicRef81045 \" href=\"UTD.htm?21/47/22267\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1692947\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioid withdrawal may appear similar to other withdrawal or intoxication syndromes. However, significant tachycardia or hypertension is rare. In addition, mental status is normal in patients with opioid withdrawal and seizures do not occur. (See",
"      <a class=\"local\" href=\"#H1693162\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of adolescents with opioid addiction requires medical, behavioral, and psychologic therapy. Short and long-acting opioids may be used in the medical management of opioid withdrawal (",
"      <a class=\"graphic graphic_table graphicRef54978 \" href=\"UTD.htm?37/35/38460\">",
"       table 6",
"      </a>",
"      ). Short-acting drugs (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      ) are preferred when the patient is in a monitored setting; long-acting agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"       methadone",
"      </a>",
"      ) are more convenient to use and are preferred in medically stable patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management of opioid withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevention of relapse after detoxification for heroin use requires proper aftercare in a comprehensive, long-term program. Long-term addiction treatment options for adolescent opioid users include residence in a drug-free community, outpatient day programs, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance programs. (See",
"      <a class=\"local\" href=\"#H1692489\">",
"       'Treatment programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-pharmacologic support services are crucial to successful maintenance therapy. The immediate institution of these services leads to higher retention and more comprehensive and effective treatment. These support services include treatment for comorbid psychiatric disorders, behavior therapy, ongoing substance abuse counseling, and other psychosocial therapies. Vocational rehabilitation is a useful adjunct to the treatment program because stable employment is a good predictor of clinical outcome. (See",
"      <a class=\"local\" href=\"#H1692649\">",
"       'Non-pharmacologic support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"       Methadone",
"      </a>",
"      is most frequently used for pharmacologic maintenance therapy in adolescents. Methadone maintenance programs usually require their participants to be at least 18 years old and to be physically dependent on opiates for at least one year (continuously or intermittently over several years). Teenagers who are younger than 18 years of age may be admitted to methadone maintenance programs if they have current physical dependence and have had two previous attempts at detoxification or drug-free substance abuse treatment. Consent of a designated responsible adult, such as a parent or guardian, is required. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Methadone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/29/26071?source=see_link\">",
"       Buprenorphine",
"      </a>",
"      has been used less often in adolescents than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"       methadone",
"      </a>",
"      but may be associated with a lower dropout rate from maintenance therapy programs than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      . The benefit of buprenorphine is enhanced if it is continued beyond 14 days. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Buprenorphine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for adolescents with opioid addiction is poor with relapse occurring in up to 70 percent of patients. Likelihood of successful treatment increases for those patients who undergo family therapy, continue their education, and undergo skills training that is linked to the maintenance program. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/1\">",
"      Minozzi S, Amato L, Davoli M. Detoxification treatments for opiate dependent adolescents. Cochrane Database Syst Rev 2009; :CD006749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/2\">",
"      Hovens JG, Cantwell DP, Kiriakos R. Psychiatric comorbidity in hospitalized adolescent substance abusers. J Am Acad Child Adolesc Psychiatry 1994; 33:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/3\">",
"      Schwartz RH. Adolescent heroin use: a review. Pediatrics 1998; 102:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/4\">",
"      Deykin EY, Buka SL, Zeena TH. Depressive illness among chemically dependent adolescents. Am J Psychiatry 1992; 149:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/5\">",
"      Hoffmann, NG, Miller, NS. Treatment outcomes for abstinence-based programs. Psychiatr Ann 1992; 22:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/6\">",
"      Smith, DE, Schwartz, Rh, Gutgesell, ME. Rehabilitation of chemically-dependent adolescents: a follow-up survey (abstract). Am J Dis Child 1989; 143:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/7\">",
"      Spear SF, Ciesla JR, Skala SY. Relapse patterns among adolescents treated for chemical dependency. Subst Use Misuse 1999; 34:1795.",
"     </a>",
"    </li>",
"    <li>",
"     Landry, MJ. Overview of addiction treatment effectiveness. Pub. No. (SMA) 96-3081. Rockville, MD: Substance abuse and mental health services administration, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/9\">",
"      Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/10\">",
"      Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005; 62:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/11\">",
"      Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008; 300:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20103/abstract/12\">",
"      Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat 2002; 23:231.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute on Drug Abuse. National Results on Drug Use From Monitoring the Future Study, 1975-1992. NIH publication 93-3597, 199.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6505 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-99E93ED354-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20103=[""].join("\n");
var outline_f19_40_20103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14461782\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS OF OPIOID WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1692947\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12678872\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12678879\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1693162\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693195\">",
"      Ethanol withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693203\">",
"      Sedative-hypnotic withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693211\">",
"      Sympathomimetic intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693219\">",
"      Cholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT OF OPIOID WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methadone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clonidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rapid detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1692489\">",
"      TREATMENT PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1692511\">",
"      Residential programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1692518\">",
"      Outpatient day programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1692649\">",
"      Non-pharmacologic support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Methadone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14461782\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6505|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/26/3499\" title=\"table 1\">",
"      Stages of opiate withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/47/22267\" title=\"table 2\">",
"      Clinical features of opioid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/18/15661\" title=\"table 3\">",
"      Moderate and severe alcohol withdrawal - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/23/18813\" title=\"table 4\">",
"      Organophosphate and carbamate poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/15/22780\" title=\"table 5\">",
"      Opioid withdrawal - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/35/38460\" title=\"table 6\">",
"      Opioid withdrawal treatment medications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=related_link\">",
"      Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20104="General principles of fracture management: Fracture patterns and description in children";
var content_f19_40_20104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of fracture management: Fracture patterns and description in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20104/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20104/contributors\">",
"     David J Mathison, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20104/contributors\">",
"     Dewesh Agrawal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20104/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20104/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/40/20104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal injuries comprise approximately 12 percent of the 10 million annual visits to US pediatric emergency departments (EDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/1\">",
"     1",
"    </a>",
"    ]. Skeletal fractures account for a significant proportion of these injuries and cause considerable cost and morbidity to children. Despite aggressive campaigns for injury prevention, the overall rate of fractures has been increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], and approximately half of all children will fracture a bone during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fractures in children exhibit unique patterns. Because of the distinctive properties of the growing bone, special attention is required to differentiate normal variants and, for the physeal fracture, to guarantee adequate healing while avoiding growth disturbance.",
"   </p>",
"   <p>",
"    This topic discusses the unique properties of pediatric fractures and illustrates different classification systems that exist to identify and describe them. Management of specific fractures is discussed separately and can be found by searching for the anatomic region of interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FRACTURE DESCRIPTION IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Describing a fracture entails a thorough explanation of both the clinical scenario and the radiographic findings (",
"    <a class=\"graphic graphic_table graphicRef61020 \" href=\"UTD.htm?25/49/26395\">",
"     table 1",
"    </a>",
"    ). The clinical narrative should include age, gender, mechanism of injury, anatomic location, soft tissue involvement (eg, open or closed), and key physical examination findings, especially neurovascular status. The radiologic interpretation of the fracture encompasses the type of imaging (including modality and view selection), anatomic location, fracture pattern, relationship of fragments, physeal involvement (ie, Salter-Harris), apophyseal disruption, and joint or soft tissue involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link&amp;anchor=H3#H3\">",
"     \"General principles of fracture management: Bone healing and fracture description\", section on 'Fracture description'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PLAIN RADIOGRAPH VIEWS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate radiologic evaluation begins with obtaining the appropriate imaging study. Multiple views are required to visualize fracture patterns in various planes. Standard radiographic series in fracture evaluations are often two or three views and vary by the anatomic region of interest (",
"    <a class=\"graphic graphic_table graphicRef51211 \" href=\"UTD.htm?27/31/28155\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The assessment of a child with suspected fracture, especially of the long bone diaphysis, requires evaluation of the joint both above and below the site of injury. In some instances, radiographs of these areas are also needed. For example, the Monteggia fracture is a well described fracture of the proximal one-third of the ulna with dislocation of the radial head. If the clinician obtains only dedicated forearm views at the site of the fracture, the elbow dislocation can be missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FRACTURE PATTERNS IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The periosteum of pediatric bone has significant osteogenic potential and is comparatively more metabolically active than the adult periosteum. This active periosteum promotes callus formation, union of fractures, and remodeling during the healing process. The periosteum is also thicker and stronger in children, which limits fracture displacement, reduces the likelihood of open fractures, and maintains fracture stability in comparison to adult fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The qualities and function of the pediatric periosteum are responsible for some of the unique fracture patterns seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ]. Examples of these fractures include buckle, greenstick, and plastic deformation (or bowing).",
"   </p>",
"   <p>",
"    A bone fails when the loading forces exceed the load bearing capacity. Depending on both the force of the injury and the properties of the bone involved, load failure results in a fracture in several unique patterns. Three fundamental forces cause fractures: shear, compressive, and tensile. Bone is least able to withstand shear forces, followed by tension, then compression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tensile bone failure causes fractures perpendicular to the direction of loading (transverse), whereas compression forces cause oblique stresses in a plane approximately 45 degrees to the bone's long axis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/11\">",
"     11",
"    </a>",
"    ]. Bending forces result in a tensile stress to the convex side and a compressive stress to the concave side, resulting in transverse and oblique fractures on the tensile and compressive sides respectively. This tensile-compressive pattern from bending can cause a resultant bone wedge referred to as a butterfly fragment or the characteristic greenstick fracture. Torsion (rotational) forces lead to more complex fractures by causing a small crack to extend into a spiral pattern (",
"    <a class=\"graphic graphic_figure graphicRef71590 \" href=\"UTD.htm?10/30/10723\">",
"     figure 1",
"    </a>",
"    ). Many fractures, however, involve combinations of forces and therefore develop complex fracture patterns (",
"    <a class=\"graphic graphic_figure graphicRef69080 \" href=\"UTD.htm?39/31/40441\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fractures specific to the pediatric patient are discussed here. Common fracture patterns (eg, transverse, oblique, spiral) seen in both children and adults are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link&amp;anchor=H6#H6\">",
"     \"General principles of fracture management: Bone healing and fracture description\", section on 'Orientation: Transverse, oblique, and spiral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Buckle (torus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buckle fractures follow compression failure, often at the junction between the porous metaphysis and the denser diaphysis. These injuries typically occur in the distal radius after longitudinal trauma (eg, fall on an outstretched hand), but are also seen in the distal tibia, fibula, and femur. Buckle fractures are also known as torus fractures, (derived from the Greek, \"tora,\" meaning ring and referring to the radiologic resemblance to the raised band around the base of a Greek column, and also from the Latin \"tori,\" for swelling or protuberance) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59992 \" href=\"UTD.htm?17/42/18095\">",
"     image 1",
"    </a>",
"    ). Buckle fractures are by definition stable and can often be managed with splinting and a single orthopedic follow-up visit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Plastic deformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plastic deformity (or bowing fracture) occurs when a longitudinal force exceeds the bone's ability to recoil to its normal position (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78420 \" href=\"UTD.htm?31/28/32206\">",
"     image 2",
"    </a>",
"    ). If the tension side cannot propagate the fracture, microscopic fractures can occur to dissipate the impact energy, thus creating a plastic deformity. Plastic deformities are most commonly seen in the ulna, the radius, and occasionally in the fibula. If the deformation is less than 20 degrees or if the deformity occurs in a young child (&lt;4 years of age), the angulation often corrects itself [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/13\">",
"     13",
"    </a>",
"    ]. Otherwise, closed reduction or operative intervention may be necessary to straighten the bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11609?source=see_link&amp;anchor=H26#H26\">",
"     \"Midshaft forearm fractures in children\", section on 'Plastic deformation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Greenstick",
"    </span>",
"    &nbsp;&mdash;&nbsp;A greenstick fracture describes a bone that is bent with a fracture line that does not extend completely through the width of the bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70786 \" href=\"UTD.htm?41/47/42750\">",
"     image 3",
"    </a>",
"    ). The greenstick fracture may be the most significant risk factor for repeat fracture, occurring in as many as 84 to 100 percent of forearm refractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physeal (growth plate)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth plate or physis represents a major anatomical difference between adult and pediatric bone. Growing long bones in children are composed of the following segments: diaphysis (shaft), metaphysis (where the bone flares), physis (growth plate), and epiphysis (secondary ossification center) (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Growth plates are susceptible to fracture and represent a weak point in pediatric bone. Because the tensile strength of pediatric bone is less than that of the ligaments, the same injury mechanism causing a ligamentous injury in adults (sprain or strain) is more likely to cause a bone injury in children: the physis will separate or fracture before disruption or \"spraining\" of an adjacent strong and flexible ligament [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Accurate description of these pediatric fractures is essential to communicating the seriousness of bone injury. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Physeal fracture description'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Physeal injuries occur in 21 to 30 percent of pediatric long bone fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], more commonly involving the distal growth plates of the radius and ulna [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/19\">",
"     19",
"    </a>",
"    ]. In girls, growth plate injuries occur between ages 9 and 12, while in boys they typically occur later, between ages 12 and 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/20\">",
"     20",
"    </a>",
"    ]. Although a majority of these fractures heal without incident, approximately 30 percent of these physeal fractures cause a growth disturbance (premature closure and unilateral long bone shortening) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/6\">",
"     6",
"    </a>",
"    ]. Appropriate anatomic alignment is critical for optimal growth and minimal deformity in physeal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, the weakest part of the physis is the third zone (zone of hypertrophic cartilage), and accordingly the most common site for physeal fractures (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 3",
"    </a>",
"    ). In infancy and early childhood, the physis is relatively thick and the epiphysis is mostly cartilaginous, serving as a shock absorber and transmitting forces to the metaphysis. During adolescence, when the epiphysis begins to ossify, these forces are less absorbed and consequently transmitted to the physis.",
"   </p>",
"   <p>",
"    The longitudinal growth of long bones occurs primarily at the physis. The germinal area of the physis borders the epiphysis. The epiphyseal cartilage cells grow toward the metaphysis and form columns of cells. These columns degenerate, undergo hypertrophy, and then calcify at the metaphysis to form new bone (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/21\">",
"     21",
"    </a>",
"    ]. The growth and change that occur at a growth plate promote rapid healing of fractures. However, injury to the physis itself can lead to asymmetric growth and subsequent deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/6,22,23\">",
"     6,22,23",
"    </a>",
"    ]. The epiphyseal cartilage cells stop duplicating at the end of puberty. The entire cartilage is eventually replaced by bone and epiphyseal lines remain at the site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Apophyseal avulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain physes contain fibrocartilage instead of columnar cartilage (eg, tibial tuberosity, inferior pole of the patella). These areas are tensile-responsive apophyseal centers and have unique failure patterns that result from the intersection of the ossification center and the fibrocartilage. These apophyseal centers are prone to overuse traction avulsions, termed apophysitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/24\">",
"     24",
"    </a>",
"    ]. Characteristic apophyseal overuse injuries include Osgood-Schlatter disease (tibial tuberosity) and Sinding-Larsen-Johansson syndrome (inferior pole of the patella) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Unlike physeal injuries, apophyseal injuries do not interfere with growth and are mostly self limited injuries in adolescent athletes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the causes of limp in children\", section on 'Apophysitis (formerly osteochondrosis)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES IN PEDIATRIC FRACTURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures represent overuse injuries that arise from accumulated microtrauma after repetitive strain. The loads from stress fractures are less than what the bone can withstand, but cumulative fatigue damage can cause small but progressive cracks in the periosteum. Stress fractures are more commonly seen in adolescents than younger children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency department clinician should be cognizant of certain fracture patterns that are associated with child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H13#H13\">",
"     \"Orthopedic aspects of child abuse\", section on 'Fracture patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any fracture in a child younger than one year of age or any lower extremity fracture in a nonambulatory child should raise suspicion of abuse. Specific fracture patterns of concern include posterior rib fractures, metaphyseal lesions (bucket-handle or corner fractures) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67241 \" href=\"UTD.htm?23/23/23922\">",
"     image 4",
"    </a>",
"    ), bilateral long bone fractures, complex skull fractures, and spinous process fractures. In addition, a repeat fracture occurring at an unusual location for repeat injury is suspicious for child abuse, and careful history and social assessment should be performed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Repeat fracture'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fracture in a radiographic stage of healing that does not correspond to the clinical description or multiple fractures in various stages of healing should also arouse suspicion of abuse. Determining the age of fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H9#H9\">",
"     \"Orthopedic aspects of child abuse\", section on 'Fracture age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any suspicion of child abuse should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathologic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fracture in bone that is weakened by disease is termed a pathologic fracture. Patients with bone tumors, rickets, McCune-Albright syndrome, juvenile osteoporosis, chronic renal insufficiency, osteogenesis imperfecta (OI), and osteopetrosis are all at greater risk for fractures. Of all bone tumors that serve as fracture lead points, the proximal femur and humerus are the most frequent sites and unicameral (simple) bone cysts, aneurysmal bone cysts, and nonossifying fibromas are the most common tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OI, also known as \"brittle bone disease,\" is the most common metabolic bone disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/28\">",
"     28",
"    </a>",
"    ]. Features of OI include multiple fractures, a suggestive family history, and clinical manifestations that can include short stature, scoliosis, basilar skull deformities, hearing loss, blue sclerae, opalescent teeth, ligamentous laxity, and easy bruisability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Repeat fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractures characterize repeat or recurrent fractures at the initial site of injury. Refractures make up only 1 in 1000 of all children's fractures, occurring frequently in the forearm and complicating 5 to 13 percent of forearm fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/14,16,29\">",
"     14,16,29",
"    </a>",
"    ]. In a series of 38 forearm refractures, the median time to refracture was eight weeks after cast removal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/30\">",
"     30",
"    </a>",
"    ]. Risk factors for refracture include incomplete bony union, residual angulation, early cast removal, radial or ulnar diaphyseal fracture, and greenstick fracture pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/16,30-32\">",
"     16,30-32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Greenstick'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHYSEAL FRACTURE DESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classification schemes for physeal fractures have been devised, including the Salter-Harris, Ogden, Peterson, and many others, most of which are specific to certain anatomical locations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. It is generally perceived that the Salter-Harris classification is easily applied and adequate for the majority of physeal fractures. It is also the most widely used system, and represents as much a means of communication between healthcare professionals as a classification schema.",
"   </p>",
"   <p>",
"    The Salter-Harris classification system grades physeal fractures as types I through V. While controversial and joint dependent, the severity of injury to the growth plate generally increases with each Salter-Harris grade [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Complications of physeal injury include growth arrest, permanent decreased range of motion, and angular deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/39\">",
"     39",
"    </a>",
"    ]. The following mnemonic can be helpful to remember the different Salter-Harris types when the long bone is in a vertical orientation with the epiphysis at the bottom. The mnemonic refers to the fracture line and its relationship to the growth plate (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       S",
"      </strong>",
"      (\"",
"      <strong>",
"       S",
"      </strong>",
"      traight across\") &ndash; Type I (low risk for growth plate injury)",
"     </li>",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      (\"",
"      <strong>",
"       A",
"      </strong>",
"      bove\") &ndash; Type II",
"     </li>",
"     <li>",
"      <strong>",
"       L",
"      </strong>",
"      (\"",
"      <strong>",
"       L",
"      </strong>",
"      ower\" or \"Be",
"      <strong>",
"       L",
"      </strong>",
"      ow\") &ndash; Type III",
"     </li>",
"     <li>",
"      <strong>",
"       T",
"      </strong>",
"      (\"",
"      <strong>",
"       T",
"      </strong>",
"      wo\" or \"",
"      <strong>",
"       T",
"      </strong>",
"      hrough\") &ndash; Type IV",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      (\"",
"      <strong>",
"       E",
"      </strong>",
"      nd\") or",
"      <strong>",
"       ER",
"      </strong>",
"      (\"",
"      <strong>",
"       ER",
"      </strong>",
"      asure of the growth plate\") &ndash; Type V (high risk for growth plate injury)",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several modifications and additions have been made to the Salter-Harris schematic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], including Ogden's system that includes injuries to surrounding elements such as the periosteum, zone of Ranvier, and perichondrium (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/43\">",
"     43",
"    </a>",
"    ]. While the five Salter-Harris types (with Ogden's elaboration) encompass the mainstay for physeal injuries, additional types have been described. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Ogden Type VI'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Ogden Type VII'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These physeal injuries are more common during times of rapid growth, such as adolescence, and generally occur through the hypertrophic zone of the physis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Salter I (Ogden IA-B)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fracture line extends through the zone of hypertrophic cartilage (zone 3), causing the epiphysis and physeal elements to separate from the metaphysis (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81082 \" href=\"UTD.htm?0/59/947\">",
"     image 5",
"    </a>",
"    ). Type I injuries can have normal radiographs and the diagnosis is therefore often made clinically when focal tenderness is found over the growth plate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A type IB Ogden fracture is characterized by the fracture line extending through the primary spongiosa bone layer resulting in a thin line of bone displaced with the epiphysis. Type IB fractures usually occur in children with systemic diseases such as myeloproliferative disorders. Subsequent growth is usually normal with Type IA and IB fractures (",
"      <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A Type IC Ogden fracture has an associated injury to the germinal portion of the physis. Type IC fractures can cause growth arrest and occur rarely after age two to three years (",
"      <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Salter II (Ogden IIA-D)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fracture line extends through the physis and then propagates across the physeal-metaphyseal junction into the metaphysis (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 4",
"    </a>",
"    ). Type II fractures are the most common physeal fractures. The resultant metaphyseal wedge in a Salter II or Ogden Type IIA fracture is called the Thurston Holland fragment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68844 \" href=\"UTD.htm?27/12/27841\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A type IIB involves further extension of the fracture line bidirectionally through the metaphysis creating a free metaphyseal fragment or multiple fragments.",
"     </li>",
"     <li>",
"      A type IIC fracture is a transverse physeal fracture that includes a thin layer of metaphysis along with the metaphyseal triangular corner segment.",
"     </li>",
"     <li>",
"      A type IID fracture is characterized by the angulation of the two segments resulting in the metaphyseal segment compressing the physis and creating an osseous bridge that leads to permanent growth arrest (",
"      <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Salter III (Ogden IIIA-D)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fracture line extends through the physis and then spreads through the epiphysis into the intraarticular space (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67403 \" href=\"UTD.htm?19/55/20336\">",
"     image 7",
"    </a>",
"    ). If the transverse fracture extends across the complete width of the physis, two epiphyseal segments may be formed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Type IIIB fracture, similar to type IB, courses through the primary spongiosa physeal layer resulting in a thin bony metaphyseal line displaced with the epiphyseal segment (",
"      <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type IIIC injuries involve epiphyses in mostly nonarticular areas.",
"     </li>",
"     <li>",
"      Type IIID fractures penetrate the germinal zone and interrupt the blood supply to the avulsed segment. These fractures are difficult to visualize on traditional radiographs (",
"      <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Salter IV (Ogden IVA-C)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fracture line spreads from the articular surface, through the epiphysis, across the physis, and through a segment of the metaphysis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82077 \" href=\"UTD.htm?7/4/7234\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Type IVB fracture is characterized by further transverse extension of the fracture through part or all of the physis creating additional epiphyseal fragments.",
"     </li>",
"     <li>",
"      Type IVC fractures involve damage to the adjacent cartilage, and type IVD fractures have multiple metaphyseal-physeal-epiphyseal fragments, usually from severe trauma (",
"      <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Salter V (Ogden V)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This fracture is thought to be caused by a force transmitted through the epiphysis and physis. The resultant disruption of the germinal matrix, hypertrophic regions, and vascular supply causes a severe injury with growth arrest and poor prognosis (",
"    <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"     figure 5",
"    </a>",
"    ). Type V injuries usually occur in joints that only move in one plane, such as the knee or ankle. Causes of type V injuries include electric shock, frostbite, and irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/44\">",
"     44",
"    </a>",
"    ]. The mechanism for this growth arrest is unknown but most theorize that compression, vascular insult, or an otherwise unrecognized direct injury are the most likely mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/45\">",
"     45",
"    </a>",
"    ]. Since displacement of the epiphysis can be minimal, this fracture pattern may go unrecognized on initial radiographs although physeal injury can be demonstrated on MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ogden Type VI",
"    </span>",
"    &nbsp;&mdash;&nbsp;First described by Rang [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/41\">",
"     41",
"    </a>",
"    ] and elaborated by Ogden [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20104/abstract/43\">",
"     43",
"    </a>",
"    ], this fracture is typically a result of glancing trauma that involves the peripheral perichondral area including the zone of Ranvier (",
"    <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ogden Type VII",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fracture line is completely intraepiphyseal, from the epiphyseal cartilage into the secondary ossification center. These fractures classically occur as avulsions of fibrocartilaginous complexes at ossification centers, such as the tibial tuberosity (",
"    <a class=\"graphic graphic_figure graphicRef67726 \" href=\"UTD.htm?21/9/21654\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Peterson fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1994, Peterson et al. developed a new classification system based on the epidemiologic results of 10 years of physeal fractures. Peterson described two patterns unique to the previous classification systems, his type I and VI fractures. A Peterson type I fracture is a complete transverse metaphyseal disruption with an additional extension that extends longitudinally to the physis. This injury typically does not cause significant growth disturbance. A Peterson type VI fracture is a partial physeal loss usually including the epiphysis. This injury occurs largely from lawn mower trauma which is frequently associated with neurovascular injury and soft tissue damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Describing a fracture entails a thorough explanation of both the clinical scenario and the radiographic findings (",
"      <a class=\"graphic graphic_table graphicRef61020 \" href=\"UTD.htm?25/49/26395\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fracture description in children'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link&amp;anchor=H3#H3\">",
"       \"General principles of fracture management: Bone healing and fracture description\", section on 'Fracture description'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An accurate radiologic evaluation begins with obtaining the appropriate imaging study. Multiple views are required to visualize fracture patterns in various planes. Standard radiographic series in fracture evaluations are often two or three views and vary by the anatomic region of interest (",
"      <a class=\"graphic graphic_table graphicRef51211 \" href=\"UTD.htm?27/31/28155\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Plain radiograph views'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children exhibit unique fracture patterns because of the relative compressibility of their bone, the increased fibrous strength of the periosteum, and the presence of the physis (growth plate). Examples of these fractures include buckle, greenstick, and plastic deformation (or bowing). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fracture patterns in children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physis is susceptible to fracture and therefore similar forces that cause ligamentous injuries in adults lead to physeal bone fractures in children. The Salter-Harris classification system has become the most widely accepted method for describing physeal fractures. Physeal fractures are graded as types I through V (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"       figure 4",
"      </a>",
"      ). Special attention is needed for physeal injuries because growth arrest can occur. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physeal fracture description'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/1\">",
"      Chamberlain JM, Patel KM, Pollack MM, et al. Recalibration of the pediatric risk of admission score using a multi-institutional sample. Ann Emerg Med 2004; 43:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/2\">",
"      Khosla S, Melton LJ 3rd, Dekutoski MB, et al. Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA 2003; 290:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/3\">",
"      Landin LA. Fracture patterns in children. Analysis of 8,682 fractures with special reference to incidence, etiology and secular changes in a Swedish urban population 1950-1979. Acta Orthop Scand Suppl 1983; 202:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/4\">",
"      J&oacute;nsson B, Bengn&eacute;r U, Redlund-Johnell I, Johnell O. Forearm fractures in Malm&ouml;, Sweden. Changes in the incidence occurring during the 1950s, 1980s and 1990s. Acta Orthop Scand 1999; 70:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/5\">",
"      Jones IE, Williams SM, Dow N, Goulding A. How many children remain fracture-free during growth? a longitudinal study of children and adolescents participating in the Dunedin Multidisciplinary Health and Development Study. Osteoporos Int 2002; 13:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/6\">",
"      Carson S, Woolridge DP, Colletti J, Kilgore K. Pediatric upper extremity injuries. Pediatr Clin North Am 2006; 53:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/7\">",
"      Della-Giustina K, Della-Giustina DA. Emergency department evaluation and treatment of pediatric orthopedic injuries. Emerg Med Clin North Am 1999; 17:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/8\">",
"      Frost HM, Sch&ouml;nau E. The \"muscle-bone unit\" in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000; 13:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/9\">",
"      Specker BL, Brazerol W, Tsang RC, et al. Bone mineral content in children 1 to 6 years of age. Detectable sex differences after 4 years of age. Am J Dis Child 1987; 141:343.",
"     </a>",
"    </li>",
"    <li>",
"     Tencer AF, Johnson KD. The biomechanics of bone fracture. In: Biomechanics in Orthopedic Trauma: Bone Fracture and Fixation, 1st, Informa Health Care, 1994. p.35.",
"    </li>",
"    <li>",
"     Hipp JA, Hayes WC. Biomechanics of fractures. In: Skeletal Trauma: Basisc Science, Management, and Reconstruction, 3rd, Browner.  (Ed), Saunders, Philadelphia 2000. p.92.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/12\">",
"      Solan MC, Rees R, Daly K. Current management of torus fractures of the distal radius. Injury 2002; 33:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/13\">",
"      Mabrey JD, Fitch RD. Plastic deformation in pediatric fractures: mechanism and treatment. J Pediatr Orthop 1989; 9:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/14\">",
"      Gruber R, von Laer LR. [The etiology of the refracture of the forearm in childhood (author's transl)]. Aktuelle Traumatol 1979; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/15\">",
"      Schwarz N, Pienaar S, Schwarz AF, et al. Refracture of the forearm in children. J Bone Joint Surg Br 1996; 78:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/16\">",
"      Park HW, Yang IH, Joo SY, et al. Refractures of the upper extremity in children. Yonsei Med J 2007; 48:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/17\">",
"      Mann DC, Rajmaira S. Distribution of physeal and nonphyseal fractures in 2,650 long-bone fractures in children aged 0-16 years. J Pediatr Orthop 1990; 10:713.",
"     </a>",
"    </li>",
"    <li>",
"     Wilkins KE, Aroojis AJ. Incidence of fractures in children. In: Rockwood &amp; Wilkins' Fractures in Children, 6th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.12.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/19\">",
"      Leung AG, Peterson HA. Fractures of the proximal radial head and neck in children with emphasis on those that involve the articular cartilage. J Pediatr Orthop 2000; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/20\">",
"      Peterson HA, Madhok R, Benson JT, et al. Physeal fractures: Part 1. Epidemiology in Olmsted County, Minnesota, 1979-1988. J Pediatr Orthop 1994; 14:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/21\">",
"      Benjamin, HJ, Hang, BT. Common acute upper extremity injuries in sports. Clin Pediatr Emerg Med 2007; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/22\">",
"      Iannotti JP. Growth plate physiology and pathology. Orthop Clin North Am 1990; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/23\">",
"      Murray DW, Wilson-MacDonald J, Morscher E, et al. Bone growth and remodelling after fracture. J Bone Joint Surg Br 1996; 78:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/24\">",
"      Micheli LJ. The traction apophysitises. Clin Sports Med 1987; 6:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/25\">",
"      Medlar RC, Lyne ED. Sinding-Larsen-Johansson disease. Its etiology and natural history. J Bone Joint Surg Am 1978; 60:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/26\">",
"      Gholve PA, Scher DM, Khakharia S, et al. Osgood Schlatter syndrome. Curr Opin Pediatr 2007; 19:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/27\">",
"      Ortiz EJ, Isler MH, Navia JE, Canosa R. Pathologic fractures in children. Clin Orthop Relat Res 2005; :116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/28\">",
"      Marini JC. Osteogenesis imperfecta: comprehensive management. Adv Pediatr 1988; 35:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/29\">",
"      Tischer W. [Forearm fractures in childhood (author's transl)]. Zentralbl Chir 1982; 107:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/30\">",
"      Bould M, Bannister GC. Refractures of the radius and ulna in children. Injury 1999; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/31\">",
"      Filipe G, Dupont JY, Carlioz H. [Recurrent fractures of both bones of the forearm in children]. Chir Pediatr 1979; 20:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/32\">",
"      Noonan KJ, Jones JW. Recurrent supracondylar humerus fracture following prior malunion. Iowa Orthop J 2001; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/33\">",
"      Chadwick CJ, Bentley G. The classification and prognosis of epiphyseal injuries. Injury 1987; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/34\">",
"      Grantham SA, Kiernan HA Jr. Displaced olecranon fracture in children. J Trauma 1975; 15:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/35\">",
"      Letts M, Locht R, Wiens J. Monteggia fracture-dislocations in children. J Bone Joint Surg Br 1985; 67:724.",
"     </a>",
"    </li>",
"    <li>",
"     Canale ST. Fractures and dislocations in children. In: Operative Orthopedics, Campbell.  (Ed), Mosby, Philadelphia 2003. p.1512.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/37\">",
"      Arkader A, Warner WC Jr, Horn BD, et al. Predicting the outcome of physeal fractures of the distal femur. J Pediatr Orthop 2007; 27:703.",
"     </a>",
"    </li>",
"    <li>",
"     Sponseller PD, Stanitski CL. Distal femoral epiphyseal fractures. In: Rockwood and Wilkins: Fractures in Children, 5th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/39\">",
"      Czitrom AA, Salter RB, Willis RB. Fractures Involving the Distal Epiphyseal plate of the femur. Int Orthop 1981; 4:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/40\">",
"      Tandberg D, Sherbring M. A mnemonic for the Salter-Harris classification. Am J Emerg Med 1999; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     Rang M. The Growth Plate and Its Disorders, Williams &amp; Wilkins, Baltimore 1969.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20104/abstract/42\">",
"      Weber BG. Fibrous interposition causing valgus deformity after fracture of the upper tibial metaphysis in children. J Bone Joint Surg Br 1977; 59:290.",
"     </a>",
"    </li>",
"    <li>",
"     Ogden JA. Injury to the Growth Mechanisms. In: Skeletal Injury in the Child, 3rd, Springer-Verlag, New York 2000. p.147.",
"    </li>",
"    <li>",
"     Canale TS. Physeal injuries: Mechanism of injuries: Classification. In: Skeletal Trauma in Children, 3rd, Green NE, Swiotkowski MF.  (Eds), Saunders, Philadelphia 2003. p.528.",
"    </li>",
"    <li>",
"     Rathjen KE, Birch JG. Physeal injuries and growth disturbances. In: Rockwood &amp; Wilkins' Fractures in Children, 6th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.111.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6536 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20104=[""].join("\n");
var outline_f19_40_20104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FRACTURE DESCRIPTION IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PLAIN RADIOGRAPH VIEWS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FRACTURE PATTERNS IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Buckle (torus)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Plastic deformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Greenstick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physeal (growth plate)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Apophyseal avulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPECIAL CIRCUMSTANCES IN PEDIATRIC FRACTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Child abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathologic fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Repeat fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHYSEAL FRACTURE DESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Salter I (Ogden IA-B)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Salter II (Ogden IIA-D)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Salter III (Ogden IIIA-D)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Salter IV (Ogden IVA-C)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Salter V (Ogden V)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ogden Type VI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ogden Type VII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Peterson fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6536|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/42/18095\" title=\"diagnostic image 1\">",
"      Buckle fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/28/32206\" title=\"diagnostic image 2\">",
"      Plastic deformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/47/42750\" title=\"diagnostic image 3\">",
"      Midshaft greenstick fracture 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/23/23922\" title=\"diagnostic image 4\">",
"      Bucket handle fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/59/947\" title=\"diagnostic image 5\">",
"      Salter I fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/12/27841\" title=\"diagnostic image 6\">",
"      Salter II fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/55/20336\" title=\"diagnostic image 7\">",
"      Salter III fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/4/7234\" title=\"diagnostic image 8\">",
"      Salter IV fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6536|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/30/10723\" title=\"figure 1\">",
"      Biomechanic loading models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/31/40441\" title=\"figure 2\">",
"      Fracture classification two",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 3\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21361\" title=\"figure 4\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/9/21654\" title=\"figure 5\">",
"      Ogden and Salter-Harris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/49/26395\" title=\"table 1\">",
"      Describing a fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/31/28155\" title=\"table 2\">",
"      Radiographic views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=related_link\">",
"      General principles of fracture management: Bone healing and fracture description",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11609?source=related_link\">",
"      Midshaft forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20105="Maternal cardiovascular and hemodynamic adaptations to pregnancy";
var content_f19_40_20105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Michael R Foley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20105/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/40/20105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major hemodynamic changes induced by pregnancy include an increase in cardiac output, sodium and water retention leading to blood volume expansion, and reductions in systemic vascular resistance and systemic blood pressure. These changes begin early in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/1\">",
"     1",
"    </a>",
"    ], reach their peak during the second trimester, and then remain relatively constant until delivery (",
"    <a class=\"graphic graphic_figure graphicRef54685 \" href=\"UTD.htm?36/59/37821\">",
"     figure 1",
"    </a>",
"    ). They contribute to optimal growth and development of the fetus and help to protect the mother from the risks of delivery, such as hemorrhage. Knowledge of these cardiovascular adaptations is required to correctly interpret hemodynamic and cardiovascular tests in the gravida, to predict the effects of pregnancy on the woman with underlying cardiac disease, and to understand how the fetus will be affected by maternal cardiac disorders.",
"   </p>",
"   <p>",
"    The cardiovascular changes associated with normal pregnancy will be reviewed here. The management of specific cardiac disorders, such as acquired and congenital heart disease, heart failure, and arrhythmias, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHANGES IN BLOOD VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expansion of the plasma volume and an increase in red blood cell mass begin as early as the fourth week of pregnancy, peak at 28 to 34 weeks of gestation, and then plateau until parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Plasma volume expansion is accompanied by a lesser increase in red cell volume (",
"    <a class=\"graphic graphic_figure graphicRef61948 \" href=\"UTD.htm?9/32/9742\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, there is a modest reduction in hematocrit, with peak hemodilution occurring at 24 to 26 weeks. The blood volume in pregnant women at term is about 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasma volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body volume expansion is accompanied by retention of 900 to 1000 meq of sodium and 6 to 8 liters of water, distributed among the fetus, amniotic fluid, and extracellular and intracellular spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Plasma volume increases by 10 to 15 percent at 6 to 12 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], expands rapidly until 30 to 34 weeks, after which there is only a modest rise. The total gain at term averages 1100 to 1600 mL and results in a plasma volume of 4700 to 5200 mL, 30 to 50 percent above that found in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Mild edema is commonly seen.",
"   </p>",
"   <p>",
"    Plasma renin activity tends to be increased and atrial natriuretic peptide levels are slightly reduced, suggesting that the increase in plasma volume represents underfilling due to systemic vasodilatation and the ensuing rise in vascular capacitance, rather than true blood volume expansion which would produce the opposite hormonal profile (low plasma renin activity, elevated atrial natriuretic peptide) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Furthermore, the degree of sodium retention is physiologically regulated, as increasing sodium intake does not produce further volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/7\">",
"     7",
"    </a>",
"    ]. Humoral factors that contribute to volume regulation during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=see_link&amp;anchor=H10#H10\">",
"     \"Maternal endocrine and metabolic adaptation to pregnancy\", section on 'Adrenal gland'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no specific measures that can be taken to expand the plasma volume in pregnant women and there is no evidence that the expansion of plasma volume would reverse or prevent associated poor pregnancy outcomes. In principle, increasing dietary protein may improve colloid oncotic pressure (COP) which would shift extravascular fluid to the intravascular space. Increasing maternal hydration may also act synergistically with a higher COP to improve intravascular volume. There is also at least one anecdotal case of a patient given serial colloid infusions and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    who had a successful pregnancy outcome, but we do not recommend this in the absence of data from well-designed studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Red blood cell mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell mass begins to increase at 8 to 10 weeks of gestation and steadily rises, in women taking iron supplements, by 20 to 30 percent (250 to 450 mL) above nonpregnant levels by the end of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/4,14-17\">",
"     4,14-17",
"    </a>",
"    ]. Among women not on iron supplements, the red cell mass may only increase by 15 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/18\">",
"     18",
"    </a>",
"    ]. Increased plasma erythropoietin induces the rise in red cell mass, which partially supports the higher metabolic requirement for oxygen during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Physiologic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A greater increase in intravascular volume compared to red cell mass results in the dilutional or physiologic anemia of pregnancy. This becomes most apparent at 30 to 34 weeks of gestation when plasma volume peaks in relation to red cell volume.",
"   </p>",
"   <p>",
"    The physiologic effects of hypervolemia and anemia during pregnancy has several benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased blood viscosity (from greater increases in plasma volume than red cell volume) results in reduced resistance to flow, facilitating placental perfusion and lowering cardiac work.",
"     </li>",
"     <li>",
"      Total blood volume increases to approximately 50 percent above nonpregnant values near term to provide some reserve against the normal blood loss during parturition (about 300 to 500 mL for vaginal delivery, 600 to 1000 mL for cesarean delivery) and peripartum hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Following delivery, as much as 500 mL of blood sequestered in the uteroplacental unit is autotransfused to the maternal circulation, thereby minimizing adverse circulatory effects from blood loss at delivery.",
"     </li>",
"     <li>",
"      Most of the increase in cardiac output is distributed to the placenta, kidneys, and skin to provide nutrients to the fetus, excrete maternal and fetal waste products, and assist maternal temperature control, respectively. The increases in renal blood flow and glomerular filtration rate during pregnancy are largely mediated by the ovarian hormone relaxin, the release of which is increased by human chorionic gonadotropin&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"       \"Renal and urinary tract physiology in normal pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absence of physiologic anemia appears to be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A population-based, case-control study using data from the Swedish Medical Birth Register found that women with a hemoglobin concentration of 14.6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or higher at the first prenatal visit were at increased risk of stillbirth (odds ratio (OR) 1.8), antepartum stillbirth without malformations (OR 2.0), and preterm and small for gestational age nonmalformed stillbirth (OR 2.7 and 4.2, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/21\">",
"     21",
"    </a>",
"    ]. The elevated risk persisted despite a subsequent fall in hemoglobin concentration and after excluding women with preeclampsia. It is hypothesized that high blood viscosity increases the risk of thrombosis in the uteroplacental circulation.",
"   </p>",
"   <p>",
"    Assuming normal renal function, blood volume and constituents return to nonpregnant values by eight weeks postpartum, a result of diuresis. Hemoglobin begins to increase from the third postpartum day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHANGES IN SYSTEMIC HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal and fetal metabolic requirements increase as pregnancy progresses. A change in the volume and distribution of cardiac output (the product of stroke volume and heart rate) occurs during pregnancy to meet these demands (",
"    <a class=\"graphic graphic_figure graphicRef55985 \" href=\"UTD.htm?37/50/38703\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiac output",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac output rises 30 to 50 percent (1.8",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    above baseline during normal pregnancy; one-half of this increase occurs by 8 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. The degree of change is acutely influenced by posture, as the cardiac output is higher when the pregnant woman is in the left lateral decubitus position, particularly in the latter part of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/5,28,29\">",
"     5,28,29",
"    </a>",
"    ]. By comparison, assumption of the supine position can lower the cardiac output by as much as 25 to 30 percent due to compression of the inferior cava by the gravid uterus, leading to a substantial reduction in venous return to the heart.",
"   </p>",
"   <p>",
"    The elevation in cardiac performance results in part from changes in three important factors that determine cardiac output:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preload is increased due to the associated rise in blood volume",
"     </li>",
"     <li>",
"      Afterload is reduced due to the decline in systemic vascular resistance (see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maternal heart rate rises by 15 to 20",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In early pregnancy, increased cardiac output is primarily related to the rise in stroke volume; in late pregnancy, heart rate is the major factor. The ejection fraction is unchanged from normal nonpregnant values, making it a reliable indicator of left ventricular function during pregnancy, although the direct effect of pregnancy on left ventricular contractility remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/30\">",
"     30",
"    </a>",
"    ]. Regardless of the mechanism, the stress induced by the increase in cardiac output can cause women with underlying and, in some cases, asymptomatic heart disease to decompensate during the latter half of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .) Changes in maternal heart rate, stroke volume, and cardiac output during pregnancy measured in the lateral and supine positions are demonstrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef55985 \" href=\"UTD.htm?37/50/38703\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Twin pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular changes in women carrying twins are greater than those described above for singleton pregnancies. Two-dimensional and M-mode echocardiography of 119 women (in the left lateral position) with twins showed that cardiac output was 20 percent higher than in women carrying singletons, and peaked at 30 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/31\">",
"     31",
"    </a>",
"    ]. This increase was due to a 15 percent increase in stroke volume and 3.5 percent increase in heart rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vascular resistance and blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic and diastolic blood pressure (BP) typically fall early in gestation and are about 5 to 10 mmHg below baseline in the second trimester, declining to a mean of about",
"    <span class=\"nowrap\">",
"     105/60",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/24,32-37\">",
"     24,32-37",
"    </a>",
"    ]. In the third trimester, blood pressure gradually increases and may normalize to nonpregnant values by term.",
"   </p>",
"   <p>",
"    The fall in BP is induced by a reduction in systemic vascular resistance, which in pregnancy appears to parallel changes in afterload [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/38\">",
"     38",
"    </a>",
"    ]. Both creation of a high flow, low-resistance circuit in the uteroplacental circulation and vasodilatation contribute to the decline in vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/24\">",
"     24",
"    </a>",
"    ]. The factors responsible for the vasodilatation are incompletely understood, but one of the major findings is decreased vascular responsiveness to the pressor effects of angiotensin II and norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Several additional mechanisms for the fall in vascular resistance have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased endothelial prostacyclin [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Enhanced nitric oxide production [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced aortic stiffness [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possible role of humoral agents, such as estrogens, progesterone, and prolactin, in mediating the vasodilation remains to be established [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/12\">",
"     12",
"    </a>",
"    ]. In animals, as an example, estrogen and prolactin can both lower vascular resistance and raise cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Central hemodynamic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, cardiac function in the structurally normal heart is determined by preload, afterload, heart rate, and contractility. Although changes in blood volume during pregnancy affect right ventricular preload, central venous pressure remains in the normal nonpregnant range throughout pregnancy due to the reduction in cardiac afterload induced by the substantial decrease in both systemic vascular resistance and pulmonary vascular resistance (ie, afterload to the left and right heart, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inherent contractility of the myocardium is stable to slightly improved in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Pulmonary capillary wedge pressure and pulmonary artery systolic and diastolic pressures remain in the normal nonpregnant range since the hypervolemia of pregnancy is balanced by the fall in pulmonary vascular resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19167356\">",
"    <span class=\"h2\">",
"     Cerebral blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have reported a small increase in cerebral blood during normal pregnancy, accompanied by a progressive decrease in cerebral vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Supine hypotensive syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine enlargement beyond about 20 weeks' size can compress the inferior vena cava (IVC), markedly reducing cardiac preload. This occurs primarily in the supine position and is relieved by displacing the uterus to the left and off the IVC by placing a wedge under the woman's right side, having the woman lie on her left side, or adjusting the operating table to a 30&ordm; left lateral tilt [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/52\">",
"     52",
"    </a>",
"    ]. Other, less common, causes of supine hypotension include aortic compression and neurogenic etiologies.",
"   </p>",
"   <p>",
"    The reduction in preload can result in maternal hypotension, usually within 3 to 10 minutes, associated with one or more signs and symptoms of reflex autonomic activation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced cardiac output (",
"    <a class=\"graphic graphic_table graphicRef80135 \" href=\"UTD.htm?13/57/14235\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The earliest sign of developing supine hypotension is an increase in maternal heart rate and a decrease in pulse pressure indicating significantly reduced venous return [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/52\">",
"     52",
"    </a>",
"    ]. Although these alterations are the best indicators of an impending attack, many women remain asymptomatic.",
"   </p>",
"   <p>",
"    In addition, a reduction in placental perfusion may result in nonreassuring changes in the fetal heart rate with no or minimal decrease in upper extremity maternal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/54\">",
"     54",
"    </a>",
"    ]. Therefore, it is important to position the parturient in the left lateral tilt position for procedures (eg, labor and delivery, surgery, nonstress test, ultrasound) and to avoid the supine position, even in symptom-free women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VASCULAR CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular system is more compliant during pregnancy. Although not consistently found, specific changes have been reported in the aortic media of pregnant women. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/55\">",
"     55",
"    </a>",
"    ]. These include: fragmentation of reticular fibers; a decrease in acid mucopolysaccharides, loss of normal corrugation of elastic fibers; and hypertrophy and hyperplasia of smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, a small increase in the aortic diameter occurs, which increases its compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aortic dissection is rare in normal young women, but when dissection occurs it usually does so during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Dissecting aneurysm may result, in part, from the alterations described above and the occasional coincidence of pregnancy and clinically isolated annuloaortic ectasia, even though this occurs with a 2:1 to 8:1 male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     UTERINE BLOOD FLOW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine artery blood flow has been reported to increase from 50 to 60",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    in the late first trimester, to 185",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    at 28 weeks, and to 450 to 750",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    at term [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Cardiac output and uterine artery diameter also increase with advancing gestation. In early pregnancy, the uterus receives 3 to 6 percent of cardiac output; at term, the proportion is about 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/62,64\">",
"     62,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHANGES IN SYSTEMIC COAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with changes in several coagulation factors that result in a 20 percent reduction of prothrombin and the partial thromboplastin times [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resistance to activated protein C increases in the second and third trimesters [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Protein S decreases [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Factors I, II, V, VII, VIII, X, and Xll increase [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/68-70\">",
"       68-70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activity of the fibrinolytic inhibitors PAI-1 and PAI-2 increases, although total fibrinolytic activity may not be impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect of these pregnancy-induced changes is to produce a hypercoagulable state, which is a double-edged sword of protection (eg, hemostasis contributing to reduced blood loss at delivery) and risk (eg, thromboembolic phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/68\">",
"     68",
"    </a>",
"    ]. Venous thrombosis in pregnancy occurs in approximately 0.7 per 1000 women, and is three to four fold higher in the puerperium than during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/69,73\">",
"     69,73",
"    </a>",
"    ]. The risk is increased in women with underlying inherited thrombophilia (eg, factor V Leiden or the prothrombin gene mutation) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H904491988\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS AND PALPITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of increased arrhythmia burden during pregnancy is unclear, but has been attributed to hemodynamic, hormonal, and autonomic changes related to pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. The differential diagnosis of palpitations is extensive and the diagnostic evaluation of pregnant women with palpitations does not differ from nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC CHANGES RELATED TO LABOR AND DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal labor and delivery is associated with significant hemodynamic changes due to anxiety, exertion, pain, uterine contractions, uterine involution, and bleeding. Cardiovascular effects also occur in some women due to infection, hemorrhage, or the administration of anesthesia or analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiac output",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood from the uterine sinusoids is forced into the systemic circulation with each uterine contraction, thereby increasing preload during labor (",
"    <a class=\"graphic graphic_figure graphicRef79834 \" href=\"UTD.htm?4/37/4702\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac output increases by 15 percent above prelabor levels in early labor and by approximately 25 percent during the active phase.",
"     </li>",
"     <li>",
"      The additional exertion associated with pushing in the second stage results in a 50 percent rise in cardiac output.",
"     </li>",
"     <li>",
"      Immediately postpartum, cardiac output increases to 80 percent above prelabor values due to significant autotransfusion associated with uterine involution that is more pronounced than the normal blood loss of delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cardiac output and systemic vascular resistance gradually return to nonpregnant levels over a period of three months or more [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic and diastolic blood pressure increase 15 to 25 and 10 to 15 percent, respectively, during each uterine contraction. The rise in systemic blood pressure is dependent upon the magnitude and intensity of uterine contractions, position of the parturient, and the amount of pain and anxiety she is feeling. The increases in arterial pressure associated with each uterine contraction are mirrored by a rise in pressure in the amniotic fluid, intrathoracic venous, cerebrospinal fluid, and extradural compartments (",
"    <a class=\"graphic graphic_figure graphicRef69056 \" href=\"UTD.htm?40/1/40982\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bearing down or pushing during the second stage of labor alters the blood pressure and heart rate in a similar way to the Valsalva maneuver; these changes are less pronounced if the gravida is positioned in the left lateral versus supine position. The hemodynamic changes resulting from a Valsalva maneuver vary with the different phases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During phase 1, with the onset of the maneuver, there is a transient increase in left ventricular output.",
"     </li>",
"     <li>",
"      During the straining phase, phase 2, there is a decrease in venous return, right and left ventricular volumes, stroke volumes, mean arterial pressure, and pulse pressure; this is associated with a reflex increase in heart rate.",
"     </li>",
"     <li>",
"      During phase 3 (release of Valsalva), which only lasts for a few cardiac cycles, there is a further reduction in left ventricular volume.",
"     </li>",
"     <li>",
"      Phase 4 is characterized by increases in stroke volume and arterial pressure and reflex slowing of heart rate (the overshoot).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changes in baroreceptor sensitivity during pregnancy and associated with maternal position may also play a role. As an example, one study of normotensive pregnant women noted a marked decrease in baroreflex sensitivity for heart rate in the supine position, but not while standing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSTPARTUM HEMODYNAMIC RESOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postpartum period is marked by significant hemodynamic alterations. Fluctuations in cardiac output, stroke volume, and heart rate occur after delivery. Within the first ten minutes following a term vaginal delivery, the cardiac output and stroke volume increase by 59 and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/79\">",
"     79",
"    </a>",
"    ]. At one hour postpartum, both the cardiac output and stroke volume remain increased (by 49 and 67 percent, respectively) while the heart rate decreases by 15 percent; blood pressure remained unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increases in stroke volume and cardiac output most likely result from improved cardiac preload from auto transfusion of utero placental blood to the intravascular space. As the uterus decompresses following delivery, a reduction in the mechanical compression of the vena cava allows for further increases in cardiac preload.",
"   </p>",
"   <p>",
"    These cardiovascular physiologic changes resolve slowly after delivery. A study that evaluated cardiac output and stroke volume in 15 healthy nonlaboring patients at 38 weeks of gestation, and again at 2, 6, 12, and 24 weeks postpartum demonstrated a gradual diminution in cardiac output from 7.42",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    at 38 weeks gestation to 4.96",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    at 24 weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/81\">",
"     81",
"    </a>",
"    ]. As early as two weeks post partum there were substantial reductions in left ventricular size and contractibility as compared to term pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE CARDIOVASCULAR SYSTEM IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic and anatomic adaptations to pregnancy influence the interpretation and evaluation of the gravida's cardiovascular status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circulatory and respiratory changes during normal pregnancy are sometimes erroneously attributed to heart disease. The clinician caring for the gravida should be aware of these normal maternal cardiovascular adaptations to pregnancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breathlessness (innocent hyperpnea), easy fatiguability, decreased exercise tolerance, basal rales that disappear with cough or deep breathing, and peripheral edema commonly occur during pregnancy in normal women.",
"     </li>",
"     <li>",
"      The systemic arterial pulse is characterized by a rapid rise and a brisk collapse (small water hammer) beginning in the first trimester.",
"     </li>",
"     <li>",
"      The jugular venous pulse is more conspicuous after the 20th week because brisk X and Y descents make the A and V waves more obvious. Mean jugular venous pressure, as estimated from the superficial jugular vein, remains normal.",
"     </li>",
"     <li>",
"      The pregnant woman's heart is shifted to the left, anterior, and rotated toward a transverse position as the uterus enlarges. As a result, the apical impulse is shifted cephalad to the fourth intercostal space and laterally to the midclavicular line. The left ventricular impulse is relatively hyperdynamic but not sustained; the right ventricle may be palpable because, like the left ventricle, it handles a larger volume of blood that is ejected against relatively low resistance. As pregnancy progresses, enlargement of the breasts and abdomen makes accurate palpation of the heart difficult, if not impossible.",
"     </li>",
"     <li>",
"      Auscultatory changes accompanying normal gestation begin in the late first trimester and generally disappear within a week after delivery. A higher basal heart rate, louder heart sounds, wide splitting of S1, splitting of S2 in the third trimester, and a systolic ejection murmur (up to grade",
"      <span class=\"nowrap\">",
"       2/4)",
"      </span>",
"      over the pulmonary and tricuspid areas are regularly detected upon cardiac auscultation. A third heart sound is present in most pregnant women; the fourth heart sound is rarely heard. The venous hum is almost universal in normal women during gestation. The mammary souffle (systolic or continuous) is heard over the breasts in late gestation and is peculiar to pregnancy; it is especially common postpartum in lactating women.",
"     </li>",
"     <li>",
"      Diastolic murmurs are uncommon in normal pregnant women. When they occur, they may reflect increased flow through the tricuspid or mitral valve or physiologic dilatation of the pulmonary artery. However, these murmurs more likely represent a pathologic condition necessitating further study [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic multivalvular regurgitation, predominantly right-sided, is a frequent normal finding during late gestation and may persist throughout the early post partum period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition, chamber enlargement, valvular annular dilatation, and a small asymptomatic pericardial effusion are frequent normal incidental findings during late gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/25,83,84\">",
"     25,83,84",
"    </a>",
"    ].These findings appear to be caused by pregnancy-related hypervolemia and are important considerations when interpreting an echocardiogram in a pregnant patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal anatomic and physiologic changes of the heart and chest wall during pregnancy cause changes in the electrocardiogram that are unrelated to disease. The heart is rotated toward the left, resulting in a 15 to 20&ordm; left axis deviation. Marked variation in chamber volumes, especially left atrial enlargement, leads to stretching of the cardiac conduction pathways and predisposes to alterations in cardiac rhythm. Periods of supraventricular tachycardia and ventricular extrasystoles are a common finding. Other findings, which can be normal, include transient ST segment and T wave changes, the presence of a Q wave and inverted T waves in lead III, an attenuated Q wave in lead AVF, and inverted T waves in leads V1, V2 and, occasionally, V3 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20105/abstract/46,85,86\">",
"     46,85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left, anterior, superior rotation of the heart and hypervolemia give the illusion of ventricular hypertrophy and cardiomegaly on chest radiographs; increased pulmonary vascular markings are also common. Rotation of the heart may also cause an indentation of the esophagus by the left atrium and straightening of the left heart border. The majority of these changes are temporary and return to normal by eight weeks postpartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expansion of the plasma volume and an increase in red blood cell mass begin as early as the fourth week of pregnancy, peak at 28 to 34 weeks of gestation, and then plateau. Plasma volume expansion exceeds the increase in red cell volume, leading to \"physiologic anemia\". (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Changes in blood volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major hemodynamic changes induced by pregnancy include an increase in cardiac output and reductions in systemic vascular resistance and systemic blood pressure. Cardiac output peaks a few minutes after delivery, before gradually returning to prepregnancy levels. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Changes in systemic hemodynamics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Postpartum hemodynamic resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in several coagulation factors produce a hypercoagulable state. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Changes in systemic coagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Labor and delivery is associated with significant hemodynamic changes due to anxiety, exertion, pain, uterine contractions, uterine involution, and bleeding. Infection, hemorrhage, and the administration of anesthesia or analgesia also play a role. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hemodynamic changes related to labor and delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic and anatomic adaptations to pregnancy influence the interpretation and evaluation of the pregnant woman's cardiac evaluation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation of the cardiovascular system in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/1\">",
"      Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998; 54:2056.",
"     </a>",
"    </li>",
"    <li>",
"     Assali, NS, Brinkman, III. Pathophysiology of Gestation, Vol 1: Maternal Disorders. Academic Press, New York 1972. p. 278.",
"    </li>",
"    <li>",
"     Ueland, K. Cardiorespiratory physiology of pregnancy. In: Gynecology and Obstetrics, Vol 3. Harper and Row, Baltimore 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/4\">",
"      PRITCHARD JA. CHANGES IN THE BLOOD VOLUME DURING PREGNANCY AND DELIVERY. Anesthesiology 1965; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/5\">",
"      Metcalfe J, Ueland K. Maternal cardiovascular adjustments to pregnancy. Prog Cardiovasc Dis 1974; 16:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/6\">",
"      Jansen AJ, van Rhenen DJ, Steegers EA, Duvekot JJ. Postpartum hemorrhage and transfusion of blood and blood components. Obstet Gynecol Surv 2005; 60:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/7\">",
"      Lindheimer MD, Katz AI. Sodium and diuretics in pregnancy. N Engl J Med 1973; 288:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/8\">",
"      Brown MA, Whitworth JA. The kidney in hypertensive pregnancies--victim and villain. Am J Kidney Dis 1992; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/9\">",
"      Lund CJ, Donovan JC. Blood volume during pregnancy. Significance of plasma and red cell volumes. Am J Obstet Gynecol 1967; 98:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/10\">",
"      Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion in early pregnancy. Obstet Gynecol 2001; 97:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/11\">",
"      Whittaker PG, Lind T. The intravascular mass of albumin during human pregnancy: a serial study in normal and diabetic women. Br J Obstet Gynaecol 1993; 100:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/12\">",
"      Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988; 319:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/13\">",
"      Nadel AS, Ballermann BJ, Anderson S, Brenner BM. Interrelationships among atrial peptides, renin, and blood volume in pregnant rats. Am J Physiol 1988; 254:R793.",
"     </a>",
"    </li>",
"    <li>",
"     Metcalfe, J, Stock, MK, Barron, DH. Maternal physiology during gestation. In: the Physiology of Reproduction, Knobil, K, Ewing, L (Eds), Raven Press, New York 1988. p. 2145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/15\">",
"      McLENNAN CE. Plasma volume late in pregnancy. Am J Obstet Gynecol 1950; 59:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/16\">",
"      Campbell DM, MacGillivray I. Comparison of maternal response in first and second pregnancies in relation to baby weight. J Obstet Gynaecol Br Commonw 1972; 79:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/17\">",
"      Ueland K. Maternal cardiovascular dynamics. VII. Intrapartum blood volume changes. Am J Obstet Gynecol 1976; 126:671.",
"     </a>",
"    </li>",
"    <li>",
"     Hytten, FE, Lind, T. Indices of cardiovascular function. In Hytten FE, Lind T. (eds): Diagnostic indices in pregnancy. Documenta Geigy, Basel 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/19\">",
"      Milman N, Graudal N, Nielsen OJ, Agger AO. Serum erythropoietin during normal pregnancy: relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 1997; 66:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/20\">",
"      Novak J, Danielson LA, Kerchner LJ, et al. Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest 2001; 107:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/21\">",
"      Stephansson O, Dickman PW, Johansson A, Cnattingius S. Maternal hemoglobin concentration during pregnancy and risk of stillbirth. JAMA 2000; 284:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/22\">",
"      Fr&oslash;en JF, M&oslash;yland RA, Saugstad OD, Stray-Pedersen B. Maternal health in sudden intrauterine unexplained death: do urinary tract infections protect the fetus? Obstet Gynecol 2002; 100:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/23\">",
"      Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 1978; 58:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/24\">",
"      Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256:H1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/25\">",
"      Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obstet Gynaecol 1987; 94:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/26\">",
"      Capeless EL, Clapp JF. Cardiovascular changes in early phase of pregnancy. Am J Obstet Gynecol 1989; 161:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/27\">",
"      van Oppen AC, Stigter RH, Bruinse HW. Cardiac output in normal pregnancy: a critical review. Obstet Gynecol 1996; 87:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/28\">",
"      KERR MG. THE MECHANICAL EFFECTS OF THE GRAVID UTERUS IN LATE PREGNANCY. J Obstet Gynaecol Br Commonw 1965; 72:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/29\">",
"      Almeida FA, Pavan MV, Rodrigues CI. The haemodynamic, renal excretory and hormonal changes induced by resting in the left lateral position in normal pregnant women during late gestation. BJOG 2009; 116:1749.",
"     </a>",
"    </li>",
"    <li>",
"     Lang, RM, Borow, KM. Heart disease. In: Medical Disorders During Pregnancy, Barron, WM, Lindheimer, MD, (Eds), Mosby Year Book, St. Louis 1991. p. 184.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/31\">",
"      Kametas NA, McAuliffe F, Krampl E, et al. Maternal cardiac function in twin pregnancy. Obstet Gynecol 2003; 102:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/32\">",
"      Grindheim G, Estensen ME, Langesaeter E, et al. Changes in blood pressure during healthy pregnancy: a longitudinal cohort study. J Hypertens 2012; 30:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/33\">",
"      MacGillivray I, Rose GA, Rowe B. Blood pressure survey in pregnancy. Clin Sci 1969; 37:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/34\">",
"      Clapp JF 3rd, Capeless E. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol 1997; 80:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/35\">",
"      Hermida RC, Ayala DE, Moj&oacute;n A, Iglesias M. High sensitivity test for the early diagnosis of gestational hypertension and preeclampsia. II. Circadian blood pressure variability in health and hypertensive pregnant women. J Perinat Med 1997; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/36\">",
"      Ayala DE, Hermida RC, Moj&oacute;n A, et al. Blood pressure variability during gestation in healthy and complicated pregnancies. Hypertension 1997; 30:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/37\">",
"      Ochsenbein-K&ouml;lble N, Roos M, Gasser T, et al. Cross sectional study of automated blood pressure measurements throughout pregnancy. BJOG 2004; 111:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/38\">",
"      Lang RM, Pridjian G, Feldman T, et al. Left ventricular mechanics in preeclampsia. Am Heart J 1991; 121:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/39\">",
"      Gant NF, Worley RJ, Everett RB, MacDonald PC. Control of vascular responsiveness during human pregnancy. Kidney Int 1980; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/40\">",
"      Goodman RP, Killam AP, Brash AR, Branch RA. Prostacyclin production during pregnancy: comparison of production during normal pregnancy and pregnancy complicated by hypertension. Am J Obstet Gynecol 1982; 142:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/41\">",
"      Curran-Everett D, Morris KG Jr, Moore LG. Regional circulatory contributions to increased systemic vascular conductance of pregnancy. Am J Physiol 1991; 261:H1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/42\">",
"      Knock GA, Poston L. Bradykinin-mediated relaxation of isolated maternal resistance arteries in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1996; 175:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/43\">",
"      Weiner CP, Thompson LP. Nitric oxide and pregnancy. Semin Perinatol 1997; 21:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/44\">",
"      Edouard DA, Pannier BM, London GM, et al. Venous and arterial behavior during normal pregnancy. Am J Physiol 1998; 274:H1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/45\">",
"      Duvekot JJ, Cheriex EC, Pieters FA, et al. Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 1993; 169:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/46\">",
"      Clark SL, Cotton DB, Lee W, et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol 1989; 161:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/47\">",
"      Geva T, Mauer MB, Striker L, et al. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Am Heart J 1997; 133:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/48\">",
"      Nevo O, Soustiel JF, Thaler I. Maternal cerebral blood flow during normal pregnancy: a cross-sectional study. Am J Obstet Gynecol 2010; 203:475.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/49\">",
"      Cipolla MJ, Sweet JG, Chan SL. Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia. J Appl Physiol 2011; 110:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/50\">",
"      Belfort MA, Tooke-Miller C, Allen JC Jr, et al. Changes in flow velocity, resistance indices, and cerebral perfusion pressure in the maternal middle cerebral artery distribution during normal pregnancy. Acta Obstet Gynecol Scand 2001; 80:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/51\">",
"      Ikeda T, Ikenoue T, Mori N, et al. Effect of early pregnancy on maternal regional cerebral blood flow. Am J Obstet Gynecol 1993; 168:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/52\">",
"      Kinsella SM, Lohmann G. Supine hypotensive syndrome. Obstet Gynecol 1994; 83:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/53\">",
"      HOWARD BK, GOODSON JH, MENGERT WF. Supine hypotensive syndrome in late pregnancy. Obstet Gynecol 1953; 1:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/54\">",
"      Marx GF. Aortocaval compression: incidence and prevention. Bull N Y Acad Med 1974; 50:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/55\">",
"      Cavanzo FJ, Taylor HB. Effect of pregnancy on the human aorta and its relationship to dissecting aneurysms. Am J Obstet Gynecol 1969; 105:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/56\">",
"      Manalo-Estrella P, Barker AE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol 1967; 83:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/57\">",
"      Easterling TR, Benedetti TJ, Schmucker BC, et al. Maternal hemodynamics and aortic diameter in normal and hypertensive pregnancies. Obstet Gynecol 1991; 78:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/58\">",
"      Hartman JD, Eftychiadis AS. Medial smooth-muscle cell lesions and dissection of the aorta and muscular arteries. Arch Pathol Lab Med 1990; 114:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/59\">",
"      PEDOWITZ P, PERELL A. Aneurysms complicated by pregnancy. I. Aneurysms of the aorta and its major branches. Am J Obstet Gynecol 1957; 73:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/60\">",
"      Katz NM, Collea JV, Moront MG, et al. Aortic dissection during pregnancy: treatment by emergency cesarean section immediately followed by operative repair of the aortic dissection. Am J Cardiol 1984; 54:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/61\">",
"      ELLIS PR, COOLEY DA, DE BAKEY ME. Clinical considerations and surgical treatment of annulo-aortic ectasia. Report of successful operation. J Thorac Cardiovasc Surg 1961; 42:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/62\">",
"      Flo K, Wilsgaard T, V&aring;rtun A, Acharya G. A longitudinal study of the relationship between maternal cardiac output measured by impedance cardiography and uterine artery blood flow in the second half of pregnancy. BJOG 2010; 117:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/63\">",
"      ASSALI NS, RAURAMO L, PELTONEN T. Measurement of uterine blood flow and uterine metabolism. VIII. Uterine and fetal blood flow and oxygen consumption in early human pregnancy. Am J Obstet Gynecol 1960; 79:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/64\">",
"      Thaler I, Manor D, Itskovitz J, et al. Changes in uterine blood flow during human pregnancy. Am J Obstet Gynecol 1990; 162:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/65\">",
"      TALBERT LM, LANGDELL RD. NORMAL VALUES OF CERTAIN FACTORS IN THE BLOOD CLOTTING MECHANISM IN PREGNANCY. Am J Obstet Gynecol 1964; 90:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/66\">",
"      Lockwood CJ. Heritable coagulopathies in pregnancy. Obstet Gynecol Surv 1999; 54:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/67\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/68\">",
"      Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/69\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/70\">",
"      Hellgren M, Blomb&auml;ck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/71\">",
"      Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/72\">",
"      Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/73\">",
"      Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet 1983; 21:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/74\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/75\">",
"      Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/76\">",
"      Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/77\">",
"      Capeless EL, Clapp JF. When do cardiovascular parameters return to their preconception values? Am J Obstet Gynecol 1991; 165:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/78\">",
"      Blake MJ, Martin A, Manktelow BN, et al. Changes in baroreceptor sensitivity for heart rate during normotensive pregnancy and the puerperium. Clin Sci (Lond) 2000; 98:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/79\">",
"      Ueland K, Hansen JM. Maternal cardiovascular dynamics. II. Posture and uterine contractions. Am J Obstet Gynecol 1969; 103:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/80\">",
"      Kjeldsen J. Hemodynamic investigations during labour and delivery. Acta Obstet Gynecol Scand Suppl 1979; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/81\">",
"      Robson SC, Dunlop W, Moore M, Hunter S. Combined Doppler and echocardiographic measurement of cardiac output: theory and application in pregnancy. Br J Obstet Gynaecol 1987; 94:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/82\">",
"      Cutforth R, MacDonald CB. Heart sounds and murmurs in pregnancy. Am Heart J 1966; 71:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/83\">",
"      Campos O, Andrade JL, Bocanegra J, et al. Physiologic multivalvular regurgitation during pregnancy: a longitudinal Doppler echocardiographic study. Int J Cardiol 1993; 40:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/84\">",
"      Desai DK, Moodley J, Naidoo DP. Echocardiographic assessment of cardiovascular hemodynamics in normal pregnancy. Obstet Gynecol 2004; 104:20.",
"     </a>",
"    </li>",
"    <li>",
"     Mendelson, CL. Cardiac disease in pregnancy. FA Davis Co, Philadelphia, 1960.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20105/abstract/86\">",
"      ORAM S, HOLT M. Innocent depression of the S-T segment and flattening of the T-wave during pregnancy. J Obstet Gynaecol Br Emp 1961; 68:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 443 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20105=[""].join("\n");
var outline_f19_40_20105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHANGES IN BLOOD VOLUME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasma volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Red blood cell mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Physiologic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHANGES IN SYSTEMIC HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiac output",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vascular resistance and blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Central hemodynamic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19167356\">",
"      Cerebral blood flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Supine hypotensive syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VASCULAR CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      UTERINE BLOOD FLOW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHANGES IN SYSTEMIC COAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H904491988\">",
"      ARRHYTHMIAS AND PALPITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEMODYNAMIC CHANGES RELATED TO LABOR AND DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSTPARTUM HEMODYNAMIC RESOLUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVALUATION OF THE CARDIOVASCULAR SYSTEM IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/443\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/443|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37821\" title=\"figure 1\">",
"      Hemodynamic changes in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/32/9742\" title=\"figure 2\">",
"      Blood volume in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/50/38703\" title=\"figure 3\">",
"      Cardiac output in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4702\" title=\"figure 4\">",
"      Cardiac output during labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/1/40982\" title=\"figure 5\">",
"      Hemodynamics with contractions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/443|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/57/14235\" title=\"table 1\">",
"      Supine hypotensive syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=related_link\">",
"      Maternal endocrine and metabolic adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20106="Adjuvant endocrine therapy for hormone receptor-positive breast cancer";
var content_f19_40_20106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20106/contributors\">",
"     Kathleen I Pritchard, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20106/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/40/20106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/40/20106/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/40/20106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H701978004\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of death from cancer in women. In the United States, breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 49 years. Breast cancer is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behavior and response to therapy.",
"   </p>",
"   <p>",
"    Estrogen (ER)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone (PR) receptor positive breast cancers comprise the most common type of breast cancer, accounting for 75 percent of all breast cancers. This topic will review adjuvant endocrine therapy for early stage breast cancer. The adjuvant treatment of human epidermal growth factor 2 (HER2) receptor negative breast cancer, HER2 positive breast cancer, male breast cancer, and triple-negative breast cancer is covered separately. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"       \"Breast cancer in men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110937283\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with hormone receptor-positive early-stage breast cancer, the treatment options are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      &mdash; Tamoxifen (20 mg daily) is indicated in premenopausal and postmenopausal women. (See",
"      <a class=\"local\" href=\"#H933462070\">",
"       'Tamoxifen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Aromatase inhibitors &mdash; The aromatase inhibitors are indicated in postmenopausal women only. Drugs in this class include anastrazole (1 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      (2.5 mg daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      (25 mg daily). (See",
"      <a class=\"local\" href=\"#H2110938219\">",
"       'Aromatase inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ovarian suppression or ablation &mdash; Blocking production of estrogens at the level of the ovaries is an option for premenopausal women with intact ovarian function. &nbsp;This includes the use of radiation therapy (RT) for ovarian ablation, surgical removal of the ovaries (oophorectomy) and the use of gonadotropin releasing hormones (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/10/17573?source=see_link\">",
"       buserelin",
"      </a>",
"      ) for temporary ovarian suppression. (See",
"      <a class=\"local\" href=\"#H14993426\">",
"       'Cessation of ovarian function'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658246\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to treatment decisions for women with hormone receptor-positive breast cancer is outlined below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658253\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most women with postmenopausal breast cancer, we administer an aromatase inhibitor (AI) rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . We prescribe AI treatment for five years because there is no data to support extended AI treatment beyond this duration. (see",
"    <a class=\"local\" href=\"#H2110938219\">",
"     'Aromatase inhibitors'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Women who are candidates for AI treatment but prefer to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    should be offered subsequent treatment with an AI at one of two opportunities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Following completion of a two to three year course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , we treat with an AI for three or two years to complete a planned five year course of treatment. (See",
"      <a class=\"local\" href=\"#H2110939171\">",
"       'Switching therapy'",
"      </a>",
"      below.)",
"      <br/>",
"     </li>",
"     <li>",
"      Following completion of a five year course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , we treat with an AI for an additional five years. (See",
"      <a class=\"local\" href=\"#H2110939194\">",
"       'Sequencing therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who refuse to take an AI (eg, due to pre-existing osteoporosis or cardiac disease) or cannot tolerate an AI due to side effects, we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for at least a five year treatment course. A further five years of tamoxifen should be offered to women with a relatively poor prognosis (ie, pathologically involved lymph nodes at diagnosis, large tumor size, higher tumor grade) and those who are tolerating treatment. For women experiencing more serious side effects from tamoxifen, stopping tamoxifen after five years is reasonable, particularly if they had a tumor with relatively good prognostic features (ie, small tumor, no evidence of nodal involvement, low tumor grade). (See",
"      <a class=\"local\" href=\"#H38114838\">",
"       'Duration of endocrine treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658260\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women with hormone receptor-positive breast cancer, including women who have experienced chemotherapy-induced amenorrhea, we administer endocrine therapy. (See",
"    <a class=\"local\" href=\"#H658371\">",
"     'Definition of menopause'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The options for premenopausal women with hormone receptor-positive breast cancer include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , ovarian",
"    <span class=\"nowrap\">",
"     ablation/suppression,",
"    </span>",
"    or a combination of ovarian suppression plus tamoxifen treatment. Aromatase inhibitors (AIs) are contraindicated because reduced feedback of estrogen to the hypothalamus and pituitary may increase gonadotropin secretion and stimulate the ovary, leading to an increase in androgen substrate and aromatase [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5674202\">",
"     'Reactivation of ovarian function'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach to treatment is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with chemotherapy-induced amenorrhea, we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . If they have been rendered permanently postmenopausal by chemotherapy, there does not appear to be any benefit to targeting ovarian function. We recommend not administering an AI to women who were menstruating at diagnosis but experienced chemotherapy-induced amenorrhea since an AI can promote re-activation and estrogen production by the ovaries.",
"     </li>",
"     <li>",
"      For women who were not treated with chemotherapy and those women who did not experience chemotherapy-induced amenorrhea (including those who have return of their menstrual cycles), we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . However, cessation of ovarian function (alone or concomitantly with tamoxifen) is an appropriate alternative. A choice between them is based on patient and provider preferences. (See",
"      <a class=\"local\" href=\"#H14993426\">",
"       'Cessation of ovarian function'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We offer treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for at least five years. Patients who are tolerating treatment well, particularly those with a relatively poor prognosis (ie, pathologically involved lymph nodes at diagnosis, large tumor size, higher tumor grade) should be offered treatment for 10 years.",
"     </li>",
"     <li>",
"      For women experiencing more serious side effects from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , stopping tamoxifen after five years is reasonable, particularly if they had a tumor with relatively good prognostic features (ie, small tumor, no evidence of nodal involvement, low tumor grade).",
"     </li>",
"     <li>",
"      Women who are permanently postmenopausal by prior treatment should be treated as described above for postmenopausal women. (See",
"      <a class=\"local\" href=\"#H658371\">",
"       'Definition of menopause'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H658253\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658371\">",
"    <span class=\"h2\">",
"     Definition of menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the endocrine options for treatment depend on whether or not a woman is in menopause, defining menopausal status is important. For women with breast cancer, particularly for women treated with adjuvant chemotherapy, amenorrhea is not a reliable indicator of menstrual status.",
"   </p>",
"   <p>",
"    For this reason, we consider women less than 60 years to be postmenopausal if they underwent a bilateral oophorectomy, have not had menstrual periods for 12 months or more in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , chemotherapy, or ovarian suppression. This definition is consistent with guidelines from the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658412\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of male breast cancers are hormone-positive and as such, they are candidates for adjuvant endocrine therapy as well. For most men with breast cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is the preferred agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link&amp;anchor=H954223#H954223\">",
"     \"Breast cancer in men\", section on 'Endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933462070\">",
"    <span class=\"h1\">",
"     TAMOXIFEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is a selective estrogen receptor modulator (SERM) that inhibits the growth of breast cancer cells by competitive antagonism of estrogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351117444\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in the adjuvant setting comes from the 2011 Early Breast Cancer Trialists Collaborative Group (EBCTCG) meta-analysis of randomized trials, which compared tamoxifen treatment for five years versus no endocrine treatment in premenopausal and postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/3\">",
"     3",
"    </a>",
"    ]. With a median follow-up of 13 years, tamoxifen resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in breast cancer recurrence by 39 percent compared to placebo (relative risk [RR] for recurrence 0.61, 95% CI 0.57-0.65), which translated into a 15-year absolute reduction of 13 percent (33 versus 46 percent). This was seen in patients with both node-negative and node-positive, ER-positive breast cancer. There was no effect on recurrence for patients with ER-negative breast cancer.",
"     </li>",
"     <li>",
"      A reduction in risk of breast cancer mortality by 30 percent (RR for death 0.70, 95% CI 0.64-0.75), which translated into a 15-year absolute reduction of 9 percent (24 versus 33 percent). The magnitude of benefit was similar in women less than 45 and in women between 55 and 69 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14992869\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has both estrogen agonist and antagonist activities. However, the benefits of treatment as noted above outweigh the risks of treatment in most patients.",
"   </p>",
"   <p>",
"    In the 2011 meta-analysis, among women with ER-positive disease (n = 10,645 women), major adverse events associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    included [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A statistically nonsignificant excess of stroke deaths (rate ratio 1.37, p = 0.27) among women taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      compared to women in the control arm. This translated into three more strokes per 1000 women during the first 15 years.",
"     </li>",
"     <li>",
"      A trend towards a lower incidence of cardiac deaths in the same period (RR 0.89, p = 0.43), which translated into three fewer cardiac deaths per 1000 women.",
"     </li>",
"     <li>",
"      An increased risk of uterine cancer associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , although this was only noted in women aged 55 to 69 years and the overall incidence was low (3.8 versus 1.1 percent in the control group, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other side effects associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    include hot flashes, vaginal discharge, sexual dysfunction, and menstrual irregularities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link\">",
"     \"Managing the side effects of tamoxifen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonadherence may limit the efficacy of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , but data on the clinical impact of taking tamoxifen at lower doses or less frequent intervals than standard recommendations are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. As an example, among the six major trials that reported compliance with the tamoxifen allocation included in the EBCTCG meta-analysis, almost 20 percent of patients did not complete at least two years of tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/3\">",
"     3",
"    </a>",
"    ]. Whether (and to what degree) noncompliance may have impacted trial outcomes is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tamoxifen resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors may contribute to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    resistance in breast cancer, including (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link&amp;anchor=H6#H6\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Tamoxifen resistance in breast cancer'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Variable expression of ER alpha and beta isoforms",
"     </li>",
"     <li>",
"      Interference with binding of coactivators and corepressors",
"     </li>",
"     <li>",
"      Alternative splicing of ER mRNA variants",
"     </li>",
"     <li>",
"      Modulators of ER expression (eg, epidermal growth factor and its receptors such as EGFR1 and EGFR2, also called HER2)",
"     </li>",
"     <li>",
"      Inherited drug metabolizing CYP2D6 genotypes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110938219\">",
"    <span class=\"h1\">",
"     AROMATASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (AIs) suppress plasma estrogen levels in postmenopausal women by inhibiting or inactivating aromatase, the enzyme responsible for synthesizing estrogens from androgenic substrates (",
"    <a class=\"graphic graphic_table graphicRef61155 \" href=\"UTD.htm?5/6/5227\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , these compounds lack partial agonist activity, and are not associated with thromboembolic events and uterine cancers. The efficacy among the AIs is generally considered comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1208114526\">",
"     'Is there a preferred agent?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48246571\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant AI therapy comes from the 2010 Early Breast Cancer Trialists&rsquo; Collaborative Group (EBCTCG) meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/8\">",
"     8",
"    </a>",
"    ]. Two separate analyses were performed based on varying trial designs. These are summarized below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110939154\">",
"    <span class=\"h3\">",
"     Single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The analysis of an AI versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    included 9856 women with mean follow-up of six years. Treatment with an AI resulted in [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the risk of recurrence within five years compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (rate ratio [RR] 0.77, p&lt;0.00001), which translated into a three percent absolute reduction in five-year risk of recurrence (12 versus 15 percent).",
"     </li>",
"     <li>",
"      A reduction in the risk of death attributed to breast cancer (RR 0.89, p&gt;0.1), which was statistically nonsignificant. This translated into a 1 percent absolute reduction in five-year breast cancer mortality (7 versus 8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110939171\">",
"    <span class=\"h3\">",
"     Switching therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second analysis included 9015 women followed for a mean of four years who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for two or three years and then were randomized to treatment using an AI (switching therapy) versus continuing on with tamoxifen to complete a five year course [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/8\">",
"     8",
"    </a>",
"    ]. Switching therapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the risk of recurrence six years after switching treatment (8 versus 11 percent; RR 0.71, p&lt;0.00001).",
"     </li>",
"     <li>",
"      A reduction in five-year breast cancer mortality (6 versus 8 percent; RR 0.79, p = 0.004).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110939194\">",
"    <span class=\"h3\">",
"     Sequencing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third method of adjuvant AI treatment is to initiate a five-year course of AIs in women completing five years of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The evidence to support sequencing therapy comes from the MA.17 trial of tamoxifen followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the National Cancer Institute of Canada Clinical Trials Group MA.17 (NCIC CTG MA.17) trial, 5187 postmenopausal women (46 percent node-positive, 98 percent ER-positive) completing five years of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    were randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    (2.5 mg daily for five years) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. With a median follow-up of 64 months, treatment with letrozole resulted in [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in disease free survival (HR 0.68, 95% CI 0.45-0.61) compared to placebo",
"     </li>",
"     <li>",
"      Improvement in overall survival (HR 0.51, 95% CI 0.42-0.61)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interestingly, women who had been randomized after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    to placebo rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and chose to take letrozole after the trial was unblinded still experienced an improvement in disease free survival despite a substantial lapse in time between therapies (median 2.8 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar study evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    alone versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    followed by exemestane [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/15\">",
"     15",
"    </a>",
"    ]. However, there was no survival advantage associated with either regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1208114526\">",
"    <span class=\"h3\">",
"     Is there a preferred agent?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AIs appear to have similar efficacy in the adjuvant setting. This was demonstrated in the National Cancer Institute of Canada Clinical Trials Group MA.27 study, which randomly assigned over 7500 postmenopausal women with breast cancer to the nonsteroidal AI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    , or the steroidal AI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/16\">",
"     16",
"    </a>",
"    ]. With a median follow-up of four years, there was no difference in the event free or overall survival rate. Of note, compliance was poor in both arms; 32 and 29 percent discontinued exemestane and anastrozole, respectively, during the study as a result of adverse events, concomitant illness, or study refusal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110938459\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , AIs are associated with musculoskeletal side effects and may result in reactivation of ovarian function (in women with chemotherapy induced amenorrhea or women using a GnRH analog for ovarian suppression). Long-term complications include an elevated risk for osteoporosis and fractures, a higher cardiovascular risk, and an increased risk of hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/17\">",
"     17",
"    </a>",
"    ]. However, they are associated with a lower risk of venous thrombosis and endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/17\">",
"     17",
"    </a>",
"    ]. In the short-term, these side effects are not detrimental to quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the long term effects of AIs (eg, bone loss) are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link&amp;anchor=H6#H6\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\", section on 'Long-term adverse effects of primary therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the toxicities associated with AIs are responsible for the lack of a survival advantage in some randomized studies is not clear. However, a 2011 meta-analysis suggested that five years of AI therapy might be associated with a trend towards an increased risk of death without recurrence compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (OR 1.11, 95% CI 0.98-1.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5674182\">",
"    <span class=\"h3\">",
"     Musculoskeletal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal side effects are responsible for treatment discontinuation in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. There are no well-established pretherapy risk factors, and the etiology is unknown. It has been suggested that decreased estrogen levels may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. In the Arimidex versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    alone or in combination (ATAC) trial, risk factors associated with the development of joint symptoms included hormone receptor positivity, obesity, and prior chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/23\">",
"     23",
"    </a>",
"    ]. In another study, one-half of the women who developed short-term arthralgias after treatment with an AI had a preexisting musculoskeletal disorder (eg, degenerative joint disease or morning stiffness) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H466325876\">",
"     'Older women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5674202\">",
"    <span class=\"h3\">",
"     Reactivation of ovarian function",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIs are contraindicated in premenopausal women, even if they are clinically in menopause (due to ovarian suppression or persistent chemotherapy-induced amenorrhea) because AIs may induce reactivation and estrogen production by the ovaries on an AI.",
"   </p>",
"   <p>",
"    In one study, 53 women with chemotherapy-induced amenorrhea were transitioned from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (taken for a minimum of two years) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/25\">",
"     25",
"    </a>",
"    ]. Of these patients, 12 had resumption of menses and five had evidence of biochemical ovarian function recovery, which occurred within six months of starting exemestane. Compared to those who did not recover ovarian function, they had a lower rate of disease free survival at two years (82 versus 100 percent, HR for recurrence 9.3, 95% CI 3.3-48.0). Although this was a relatively small study, it supports the risk of ovarian reactivation from AIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21032148\">",
"    <span class=\"h3\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because aromatase inhibitors block peripheral estrogen production, women were felt to be at an increased risk for vaginal symptoms and sexual dysfunction. A 2012 study appears to confirm this concern [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/26\">",
"     26",
"    </a>",
"    ]. Researchers compared 35 women on an AI with two control groups of women without breast cancer who were being treated with estrogen (n = 48) or were not (n = 54). Compared to both groups, AI treatment was significantly associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced sexual interest (50 versus 28 percent in both control groups)",
"     </li>",
"     <li>",
"      Reduced vaginal lubrication (74 versus 41 percent in both control groups)",
"     </li>",
"     <li>",
"      Dyspareunia (57 versus 21 percent with estrogen treatment and 9 percent without estrogen treatment)",
"     </li>",
"     <li>",
"      Orgasmic dysfunction (50 versus 31 and 37 percent, respectively)",
"     </li>",
"     <li>",
"      Global dissatisfaction with their sex life (42 versus 27 and 14 percent, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms can be detrimental to quality of life in breast cancer survivors. Therefore, patients should be counselled about these potential toxicities and on methods that may help alleviate them. The approach to breast cancer survivors who complain of sexual dysfunction is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link&amp;anchor=H463691037#H463691037\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Sexual health'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38114838\">",
"    <span class=\"h1\">",
"     DURATION OF ENDOCRINE TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38115884\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , the results of a large randomized trial support the administration of tamoxifen for 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/27\">",
"     27",
"    </a>",
"    ]. This is in contrast to data from smaller clinical trials that found no benefit to extending treatment with tamoxifen beyond five years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The Adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    : Longer Against Shorter (ATLAS) trial enrolled 15,244 women and randomly assigned them to 5 or 10 years of tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/27\">",
"     27",
"    </a>",
"    ]. Among 6846 women with ER-positive disease, tamoxifen administration for 10 years resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction in the risk of recurrence compared to a five-year treatment course (18 versus 21 percent; RR 0.84, 95% CI 0.76-0.94). After year 10, there was a 25 percent reduction in the risk of recurrence (RR 0.75, 95% CI 0.62-0.90).",
"     </li>",
"     <li>",
"      Reduction in breast cancer mortality (10 versus 12 percent, p = 0.01) and overall mortality (18 versus 21 percent, p = 0.01). After year 10, there was an almost 30 percent reduction in the risk of death (RR 0.71, 95% CI 0.58-0.88).",
"     </li>",
"     <li>",
"      A reduction in the incidence of contralateral breast cancer (12 versus 14 percent, p = 0.05).",
"     </li>",
"     <li>",
"      The adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      do not dissipate with time. Tamoxifen treatment for 10 years resulted in a significant cumulative increase in the incidence of endometrial cancer (3.1 versus 1.6 percent with a five year treatment course, p = 0.0002) and higher incidences of pulmonary embolus (1.2 versus 0.6 percent, p = 0.01) and ischemic heart disease (4 versus 2 percent, p = 0.02).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38115939\">",
"    <span class=\"h2\">",
"     Aromastase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women on an AI, the benefits of extended treatment (following a five year treatment course as a single agent or after two to five years of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ) are not known. The National Surgical Adjuvant Breast and Bowel Project B-42 trial (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00382070\">",
"     NSABP B-42 trial",
"    </a>",
"    ) and the NCIC Clinical Trials Group (NCIC CTG) MA17R trial, each of which randomly assigned postmenopausal women who completed five years of endocrine therapy to an additional five years of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    or placebo, have both completed enrollment. We await results of these trials to further inform the benefits and risks of extended AI therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38116045\">",
"    <span class=\"h2\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, it is not clear that",
"    <strong>",
"     all",
"    </strong>",
"    women require endocrine treatment for ten years. This is particularly true for patients with low-risk breast cancer in whom the toxicities of therapy could outweigh the benefits of treatment. Our approach to the duration of endocrine therapy is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ATLAS study supports ongoing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      therapy beyond five years. However, there are side effects of treatment, ranging from persistent menopausal symptoms to persistent risks of either uterine cancer or thrombotic events. Therefore, women who have tolerated tamoxifen treatment for at least five years and are interested in ongoing adjuvant endocrine therapy should be offered an additional five years of tamoxifen. This is particularly important for patients with a relatively poor prognostic breast cancer (ie, larger tumor size &gt;2 cm, pathologically involved lymph nodes, or higher tumor grade) who face a higher risk of relapse over a span of 10 years or longer after the initial diagnosis. In addition, it is reasonable to offer extended tamoxifen treatment to women who are pre- or perimenopausal after five years of tamoxifen and for postmenopausal women who prefer extended adjuvant therapy with tamoxifen rather than treatment with an AI, for whatever reasons.",
"     </li>",
"     <li>",
"      There are no data to inform either the safety or the efficacy of extended AI therapy beyond five years. Therefore, in the absence of data, we would not offer extended treatment with an AI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14993426\">",
"    <span class=\"h1\">",
"     CESSATION OF OVARIAN FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women, cessation of ovarian function can be accomplished by surgery (oophorectomy), pelvic radiation (ovarian ablation), or by using pharmacologic interventions to induce ovarian suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160596771\">",
"    <span class=\"h2\">",
"     Ovarian suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian suppression is accomplished by the use of agents that result in ovarian suppression, such as the leuteinizing-hormone releasing hormone (LHRH) agonists. The benefit of ovarian suppression was shown in the 2007 EBCTCG meta-analysis evaluated ovarian suppression using LHRH as part of the treatment of early stage breast cancer with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a single agent, LHRH agonists resulted in a trend towards a lower risk of breast cancer recurrence compared to no further systemic treatment (hazard ratio [HR] 0.72, 95% CI 0.49-1.04). There was also a trend toward a reduction in mortality (HR 0.82, 95% CI 0.47-1.43), though the analysis was likely underpowered for this outcome.",
"     </li>",
"     <li>",
"      When administered with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , the combination resulted in a trend towards a lower risk of recurrence compared to tamoxifen alone (HR 0.85, 95% CI 0.67-1.09) and mortality (HR 0.84, 95% CI 0.59-1.19).",
"     </li>",
"     <li>",
"      When administered with non-anthracycline containing adjuvant chemotherapy, there was no detectable difference in the risk of recurrence (HR 1.04, 95% CI 0.92-1.17) or mortality (HR 0.90, 95% CI 0.79-1.10) compared to treatment with adjuvant chemotherapy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that LHRH agonists have limited efficacy when administered in patients treated with non-anthracycline based chemotherapy perhaps because of the high rate of treatment-induced suppression caused by regimens such as CMF. However, ovarian suppression may provide an additional benefit for women treated with contemporary anthracycline-based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the North American Intergroup trial (INT 0101), 1503 premenopausal women with node-positive, hormone receptor-positive breast cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and 5-fluorouracil (CAF), CAF followed by five years of the LHRH agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    (CAF-Z), or CAF-Z plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (CAF-ZT) with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CAF-Z resulted in a trend towards a lower risk of recurrence (hazard ratio [HR] 0.91, 95% CI 0.74-1.11) and a trend towards a lower risk of mortality (HR 0.86, 95% CI 0.68-1.08) compared to CAF.",
"     </li>",
"     <li>",
"      CAF-ZT resulted in a lower risk of recurrence (HR 0.73, 95% CI 0.59-0.90) and a trend towards a lower risk of mortality (HR 0.91, 95% CI 0.72-1.16) compared to CAF-Z.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a post-hoc analysis of data from the North American Intergroup trial INT 0101, CAF-Z seemed to be more effective for women under the age of 40 than CAF, which has been noted in other trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00917969\">",
"     Suppression of Ovarian Function Trial (SOFT) trial",
"    </a>",
"    is underway to address the impact of ovarian suppression in premenopausal women. Another trial, the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00066807\">",
"     Tamoxifen and Exemestane Trial (TEXT)",
"    </a>",
"    , which combines ovarian suppression with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    in premenopausal women treated with or without adjuvant chemotherapy, has completed accrual and results are anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351118820\">",
"    <span class=\"h3\">",
"     Ovarian suppression plus aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (AIs) are generally avoided in premenopausal women because of concerns that reduced feedback of estrogen to the hypothalamus and pituitary will increase gonadotropin secretion and stimulate the ovary, leading to an increase in androgen substrate and aromatase [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the combination of ovarian suppression and AIs may be equivalent to ovarian suppression plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the Austrian Breast and Colorectal Cancer Study Group randomized trial (ABCSG-12), 1803 premenopausal women with early breast cancer (the majority of whom did not receive chemotherapy) were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    for three years and randomly assigned to endocrine treatment (for five years) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or anastrazole, with a second randomization to treatment with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/34\">",
"     34",
"    </a>",
"    ]. With a median follow-up of 48 months, goserelin plus anastrazole resulted in similar disease free survival compared to goserelin plus tamoxifen (hazard ratio for progression in the anastrazole group 1.10, 95% CI 0.78-1.53). The survival outcomes with or without zoledronic acid are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\", section on 'Prevention of breast cancer recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14994381\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effect profile of ovarian suppression or ablation",
"    <span class=\"nowrap\">",
"     (OS/OA)",
"    </span>",
"    mimics symptoms of estrogen deprivation, as with menopause. These include hot flashes, sweats, weight gain, and decreased libido. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160596922\">",
"    <span class=\"h2\">",
"     Ovarian ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian ablation can be accomplished by surgical removal of the ovaries (oophorectomy) or with pelvic radiation therapy (RT) targeted to the ovaries. The end result is irreversible premature menopause, which may be associated with long-term health effects, including cardiovascular disease and permanent loss of fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link&amp;anchor=H21231548#H21231548\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Introduction'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Oophorectomy results in reliable and prompt reduction in the levels of circulating estrogens but carries the risks associated with anesthesia and surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/35\">",
"     35",
"    </a>",
"    ]. The technical aspects of oophorectomy are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H17#H17\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Procedure'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Ovarian irradiation can be used to ablate ovarian function, although the limited data available suggest it may be more effective in women less than 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/36\">",
"     36",
"    </a>",
"    ]. This requires cumulative doses over 12 Gy, as lower doses are associated with decreased efficacy. Despite tailoring the treatment field to the ovaries, there is a risk of radiation to the normal tissue surrounding the ovary, including the bowels. In addition, limited data suggest it may not be as effective in younger compared to older women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160596807\">",
"    <span class=\"h2\">",
"     Is there a preferred approach?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no preferred approach to targeting ovarian function, and ovarian suppression appears to be equivalent to ovarian ablation. This was shown in the 2005 Early Breast Cancer Trialists Collaborative Group (EBCTCG) meta-analysis that included nearly 8000 women under the age 50 years with ER-positive or ER-unknown breast cancer who were randomly assigned to treatment with either ovarian ablation or ovarian suppression or no further treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/37\">",
"     37",
"    </a>",
"    ]. Both approaches resulted in similar outcomes compared to no further treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the risk of recurrence (relative risk [RR] 0.75, p&lt;0.00001)",
"     </li>",
"     <li>",
"      A reduction in breast cancer mortality (RR 0.71, p = 0.004) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466326046\">",
"    <span class=\"h1\">",
"     TIMING OF ENDOCRINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most women who are candidates for endocrine therapy, we begin treatment four to six weeks after surgery or after completion of chemotherapy (if administered). Questions on the sequencing of endocrine therapy with other breast cancer treatments have been performed using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , but extrapolated to the use of the aromatase inhibitors and ovarian suppression or ablation. At the very least, the use of endocrine therapy following chemotherapy (sequentially) is not worse than when it is administered at the same time as chemotherapy (concomitantly).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376566183\">",
"    <span class=\"h2\">",
"     With or following chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients receiving adjuvant chemotherapy, the initiation of endocrine therapy is commonly begun after the completion of chemotherapy (ie, sequentially). However, the optimal timing of endocrine therapy in patients receiving adjuvant chemotherapy has not been determined. As examples:",
"   </p>",
"   <p>",
"    In a North American Intergroup trial, 637 postmenopausal women with node positive, hormone receptor-positive breast cancer were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for five years) started concurrently with chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and 5-fluorouracil [CAF]) or following completion of chemotherapy (sequential therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/38\">",
"     38",
"    </a>",
"    ]. After a maximum follow-up of 13 years, sequential treatment resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trend towards improvement in disease-free survival compared to concurrent treatment, which may be clinically meaningful (hazard ratio [HR] 0.84, 95% CI 0.70-1.01)",
"     </li>",
"     <li>",
"      A trend towards an improvement in overall survival (HR 0.90, 95% CI 0.73-1.10) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study, 431 women with node-positive disease received chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and 5-fluorouracil) alternating with CMF every three weeks for a total of 12 cycles and were randomized to concurrent or sequential treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/39\">",
"     39",
"    </a>",
"    ]. There was no difference in the risk of relapse or risk of death between the two arms after adjustment for prognostic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376566212\">",
"    <span class=\"h2\">",
"     With or following radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women receiving adjuvant radiation therapy (RT) for breast cancer, we prefer to begin endocrine therapy concurrently with RT rather than at the completion of RT. However, multiple studies have shown that the timing of endocrine therapy given during or after radiation therapy does not appear to impact survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is illustrated in an exploratory analysis of Southwest Oncology Group 8897 (SWOG 8897) trial in which women on the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    treated arm either took tamoxifen concurrently with RT (n = 202) or following RT (n = 107) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/41\">",
"     41",
"    </a>",
"    ]. With 10 year follow-up, tamoxifen taken during RT resulted in similar rates of 10-year disease free survival (83 percent in both arms) and overall survival (88 versus 90 percent) compared to tamoxifen taken following RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H659778\">",
"    <span class=\"h1\">",
"     PATIENTS WITH HER2-POSITIVE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ER-positive, HER2-positive early breast cancer are treated with adjuvant chemotherapy plus HER2-directed therapy followed by maintenance single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to complete one year of treatment. Following completion of chemotherapy, we and others initiate endocrine therapy concurrently during HER2 directed maintenance treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the use of HER2-directed therapy without adjuvant chemotherapy in selected, strongly ER-positive, HER2-positive breast cancer has been suggested, there are no data to support it being as effective as chemotherapy plus HER2-directed treatment (followed by endocrine therapy). In the absence of data, this approach should be considered investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466325609\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72864709\">",
"    <span class=\"h2\">",
"     Obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that obese women with hormone receptor-positive breast cancer have a higher risk of recurrence and death compared to women who are of normal weight despite treatment with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/44-47\">",
"     44-47",
"    </a>",
"    ], although other data have not replicated this association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/48\">",
"     48",
"    </a>",
"    ]. The impact of obesity on the effectiveness of endocrine therapy is illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       ATAC Trial",
"      </strong>",
"      &mdash; In a posthoc analysis of the Arimidex versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      Alone or in Combination (ATAC) trial that included over 4900 women, the main results were [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/44\">",
"       44",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women with a higher BMI (&gt;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      at baseline were at a greater risk for recurrence compared to women with a lower BMI (&lt;23",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      (21 versus 14 percent, respectively; HR 1.39, 95% CI 1.06-1.82).",
"     </li>",
"     <li>",
"      Compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      alone, single agent anastrazole resulted in a lower proportion of recurrences across all BMI quintiles. The total incidence of recurrences was 15 versus 19 percent, respectively (HR 0.73, 95% CI 0.63-0.83). However, the effectiveness of anastrazole was lower at higher BMIs. In contrast, the effectiveness of tamoxifen was similar across BMI quintiles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       BIG 1-98",
"      </strong>",
"      &mdash; In a separate analysis of the Breast International Group 1-98 Trial (BIG 1-98), the impact of obesity (defined as a BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      on outcomes in over 4700 women randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      was evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/46\">",
"       46",
"      </a>",
"      ]. With almost nine years of follow-up, obesity was associated with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An increased risk of recurrence compared to women with a BMI &lt;25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (30 versus 25 percent; HR 1.09, 95% CI 0.94-1.27).",
"     </li>",
"     <li>",
"      An increased risk of mortality from all causes (21 and 15 percent, HR 1.19, 95% CI 0.99-1.44).",
"     </li>",
"     <li>",
"      The increased mortality risk among obese women was similar regardless of endocrine therapy administered (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , HR 1.18, 95% CI 0.91-1.52;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      , HR 1.22, 95% CI 0.93-1.60).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A separate retrospective study compared the outcomes between women with a BMI &lt;25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (n = 102) and those with a higher BMI (n = 399) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/48\">",
"       48",
"      </a>",
"      ]. Unlike the prior studies, there was no association between obesity and disease free survival at three years (78 versus 86 percent, respectively) or the three-year survival rate (98 percent in both groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective data are needed to understand the impact of obesity on the outcomes of women with hormone receptor-positive breast cancer. In addition, whether dietary and lifestyle interventions have an effect on survival outcomes in women with breast cancer require further study. A discussion on the impact of obesity among women treated with chemotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H2719278#H2719278\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Obese women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466325890\">",
"    <span class=\"h2\">",
"     Women of child-bearing potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women receiving adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    are discouraged from becoming pregnant during treatment. Tamoxifen does not cause infertility and can induce ovulation. For women who are of child-bearing potential, an effective means of contraception is recommended while on tamoxifen treatment. Following completion of tamoxifen treatment, a waiting period of two months from drug discontinuation prior to attempting pregnancy is suggested to ensure that it has been cleared from the body [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/49\">",
"     49",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524708359\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of selective estrogen receptor modulators (SERMs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    during pregnancy and lactation is generally avoided. The management of women diagnosed with breast cancer during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link&amp;anchor=H84662691#H84662691\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\", section on 'Endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who become pregnant, we recommend discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    during pregnancy because there is a relatively high frequency of congenital anomalies associated with tamoxifen if taken during pregnancy. As an example, one study evaluated the frequency of birth defects associated with tamoxifen through a literature review and access to the records from the drug manufacturer of tamoxifen and reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of seven live births from women who took",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      before pregnancy, three babies (43 percent) were born with a congenital anomaly.",
"     </li>",
"     <li>",
"      Of 138 live births from women who took",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      during pregnancy, 16 (12 percent) were born with a congenital malformation. By comparison, the baseline rate of congenital malformations is 3 to 4 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466325876\">",
"    <span class=\"h2\">",
"     Older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women &gt;70 years, we recommend individualized treatment based on patient-specific issues such as cardiac risk factors, bone health, and other medical comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of age, women with hormone-positive breast cancer derive a reduction in the risk of recurrence and improvement in relapse-free survival with the use of endocrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/3\">",
"     3",
"    </a>",
"    ]. However, both age and the presence of comorbidities have a significant impact on breast cancer outcomes, which should be considered in any discussion on adjuvant treatment. &nbsp;In one trial of over 1600 women looking at the use of endocrine therapy, older age was independently associated with worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/50\">",
"     50",
"    </a>",
"    ]. With 10-year follow-up, compared to women &lt;70 years, those 70 years or older had:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher risk of recurrence (hazard ratio [HR] 1.21, 95% CI 1.08-1.37)",
"     </li>",
"     <li>",
"      A higher risk of death without a recurrence (HR 4.13, 95% CI 3.53-4.83).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466325883\">",
"    <span class=\"h2\">",
"     Patients with cardiac risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with cardiac risk factors who are candidates for endocrine therapy, aromatase inhibitors appear to be associated with a long term increased risk of cardiovascular disease compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/40/20106/abstract/51\">",
"     51",
"    </a>",
"    ]. The risks and benefits of treatment should be individualized to patient-specific circumstances when choosing endocrine therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"       \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5673555\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females. Estrogen (ER)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progesterone (PR) receptor positive breast cancers comprise the most common type of breast cancer, accounting for 75 percent of all breast cancers. (See",
"      <a class=\"local\" href=\"#H701978004\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adjuvant endocrine therapy for all men and women with hormone receptor-positive breast cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Because the endocrine options for treatment depend on whether or not a woman is in menopause, defining menopausal status is important. We consider women less than 60 years to be postmenopausal if they underwent a bilateral oophorectomy or have been amenorrheic for 12 months or more in the absence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , chemotherapy, or ovarian suppression. (See",
"      <a class=\"local\" href=\"#H701978004\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H658371\">",
"       'Definition of menopause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no optimal strategy in the initiation of endocrine therapy in relation to surgery, chemotherapy, biologic therapy, or RT. The timing of endocrine therapy is based on provider and institutional preferences. (See",
"      <a class=\"local\" href=\"#H466326046\">",
"       'Timing of endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HER2-positive breast cancer, we initiate endocrine therapy concomitantly with maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , if this was indicated in the adjuvant setting. (See",
"      <a class=\"local\" href=\"#H659778\">",
"       'Patients with HER2-positive tumors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link&amp;anchor=H517953427#H517953427\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Trastuzumab-based therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1597562527\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most women, we suggest an aromatase inhibitor (AI) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for a five year treatment course (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2110938219\">",
"       'Aromatase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are candidates for an AI but initiate adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      instead, we suggest an AI for two or three years following completion of the first two to three years with tamoxifen rather than tamoxifen alone for five years (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2110939171\">",
"       'Switching therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are candidates for an AI but took",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for five years, we suggest a five year course of an AI rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2110939194\">",
"       'Sequencing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are not candidates for an AI (eg, those who refuse an AI, experience side effects to an AI, or may be at an increased risk for toxicity from an AI due to pre-existing osteoporosis or cardiac disease) we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for at least a five year treatment course rather than observation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women who are receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      because they are not candidates for an aromatase inhibitor, and who are tolerating tamoxifen treatment well, we recommend treatment with tamoxifen for 10 years rather than five years (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This is particularly important for patients with a relatively poor prognosis (ie, pathologically involved lymph nodes at diagnosis, large tumor size, higher tumor grade). (See",
"      <a class=\"local\" href=\"#H38114838\">",
"       'Duration of endocrine treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women experiencing more serious side effects from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , discontinuation of tamoxifen after five years is reasonable, particularly if they had a tumor with relatively good prognostic features (ie, small tumor, no evidence of nodal involvement, low tumor grade).",
"     </li>",
"     <li>",
"      For older women (&gt;70 years), we base decisions about adjuvant endocrine therapy on patient-specific issues such as age, cardiac risk factors, bone health, and other medical comorbidities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"       \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5673599\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with chemotherapy-induced amenorrhea, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      rather than cessation of ovarian function (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H933462070\">",
"       'Tamoxifen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are not menopausal after chemotherapy (and those who have return of their menstrual cycles), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, cessation of ovarian function (alone or in combination with tamoxifen) is an appropriate alternative. A choice between them is based on patient and provider preferences. (See",
"      <a class=\"local\" href=\"#H658260\">",
"       'Premenopausal women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H933462070\">",
"       'Tamoxifen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14993426\">",
"       'Cessation of ovarian function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , we recommend treatment for at least five years (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"      For women with poor prognostic breast cancer characteristics (ie, large tumor size &gt;2 cm, pathologically involved lymph nodes, high tumor grade) we recommend tamoxifen treatment for 10 years (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H658260\">",
"       'Premenopausal women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H933462070\">",
"       'Tamoxifen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2110938219\">",
"       'Aromatase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women of child-bearing potential, we recommend an effective means of contraception while on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Following completion of tamoxifen treatment, a waiting period of two months from drug discontinuation is suggested before attempting pregnancy. (See",
"      <a class=\"local\" href=\"#H466325890\">",
"       'Women of child-bearing potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who become pregnant, we recommend discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      during pregnancy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). There is a relatively high frequency of congenital anomalies associated with tamoxifen if taken during pregnancy. (See",
"      <a class=\"local\" href=\"#H524708359\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aromatase inhibitors (AI) are contraindicated in menstruating women and those who have the potential of resuming ovarian function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5673735\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of male breast cancers are hormone-positive and as such, they are candidates for adjuvant endocrine therapy as well. For most men with breast cancer, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    rather than an AI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link&amp;anchor=H954223#H954223\">",
"     \"Breast cancer in men\", section on 'Endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/1\">",
"      Miller WR. Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network guidelines (Version 2.2011): Invasive breast cancer.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/3\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/4\">",
"      Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/5\">",
"      Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/6\">",
"      Dezentj&eacute; VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010; 28:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/7\">",
"      Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/8\">",
"      Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/9\">",
"      L&oslash;nning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol 2011; 22:503.",
"     </a>",
"    </li>",
"    <li>",
"     Goss PE, Ingle JN, Chapman J-AW, et al. Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, abstr S1-1. Available online at file://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_761&amp;terms= (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/11\">",
"      Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/12\">",
"      Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012; 30:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/13\">",
"      Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/14\">",
"      Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/15\">",
"      van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/16\">",
"      Goss PE, Ingle JN, Pritchard KI, et al. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/17\">",
"      Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/18\">",
"      Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23:6931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/19\">",
"      Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25:3877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/20\">",
"      Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007; 7:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/21\">",
"      Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/22\">",
"      Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/23\">",
"      Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/24\">",
"      Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009; 115:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/25\">",
"      Guerrero A, Gavil&aacute; J, Folkerd E, et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/26\">",
"      Baumgart J, Nilsson K, Evers AS, et al. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013; 20:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/27\">",
"      Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/28\">",
"      Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/29\">",
"      Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/30\">",
"      LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/31\">",
"      Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005; 23:5973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/32\">",
"      Arriagada R, L&ecirc; MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/33\">",
"      International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/34\">",
"      Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/35\">",
"      Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004; 9:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/36\">",
"      Leung SF, Tsao SY, Teo PM, et al. Ovarian ablation failures by radiation: a comparison of two dose schedules. Br J Radiol 1991; 64:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/37\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/38\">",
"      Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/39\">",
"      Bedognetti D, Sertoli MR, Pronzato P, et al. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst 2011; 103:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/40\">",
"      Ahn PH, Vu HT, Lannin D, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/41\">",
"      Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 2005; 23:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/42\">",
"      Harris EE, Christensen VJ, Hwang WT, et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005; 23:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/43\">",
"      Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/44\">",
"      Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010; 28:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/45\">",
"      Pfeiler G, K&ouml;nigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/46\">",
"      Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/47\">",
"      Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012; 118:5937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/48\">",
"      Sendur MA, Aksoy S, Zengin N, Altundag K. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer 2012; 107:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/49\">",
"      Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy. Oncologist 2011; 16:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/50\">",
"      Ring A, Sestak I, Baum M, et al. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol 2011; 29:4266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/40/20106/abstract/51\">",
"      Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008; 112:260.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 749 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20106=[""].join("\n");
var outline_f19_40_20106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701978004\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2110937283\">",
"      OVERVIEW OF TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H658246\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H658253\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H658260\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H658371\">",
"      Definition of menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H658412\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933462070\">",
"      TAMOXIFEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351117444\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14992869\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tamoxifen resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2110938219\">",
"      AROMATASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48246571\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110939154\">",
"      - Single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110939171\">",
"      - Switching therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110939194\">",
"      - Sequencing therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1208114526\">",
"      - Is there a preferred agent?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2110938459\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5674182\">",
"      - Musculoskeletal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5674202\">",
"      - Reactivation of ovarian function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21032148\">",
"      - Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38114838\">",
"      DURATION OF ENDOCRINE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38115884\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38115939\">",
"      Aromastase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38116045\">",
"      Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14993426\">",
"      CESSATION OF OVARIAN FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160596771\">",
"      Ovarian suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351118820\">",
"      - Ovarian suppression plus aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14994381\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160596922\">",
"      Ovarian ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160596807\">",
"      Is there a preferred approach?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H466326046\">",
"      TIMING OF ENDOCRINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H376566183\">",
"      With or following chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H376566212\">",
"      With or following radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H659778\">",
"      PATIENTS WITH HER2-POSITIVE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H466325609\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72864709\">",
"      Obese women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466325890\">",
"      Women of child-bearing potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H524708359\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466325876\">",
"      Older women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466325883\">",
"      Patients with cardiac risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5673555\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1597562527\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5673599\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5673735\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/6/5227\" title=\"table 1\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_40_20107="Antichol drugs and plants";
var content_f19_40_20107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Substances possessing anticholinergic properties",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"       <td>",
"        Chlorpheniramine, Cyproheptadine, Doxylamine, Hydroxyzine, Diphenhydramine, Meclizine, Promethazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroleptics",
"       </td>",
"       <td>",
"        Chlorpromazine, Clozapine, Mesoridazine, Olanzapine, Quetiapine, Thioridazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"       <td>",
"        Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiparkinsonian drugs",
"       </td>",
"       <td>",
"        Trihexyphenidyl, Benztropine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmic drugs",
"       </td>",
"       <td>",
"        Atropine, Cyclopentolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antispasmodics",
"       </td>",
"       <td>",
"        Clidinium, Dicyclomine, Hyoscyamine, Oxybutynin, Propantheline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plants",
"       </td>",
"       <td>",
"        Jimson Weed (Datura stramonium), Deady Nightshade (Atropa belladonna), Henbane (Hyoscyamus niger)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20107=[""].join("\n");
var outline_f19_40_20107=null;
var title_f19_40_20108="MEN syndromes";
var content_f19_40_20108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of multiple endocrine neoplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary hyperparathyroidism (&gt;90 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pituitary tumors (10 to 20 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prolactinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Growth hormone-secreting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Corticotropin-secreting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-hormone-secreting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Enteropancreatic tumors (60 to 70 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gastrinoma (Zollinger-Ellison syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Insulinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasoactive-intestinal polypeptide-secreting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucagonoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatic polypeptide-secreting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-hormone-secreting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 2A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary thyroid cancer (&gt;90 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma (40 to 50 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parathyroid hyperplasia (10 to 20 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous lichen amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 2B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary thyroid cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mucosal neuromas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intestinal ganglioneuromas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Marfanoid habitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Familial medullary thyroid cancer (variant of 2A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary thyroid cancer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20108=[""].join("\n");
var outline_f19_40_20108=null;
var title_f19_40_20109="Approach to the child with blurry vision";
var content_f19_40_20109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Approach to the child with blurry vision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 236px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FB: foreign body.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20109=[""].join("\n");
var outline_f19_40_20109=null;
var title_f19_40_20110="SPECT imaging and outcome";
var content_f19_40_20110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    SPECT imaging predicts cardiac death and myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 5183 patients who underwent myocardial perfusion imaging, the presence and severity of an abnormal scan was predictive of cardiac death or a myocardial infarction during a two year follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hachamovitch, R, Berman, DS, Shaw, LJ, et al, Circulation 1998; 97:535.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20110=[""].join("\n");
var outline_f19_40_20110=null;
var title_f19_40_20111="Sedative dosage regimens";
var content_f19_40_20111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sedative dosage regimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loading dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maintenance dose range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of intermittent dose (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics and role",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Opioid analgesics*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fentanyl",
"       </td>",
"       <td>",
"        <p>",
"         1 to 2 mcg/kg",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (50-200 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        0.7 to 10 mcg/kg/hour infusion",
"       </td>",
"       <td>",
"        &lt;0.5",
"       </td>",
"       <td>",
"        30-60+",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Potent analgesic-sedative with immediate onset, minimal venodilation, relative cardiovascular stability, less hypotension, and relative lack of histamine release. Hepatically metabolized by cytochrome P450-3A4 to inactive metabolites.",
"        </p>",
"        <p>",
"         Disadvantages: Highly lipophilic parent drug accumulates with repeated or prolonged administration. As with all opioids, tolerance may require dose escalation and withdrawal syndrome may be precipitated upon abrupt discontinuation. Chest wall rigidity may occur with higher dosing.",
"        </p>",
"        <p>",
"         Role: A good choice for analgesia and sedation for most critically ill patients.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydromorphone",
"       </td>",
"       <td>",
"        <p>",
"         10 to 30 mcg/kg",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (1-4 mg)",
"        </p>",
"       </td>",
"       <td>",
"        7 to 15 mcg/kg/hour infusion",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        240-300",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Advantages: No consistent advantage over fentanyl.",
"        </p>",
"        <p>",
"         Disadvantages: Hepatically metabolized to inactive and active metabolites which can accumulate in organ failure and prolong effects. Some metabolites linked to neurotoxicity based on preliminary evidence. Histamine release and vagally-mediated venodilation and bradycardia can be significant. Histamine release may precipitate bronchospasm.",
"        </p>",
"        <p>",
"         Role: Limited to analgesia and sedation in critically ill patients where preload reduction and myocardial depressive effects are desirable or tolerable.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Morphine sulfate",
"       </td>",
"       <td>",
"        <p>",
"         0.05 to 0.2 mg/kg",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (2-10 mg)",
"        </p>",
"       </td>",
"       <td>",
"        0.07 to 0.5 mg/kg/hour infusion",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Remifentanil",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        0.6 to 15 mcg/kg/hour infusion",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        5-10 (after cessation of infusion)",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Ultra short acting. Cleared by non-specific plasma esterases to inactive metabolites. Does not accumulate in renal or hepatic insufficiency. Prompt reversal of analgesia and sedation upon discontinuation.",
"        </p>",
"        <p>",
"         Disadvantages: Anticipate pain and discomfort upon abrupt cessation. Glycine excipient may accumulate in renal insufficiency.",
"        </p>",
"        <p>",
"         Role: An alternate to fentanyl for patients requiring frequent neurological assessments or with multi-organ failure.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Benzodiazepines*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lorazepam",
"       </td>",
"       <td>",
"        <p>",
"         0.02-0.06 mg/kg",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (1 to 4 mg)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.02-0.06 mg/kg every 2-6 hours",
"        </p>",
"        <p>",
"         <strong>",
"          AND/OR",
"         </strong>",
"        </p>",
"        <p>",
"         0.01-0.1 mg/kg/hour infusion",
"        </p>",
"        <p>",
"         (0.5-10 mg/hour)",
"        </p>",
"       </td>",
"       <td>",
"        5-20",
"       </td>",
"       <td>",
"        360-480+",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Sedative, amnestic, potent anxiolysis with anti-convulsant properties. Hepatically metabolized to inactive metabolites. Relatively low risk of drug interactions and safety in mild to moderate hepatic and renal insufficiency.",
"        </p>",
"        <p>",
"         Disadvantages: Relatively slow onset. Risk of over-sedation when titrating due to delayed response and accumulation in peripheral tissues. IV incompatibilities and risk of line precipitate. Propylene glycol solvent may accumulate with high dosing causing metabolic acidosis and end-organ dysfunction. See text.",
"        </p>",
"        <p>",
"         Role: A good choice for sedation and anxiolysis for most patients, including those who may require long-term ongoing sedation. Although intermittent bolus dosing may be preferred, a continuous infusion may be initiated for patients requiring frequently repeated higher dosing.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Midazolam",
"       </td>",
"       <td>",
"        <p>",
"         0.02 to 0.08 mg/kg",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (1 to 5 mg)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.02 to 0.04 mg/kg (1 to 2 mg) intermittent",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         0.04 to 0.2 mg/kg/hour infusion",
"        </p>",
"        <p>",
"         (2 to 8 mg/hour)",
"        </p>",
"       </td>",
"       <td>",
"        1-5",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: A potent amnestic and anxiolytic agent with an immediate onset of action and a short duration of effect when administered short-term (&lt;48 hours). It is the only intravenous benzodiazepine that is not delivered in propylene glycol.",
"        </p>",
"        <p>",
"         Disadvantages: Metabolized to active metabolites that may accumulate and cause prolonged sedation if delivered long-term. Also, it interacts with numerous common ICU drugs.",
"        </p>",
"        <p>",
"         Role: A good choice for short-term anxiolysis and treatment of acute agitation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam",
"       </td>",
"       <td>",
"        <p>",
"         0.1 to 0.2 mg/kg",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (5 to 20 mg)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.03 to 0.1 mg/kg every 0.5 to 6 hours",
"        </p>",
"        <p>",
"         Continuous infusion is not recommended",
"        </p>",
"       </td>",
"       <td>",
"        &cong;1",
"       </td>",
"       <td>",
"        20-60 (prolonged with repeated dosing)",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Rapid onset with potent sedative and muscle-relaxant effects.",
"        </p>",
"        <p>",
"         Disadvantages: Hepatically metabolized to active metabolites that may accumulate and cause prolonged sedation if delivered long-term. Also, it interacts with numerous common ICU drugs. Injection solution contains propylene glycol solvent and cannot be delivered as a continuous infusion. Injection site pain and risk of phlebitis limits usefulness of intravenous injections.",
"        </p>",
"        <p>",
"         Role: Seldom used for sedation of critically ill patients. May be useful for critically ill patient at risk of alcohol withdrawal or seizures due to drug overdose or poisoning.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Anesthetic-sedative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propofol",
"       </td>",
"       <td>",
"        Loading dose is not recommended",
"       </td>",
"       <td>",
"        <p>",
"         5 to 80 mcg/kg/minute",
"        </p>",
"        <p>",
"         Initiate at 5 mcg/kg/minute and titrate every 5-10 minutes in increments of 5-10 mcg/kg/minute",
"        </p>",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        3-10+",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Potent sedative hypnotic with an immediate onset and rapid awakening upon discontinuation when delivered for short term use. Metabolism is reportedly unaltered in hepatic or renal insufficiency and subject to few significant drug interactions. Infusion is readily titratable to desired depth of sedation minimizing risk of over-sedation. Propofol effectively decreases intracranial pressure, lowers cerebral metabolism, controls intractable seizures and may reduce shivering in rewarming phase of induced hypothermia following resuscitation from cardiac arrest.",
"        </p>",
"        <p>",
"         Disadvantages: With long term use propofol has no advantage over lorazepam or midazolam regarding the duration of vent weaning. Adverse effects include hypotension, decreased myocardial contractility, elevated triglycerides, peripheral injection site pain, and propofol infusion syndrome. See text. Specific product presentations may include potential allergens (egg, soy, peanut, others). Consult product label information.",
"        </p>",
"        <p>",
"         Role: A good choice for short term sedation for patients in whom rapid awakening is advantageous such as neurosurgical patients requiring frequent neurologic assessments. Also a good choice to decrease elevated intracranial pressure or for short-term sedation in a general critical care population that is likely to be ready soon for ventilator weaning trials.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Central alpha-2 agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexmedetomidine",
"       </td>",
"       <td>",
"        Loading dose is not recommended",
"       </td>",
"       <td>",
"        <p>",
"         0.2 to 1.4 mcg/kg/hour",
"        </p>",
"        <p>",
"         Initiate at 0.2 mcg/kg/hour and titrate every 30 minutes",
"        </p>",
"       </td>",
"       <td>",
"        &gt;5-10",
"       </td>",
"       <td>",
"        60-120",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Effective sedative sympatholytic (central alpha-2 agonist) with moderate anxiolysis and analgesia, yet no clinically significant effect on respiratory drive. Character and depth of sedation may permit critically ill mechanically ventilated patients to be interactive or easily awakened, yet comfortable. Reduces shivering in rewarming phase of induced hypothermia following resuscitation from cardiac arrest. May be less likely to cause delirium than other sedative choices.",
"        </p>",
"        <p>",
"         Disadvantages: Potentially significant hypotension and bradycardia or hypertension that do not resolve quickly upon abrupt discontinuation. Hepatically metabolized by glucuronidation and cytochrome P450-2A6. Dose reduction recommended with renal and/or hepatic insufficiency. Rapid administration of loading dose may be associated with cardiovascular instability, tachycardia, bradycardia, or heart-block. Limited data support higher dose and longer term use (&gt;24 hours) than in the US FDA approved information. Does not induce deep sedation needed for neuromuscular blockade.",
"        </p>",
"        <p>",
"         Role: An alternate choice for short and long-term sedation in critically ill patients without relevant cardiac conditions. May be useful for sedation of patients with or at high risk of developing delirium, although this has not been well established.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Neuroleptics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haloperidol",
"       </td>",
"       <td>",
"        <p>",
"         0.03-0.15 mg/kg",
"        </p>",
"        <p>",
"         (2-10 mg)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.03 to 0.15 mg/kg every 30 minutes to 6 hours",
"        </p>",
"        <p>",
"         Various regimens; see text",
"        </p>",
"       </td>",
"       <td>",
"        30-60 minutes",
"       </td>",
"       <td>",
"        30-360+",
"       </td>",
"       <td>",
"        <p>",
"         CAUTION: Not recommended as a first or second line of treatment for",
"         <strong>",
"          burn",
"         </strong>",
"         patients.",
"        </p>",
"        <p>",
"         Advantages: Sedating dopamine 2 antagonist for control of positive symptoms of delirium and ICU psychoses. Minimal cardiorespiratory effects in euvolemic hemodynamically stable patients.",
"        </p>",
"        <p>",
"         Disadvantages: Complex hepatic metabolism includes cytochrome P450-3A4 and cytochrome P450-2D6 transformations. Some experts consider certain metabolites to be active or potentially neurotoxic. Half-life becomes prolonged with repeated administration. Adverse effects include dose dependent QT interval prolongation and hypotension. Interacts with some common ICU drugs by interference with metabolism and/or additive QT prolongation. Extrapyramidal symptoms and neuroleptic malignant syndrome rare in critical care use.",
"        </p>",
"        <p>",
"         Role: A commonly used treatment for delirium in critically ill patients or for prevention of delirium while tapering sedation in preparation for ventilator weaning. Use with extreme caution in burn patients.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quetiapine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Initially 50 mg orally every 12 hours; increase every 24 hours as needed up to 400 mg per day",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        <p>",
"         Advantages: Relatively lower risk of extrapyramidal symptoms and less QT prolongation than haloperidol.",
"        </p>",
"        <p>",
"         Disadvantages: Requires enteral route of administration and scheduled dosing due to slow onset of action and relatively gradual titration schedule. Adverse effects may include sedation or orthostatic hypotension. Hepatically metabolized by cytochrome P450-3A4 to active and inactive metabolites. Dose reduction in hepatic insufficiency needed.",
"        </p>",
"        <p>",
"         Role: A potential choice as adjunct to as-needed intravenous haloperidol for treatment or prevention of delirium. The precise role of quetiapine in treating or preventing ICU delirium is not yet well established.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Doses shown are for adult patients, intravenous administration, unless stated otherwise. Data on drug metabolism and activity of metabolite(s) are for assessment of potential for drug interactions and risk of accumulation.",
"    <div class=\"footnotes\">",
"     +: Duration of action shown for initial dose. Duration becomes significantly prolonged after repeated dosing or with administration as a continuous infusion due to accumulation of drug in non-lean tissue.",
"     <br>",
"      * For patients with significant obesity, standard initial dosing (shown in parentheses based on ideal body weight) is preferred. For additional information see \"Management of the critically ill obese patient\".",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       One or more loading doses may be needed. See onset of action data for minimum time between re-dosing. Loading dose should be reduced or omitted in patients that are older, hypovolemic, having increasing vasopressor requirements or at-risk of hemodynamic compromise.",
"       <br>",
"        &Delta; Quetiapine recommendations and data based on limited experience and small trial results (CCM 2010; 38:419).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"       </li>",
"       <li>",
"        Brunton BL, et al. (Eds). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics 11th ed. McGraw-Hill, NY. Copyright &copy; 2006.",
"       </li>",
"       <li>",
"        Wynn GH, et al. (Eds). Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington, DC. Copyright &copy; 2009.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_40_20111=[""].join("\n");
var outline_f19_40_20111=null;
